Clinical trial NCT02401542
Conditions: Locally Advanced or Metastatic Urothelial Cell Carcinoma Urinary Bladder Disease Urological Diseases
Keywords: Urothelial Cell Carcinoma UCC bladder cancer vofatamab FGFR3 invasive bladder cancer targeted therapy Transitional Cell Carcinoma TCC Phase 2 second line therapy monoclonal antibody docetaxel combination therapy Phase 1 monotherapy B-701
Sponsor: Rainier Therapeutics
Start date: 2015-06-01; Completion date: 2019-11-01
Enrollment: 71 participants; Allocation: RANDOMIZED; Intervention model: PARALLEL

Brief summary:
This is a Phase 1/2(b), sequential, dose escalation, open-label, randomized expansion, multicenter, efficacy and safety study of vofatamab alone or in combination with docetaxel, or versus docetaxel in FGFR3 mutant/fusion subjects with Stage IV, locally advanced or metastatic UCC who have relapsed after, or are refractory to at least one prior line of chemotherapy. This study is divided into 3 phases: Phase 1b (Cohort 1), Phase 2 (Cohorts 2 and 3), and Phase 2b (Monotherapy Expansion Phase and Randomized Phase).

Detailed description:
This is a Phase 1/2(b), sequential, dose escalation, open-label, randomized expansion, multicenter, efficacy and safety study of vofatamab alone or in combination with docetaxel, or versus docetaxel in FGFR3 mutant/fusion subjects with Stage IV, locally advanced or metastatic UCC who have relapsed after, or are refractory to at least one prior line of chemotherapy. Vofatamab is a novel monoclonal antibody specific for fibroblast growth factor receptor 3 (FGFR3) that is being developed to target FGFR3-positive tumors.

This study is divided into 3 phases: Phase 1b (Cohort 1), Phase 2 (Cohorts 2 and 3), and Phase 2b (Monotherapy Expansion Phase and Randomized Phase).

Arms: arm 1: IV infusion of docetaxel, 75 mg/m2, followed by IV infusion of vofatamab, 25 mg/kg, on day one of each 21-day cycle. One additional IV infusion of vofatamab (25 mg/kg) given on Day 8 of Cycle 1.

Dosing with vofatamab and docetaxel will continue in each patient until disease progression, unacceptable toxicity, death, or study exit, including withdrawal of patient consent or study termination. Docetaxel treatment beyond 12 cycles of therapy may be considered at the discretion of the treating investigator and Medical Monitor. arm 2: IV infusion of docetaxel, 75 mg/m2, followed by IV infusion of placebo on day one of each 21-day cycle.

One additional IV infusion of placebo given on Day 8 of Cycle 1. Dosing of docetaxel and placebo will continue in each patient until disease progression, unacceptable toxicity, death, or study exit, including withdrawal of patient consent or study termination. Docetaxel treatment beyond 12 cycles of therapy may be considered at the discretion of the treating investigator and Medical Monitor arm 3: IV infusion vofatamab, 25 mg/kg on day one each 21-day cycle. One additional IV infusion of vofatamab (25 mg/kg) given on Day 8 of Cycle 1.

Dosing of vofatamab will continue in each patient until disease progression, unacceptable toxicity, death, or study exit, including withdrawal of patient consent or study termination.
Interventions: intervention 1: Vofatamab intervention 2: Docetaxel intervention 3: Placebo
Intervention descriptions: intervention 1: None intervention 2: None intervention 3: None

Protocol documents:
Prot_SAP_000.pdf: 
 
BioClin 
CLINICAL RESEARCH PROTOCOL 
Study Title: 
A Dose Escalation, Expansion Study of Vofatamab 
(B-701) Alone, Plus Docetaxel, or Versus Docetaxel in 
Subjects with Locally Advanced or Metastatic Urothelial 
Cell Carcinoma who have Relapsed After, or are 
Refractory to Standard Therapy 
 
 
Protocol Number: 
FIERCE-21 (B-701-U21) 
Investigational Product: 
Vofatamab (B-701) (anti-FGFR3 human monoclonal antibody) 
IND Number: 
123185 
Eudra CT Number: 
2017-001319-36 
 
 
Indication: 
Treatment of Relapsed or Refractory Urothelial Cell 
Carcinoma 
 
 
Sponsor: 
BioClin Therapeutics, Inc. 
1040 Davis Street, Suite 210 
San Leandro, CA 94577  
USA 
 
 
Medical Monitor: 
Steve Abella, M.D.  
BioClin Therapeutics, Inc. 
+1-650-529-4788  
 
 
Development Phase: 
Phase 1/2(b) 
 
 
Amendment 6: 
Amendment 5: 
Amendment 4: 
Amendment 3 
Amendment 2: 
Amendment 1: 
Original Protocol: 
31 July 2018 
06 July 2017 
21 November 2016 
17 February 2016 
28 December 2015 
24 February 2015  
26 November 2014 
 
Confidential 
The information contained in this document and all information provided to you related to B-701 is the 
confidential and proprietary information of BioClin Therapeutics, Inc. It is intended solely for the recipient 
clinical investigator(s) and must not be disclosed to any other party. This material may be used only for 
evaluating or conducting clinical investigations; any other proposed use requires written consent from BioClin 
Therapeutics, Inc. 


Protocol Number: B-701-U21 
CONFIDENTIAL 
Amendment 6 
BioClin Therapeutics, Inc. 
 
31 July 2018 
2 
TABLE OF CONTENTS 
CLINICAL RESEARCH PROTOCOL .....................................................................................1 
TABLE OF CONTENTS ...........................................................................................................2 
LIST OF TABLES .....................................................................................................................7 
LIST OF FIGURES ...................................................................................................................7 
LIST OF APPENDICES ............................................................................................................7 
PROTOCOL SYNOPSIS ..........................................................................................................8 
GLOSSARY OF TERMS ........................................................................................................30 
1 
INTRODUCTION .................................................................................................33 
1.1 
Background on Urothelial Cell Carcinoma ......................................................33 
1.1.1 
FGFR3 in Bladder Cancer ...................................................................33 
1.2 
Background on Vofatamab ..............................................................................34 
1.2.1 
Nonclinical Data with Vofatamab .......................................................34 
1.2.2 
Clinical Data with Vofatamab .............................................................35 
2 
OBJECTIVES ........................................................................................................41 
2.1 
Phase 1b (Cohort 1) .........................................................................................41 
2.1.1 
Primary Objective ................................................................................41 
2.2 
Phase 2 (Cohorts 2 and 3) ................................................................................41 
2.2.1 
Primary Objective ................................................................................41 
2.3 
Phase 2b Monotherapy Expansion and Randomized Phase ............................41 
2.3.1 
Phase 2b Monotherapy Expansion Primary Objective ........................41 
2.3.2 
Secondary Objectives...........................................................................41 
2.3.3 
Exploratory Objective ..........................................................................41 
2.4 
Phase 2b Randomized Phase ............................................................................41 
2.4.1 
Primary Objective ................................................................................41 
2.4.2 
Secondary Objectives...........................................................................42 
2.4.3 
Exploratory Objectives ........................................................................42 
3 
STUDY DESIGN...................................................................................................43 
3.1 
Overall Study Design .......................................................................................43 
3.1.1 
Phase 1b ...............................................................................................43 
3.1.2 
Phase 2 .................................................................................................44 
3.1.3 
Phase 2b ...............................................................................................44 
3.1.4 
Phase 1b, Phase 2, and Phase 2b Assessments ....................................46 
3.2 
Discussion of Study Design .............................................................................48 
3.2.1 
Selection of Dose and Dosing Schedule ..............................................48 
3.2.2 
Selection of Control .............................................................................50 
3.2.3 
Selection of Study Population ..............................................................50 
3.2.4 
Duration of Subject Participation.........................................................51 


Protocol Number: B-701-U21 
CONFIDENTIAL 
Amendment 6 
BioClin Therapeutics, Inc. 
 
31 July 2018 
3 
4 
STUDY POPULATION AND WITHDRAWAL .................................................52 
4.1 
Inclusion Criteria .............................................................................................52 
4.1.1 
Disease Specific Inclusion Criteria ......................................................52 
4.1.2 
Phase 2 and Phase 2b Specific Inclusion Criteria ................................53 
4.1.3 
General Inclusion Criteria ....................................................................53 
4.2 
Exclusion Criteria ............................................................................................55 
4.3 
Discontinuation Criteria ...................................................................................57 
4.3.1 
Subject Discontinuation .......................................................................57 
4.3.2 
Study Discontinuation ..........................................................................57 
5 
TREATMENT OF SUBJECTS .............................................................................59 
5.1 
Treatment Regimen ..........................................................................................59 
5.1.1 
Premedication ......................................................................................59 
5.1.2 
Cohort 1 of Phase 1b ............................................................................59 
5.1.3 
Cohort 2 of Phase 2 ..............................................................................61 
5.1.4 
Cohort 3 of Phase 2 ..............................................................................61 
5.1.5 
Phase 2b Monotherapy Expansion .......................................................62 
5.1.6 
Phase 2b Randomized Phase ................................................................62 
5.1.7 
Post-Study Access to Study Drug ........................................................64 
5.2 
Preparation, Administration, and Storage of Study Drug ................................64 
5.2.1 
Vofatamab ............................................................................................65 
5.2.2 
Docetaxel .............................................................................................67 
5.2.3 
Placebo .................................................................................................67 
5.3 
Study Drug Accounting ...................................................................................67 
5.3.1 
Receipt of Drug Supplies .....................................................................67 
5.3.2 
Return or Destruction of Study Drug ...................................................67 
5.4 
Method of Assigning Subjects to Treatment Groups .......................................68 
5.4.1 
Phase 1b (Cohort 1) .............................................................................68 
5.4.2 
Phase 2 (Cohorts 2 and 3) ....................................................................68 
5.4.3 
Phase 2b Randomized Phase ................................................................68 
5.5 
Blinding of Study Drug ....................................................................................68 
5.5.1 
Unblinding ...........................................................................................68 
5.6 
Treatment Compliance .....................................................................................69 
5.7 
Concomitant and Prohibited Therapies ............................................................69 
5.7.1 
Concomitant Therapy...........................................................................69 
5.7.2 
Prohibited Therapy...............................................................................69 
6 
STUDY ASSESSMENTS AND PROCEDURES .................................................70 
6.1 
Assessments by Study Visit .............................................................................70 
6.1.1 
Screening..............................................................................................70 


Protocol Number: B-701-U21 
CONFIDENTIAL 
Amendment 6 
BioClin Therapeutics, Inc. 
 
31 July 2018 
4 
6.1.2 
Phase 1b, Phase 2 and Phase 2b (Cycle 1 Through Cycle 12 and 
Beyond: Week 1 Through Week 36 and Beyond) ...............................71 
6.1.3 
End of Treatment/Early Termination ...................................................76 
6.1.4 
End of Study ........................................................................................77 
6.2 
Description of Assessments and Procedures ....................................................77 
6.2.1 
Informed Consent.................................................................................77 
6.2.2 
Archival Tissue Collection ..................................................................78 
6.2.3 
Subject Eligibility ................................................................................78 
6.2.4 
Medical History and Demographics ....................................................78 
6.2.5 
Physical Examination, Height, and Weight .........................................78 
6.2.6 
Vital Signs ............................................................................................79 
6.2.7 
Adverse Events ....................................................................................79 
6.2.8 
Tumor and Response Assessments ......................................................79 
6.2.9 
Laboratory Assessments ......................................................................80 
6.2.10 
Electrocardiogram Assessments ..........................................................82 
6.2.11 
PROMIS Global Physical Health Short Survey...................................82 
6.2.12 
European Organization for Research and Treatment Quality of Life 
Questionnaire .......................................................................................82 
6.2.13 
Survival ................................................................................................82 
6.3 
Appropriateness of Measurements ...................................................................82 
7 
STATISTICAL PLAN ...........................................................................................83 
7.1 
Sample Size Determination for All Phases ......................................................83 
7.2 
Phase 1b and Phase 2 .......................................................................................83 
7.3 
Phase 2b Monotherapy Expansion ...................................................................84 
7.3.1 
Pharmacokinetic Sub-Study .................................................................84 
7.4 
Phase 2b Randomized Phase ............................................................................84 
7.5 
Efficacy Analysis .............................................................................................84 
7.5.1 
Primary Efficacy Endpoint ..................................................................84 
7.5.2 
Secondary Efficacy Endpoints .............................................................85 
7.6 
Exploratory Endpoints .....................................................................................86 
7.7 
Safety ...............................................................................................................87 
7.7.1 
Adverse Events ....................................................................................87 
7.8 
Analysis Populations ........................................................................................87 
7.9 
Subject Disposition ..........................................................................................88 
7.10 
Demographic and Baseline Characteristics .....................................................88 
7.11 
Medical History and Physical Examination .....................................................88 
7.12 
Study Drug Administration ..............................................................................88 
7.13 
Laboratory Tests ..............................................................................................88 
7.14 
Vital Signs and Physical Examination .............................................................88 


Protocol Number: B-701-U21 
CONFIDENTIAL 
Amendment 6 
BioClin Therapeutics, Inc. 
 
31 July 2018 
5 
7.15 
12-Lead Electrocardiogram (ECG) ..................................................................89 
7.16 
ECOG Performance Status ..............................................................................89 
7.17 
Concomitant Medications ................................................................................89 
7.18 
Interim Analysis ...............................................................................................89 
7.19 
Safety Review ..................................................................................................89 
8 
SAFETY AND ADVERSE EVENTS ...................................................................90 
8.1 
Definitions........................................................................................................90 
8.2 
Severity of Adverse Events ..............................................................................91 
8.3 
Relationship of Adverse Events to Study Drug ...............................................92 
8.4 
Adverse Event Reporting Period .....................................................................93 
8.4.1 
Eliciting Adverse Events......................................................................94 
8.5 
Recording of Adverse Events ..........................................................................94 
8.5.1 
Recording Adverse Events on the eCRF .............................................94 
8.6 
Expedited Reporting Requirements for Serious Adverse Events and 
Serious Drug Reactions....................................................................................97 
8.6.1 
Reporting Requirements for All SAEs and DLTs ...............................97 
8.6.2 
Reporting Requirements for Fatal/Life-Threatening SAEs Related 
to Investigational Product ....................................................................97 
8.6.3 
IRB/EC Notification by the Investigator .............................................98 
8.6.4 
Regulatory Agency Notification by the Sponsor .................................98 
8.7 
Type and Duration of Follow-Up after Adverse Events ..................................98 
8.8 
Post-Study Adverse Events ..............................................................................98 
9 
STUDY CONDUCT ..............................................................................................99 
9.1 
Ethics................................................................................................................99 
9.1.1 
Institutional Review Board (IRB) / Independent Ethics Committee 
(IEC) ....................................................................................................99 
9.1.2 
Ethical Conduct of the Study ...............................................................99 
9.1.3 
Informed Consent.................................................................................99 
9.2 
Regulatory Requirements...............................................................................100 
9.3 
Investigators and Administrative Structure ...................................................100 
9.4 
Data Handling and Record Keeping ..............................................................101 
9.4.1 
Case Report Forms and Source Documents.......................................101 
9.4.2 
Data Quality Assurance .....................................................................101 
9.4.3 
Records Retention ..............................................................................102 
9.4.4 
Disclosure of Source Data and Documents .......................................102 
9.5 
Subject Confidentiality ..................................................................................102 
9.6 
Procedures for Protocol Amendments ...........................................................103 
9.7 
Study Report ..................................................................................................103 
9.8 
Financing and Insurance ................................................................................103 


Protocol Number: B-701-U21 
CONFIDENTIAL 
Amendment 6 
BioClin Therapeutics, Inc. 
 
31 July 2018 
6 
9.9 
Publication Policy ..........................................................................................103 
10 
REFERENCES ....................................................................................................104 
11 
SIGNATURE PAGE ...........................................................................................108 
 


Protocol Number: B-701-U21 
CONFIDENTIAL 
Amendment 6 
BioClin Therapeutics, Inc. 
 
31 July 2018 
7 
LIST OF TABLES 
Table 1 
Schedule of Assessments ...........................................................................25 
Table 2. 
B-701-U21:  Summary of Adverse Events in Cohort 1 .............................39 
Table 3. 
B-701-U21:  Summary of Best Overall Response, Disease Control 
Rate, Progression-Free Survival, and Overall Survival in Cohort 1 ..........40 
Table 4 
Management of Infusion-Related Symptoms (e.g., fever, chills/rigors, 
nausea, vomiting, pruritus, headache, rhinitis, rash, hypotension, 
hypersensitivity, anaphylaxis, dyspnea, wheezing, bronchospasm, 
tachycardia, reduced oxygen saturation, or respiratory distress) ...............66 
Table 5 
Adverse Event Severity Grading Scale ......................................................92 
Table 6 
Time Point Response: Subjects with Target Disease (With or Without 
Non-Target Lesions) ................................................................................117 
Table 7 
Time Point Response: Subjects with Non-Target Disease Only .............118 
Table 8 
Best Overall Response When Confirmation of CR and PR required ......119 
 
LIST OF FIGURES 
Figure 1 
Progression-Free Survival in Subjects with UCC (Study MFG4991g) .....37 
Figure 2 
Study Design ..............................................................................................47 
Figure 3 
Tumor Suppression Following Vofatamab Treatment in a Bladder 
Cancer Xenograft Model (UMUC-1).........................................................48 
 
 
LIST OF APPENDICES 
Appendix 1 
Eastern Cooperative Oncology Group Performance Status Scale ...........109 
Appendix 2 
New York Heart Association Classification of Functional Cardiac 
Capacity ...................................................................................................110 
Appendix 3 
Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1...111 
Appendix 4 
Anaphylaxis Precautions and Procedures ................................................121 
Appendix 5 
PROMIS Global Physical Health Short Survey.......................................122 
Appendix 6 
INFORMATION REGARDING EFFECTIVENESS OF 
CONTRACEPTIVE METHODS ............................................................123 
Appendix 7 
European Organization for Research and Treatment Quality of Life 
Questionnaire (EORTC QLQ-C30) .........................................................125 
Appendix 8 
Pharmacokinetic Sub-Study .....................................................................127 


Protocol Number: B-701-U21 
CONFIDENTIAL 
Amendment 6 
BioClin Therapeutics, Inc. 
 
31 July 2018 
8 
PROTOCOL SYNOPSIS 
Title of Study: 
A Dose Escalation, Expansion Study of Vofatamab (B-701) 
Alone, Plus Docetaxel, or Versus Docetaxel in Subjects with 
Locally Advanced or Metastatic Urothelial Cell Carcinoma 
who have Relapsed After, or are Refractory to Standard 
Therapy 
Protocol Number: 
FIERCE-21 (B-701-U21) 
Location: 
United States (US), European Union (EU), and Asia 
Study Centers: 
Approximately 50 to 100 sites will participate in this study. 
Study Period:  
Subjects will participate in the study for approximately 
36 months, including a 28-day screening period, 21-day 
cycles of treatment, and telephone follow-up to monitor 
survival. 
Phase of Development: 
1/2(b) 
Study Rationale: 
Vofatamab (formerly referred to as B-701 and MFGR1877S) is a novel monoclonal 
antibody specific for fibroblast growth factor receptor 3 (FGFR3) that is being developed 
to target FGFR3-positive tumors. Studies have shown that the majority of subjects with 
urothelial cell carcinoma (UCC) overexpress FGFR3 on the tumor cell surface. Preclinical 
studies have also shown that vofatamab suppresses FGFR3-mediated cell proliferation and 
exerts strong anti-tumor activity in mouse xenograft models of bladder cancer. 
Furthermore, the combination regimen of vofatamab plus a taxane showed better 
anti-tumor activity than either agent alone. Potential signals of clinical efficacy following 
treatment with vofatamab were also observed in a Phase 1 study in subjects with advanced 
solid tumors, including UCC. 
Study Objectives: 
Phase 1b (Cohort 1) 
• Primary Objective: To determine an acceptable maximum tolerated dose (MTD) of 
vofatamab plus docetaxel in subjects with Stage IV, locally advanced or metastatic 
UCC who have relapsed after, or are refractory to at least one prior line of 
chemotherapy. 
Phase 2 (Cohorts 2 and 3) 
• Primary Objective: To evaluate the initial safety and efficacy of vofatamab in 
combination with docetaxel and vofatamab monotherapy in advanced UCC with 
FGFR3 genomic aberrations.  


Protocol Number: B-701-U21 
CONFIDENTIAL 
Amendment 6 
BioClin Therapeutics, Inc. 
 
31 July 2018 
9 
Phase 2b Monotherapy Expansion and Randomized Phases: 
Phase 2b Monotherapy Expansion Phase  
• Primary Objective: To evaluate the efficacy of vofatamab in the treatment of subjects 
with Stage IV, locally advanced or metastatic UCC who have relapsed after, or are 
refractory to, at least one prior line of chemotherapy, as measured by progression-free 
survival (PFS). 
• Secondary Objectives: 
o To evaluate overall survival (OS) of vofatamab in the treatment of subjects with 
UCC. 
o To evaluate the efficacy of vofatamab in the treatment of subjects with UCC as 
measured by objective response rate (ORR), disease control rate (DCR), duration of 
objective response (DOR), time to response (TTR), and quality of life (QOL). 
o To evaluate the safety and tolerability of vofatamab in the treatment of subjects 
with UCC as measured by anti-vofatamab antibodies (ATA), adverse events (AEs), 
physical examination, laboratory, and other clinically relevant results. 
• Exploratory Objectives: 
o To evaluate the pharmacokinetics (PK) of vofatamab in advanced UCC 
 
Phase 2b Randomized Phase 
• Primary Objective: To evaluate the efficacy of vofatamab plus docetaxel compared 
with placebo plus docetaxel in the treatment of subjects with Stage IV, locally 
advanced or metastatic UCC who have relapsed after, or are refractory to at least one 
prior line of chemotherapy which has not included a taxane, as measured by 
progression-free survival (PFS). 
• Secondary Objectives: 
o To evaluate overall survival (OS) of vofatamab plus docetaxel compared with 
placebo plus docetaxel in the treatment of subjects with UCC. 
o To evaluate the efficacy of vofatamab plus docetaxel compared with placebo plus 
docetaxel in the treatment of subjects with UCC as measured by objective response 
rate (ORR), disease control rate (DCR), duration of objective response (DOR), time 
to response (TTR), and quality of life (QOL). 
o To evaluate the safety and tolerability of vofatamab plus docetaxel compared with 
placebo plus docetaxel in the treatment of subjects with UCC as measured by 
anti-vofatamab antibodies (ATA), adverse events (AEs), physical examination, 
laboratory, and other clinically relevant results. 
 
 


Protocol Number: B-701-U21 
CONFIDENTIAL 
Amendment 6 
BioClin Therapeutics, Inc. 
 
31 July 2018 
10 
• Exploratory Objectives: 
o To study the association between the level of FGFR3 expression, the presence of 
FGFR3 mutations or fusions, as well as other potential biomarkers (e.g., genetic 
alterations in other cancer-related genes), in primary tumors or metastases, with 
efficacy and/or adverse event (AE) outcomes. 
o To evaluate the pharmacokinetics (PK) of vofatamab monotherapy and vofatamab 
in combination with docetaxel in advanced UCC. 
 
Study Design and Methodology: 
This is a Phase 1/2(b), sequential, dose escalation, open-label, randomized expansion, 
multicenter, efficacy and safety study of vofatamab alone or in combination with 
docetaxel, or versus docetaxel in subjects with Stage IV, locally advanced or metastatic 
UCC who have relapsed after, or are refractory to at least one prior line of chemotherapy. 
This study is divided into 3 phases: Phase 1b (Cohort 1), Phase 2 (Cohorts 2 and 3), and 
Phase 2b (Monotherapy Expansion Phase and Randomized Phase). 
Phase 1b: 
The clinical trial will commence with Phase 1b, which consists of Cohort 1 as follows: 
• Cohort 1: Approximately 20 subjects with Stage IV, locally advanced or metastatic 
UCC who have relapsed after, or are refractory to at least one prior line of 
chemotherapy which has not included a taxane. All subjects in this cohort will receive 
both vofatamab plus docetaxel. 
Cohort 1 of Phase 1b: 
Cohort 1 of Phase 1b of the study will utilize the following 3 + 3 design: 
Initially, one subject will be enrolled in Cohort 1. On Day 1 of Cycle 1, the initial 
subject in this cohort will be treated with a combination regimen consisting of an 
intravenous (IV) infusion of docetaxel (75 mg/m2) followed by an IV infusion of 
vofatamab (25 mg/kg). On Day 8 of Cycle 1, the subject will be treated with an IV 
infusion of vofatamab (25 mg/kg) alone. If the subject experiences a dose limiting 
toxicity (DLT) during the DLT observation period (defined as the first 21-day cycle), 
then additional subjects will be enrolled at the same dose until 6 subjects are enrolled 
or until ≥ 2 subjects have experienced DLTs. If no DLT is observed through Day 21, an 
additional 2 subjects will be treated, on different days, with the same regimen. If a DLT 
is observed in 1 of the 3 subjects during the DLT observation period, then additional 
subjects will be enrolled until at least 6 subjects are enrolled or until ≥ 2 subjects have 
experienced DLT (i.e., with docetaxel 75 mg/m2 and vofatamab 25 mg/kg). If 0 of 
3 subjects or ≤ 1 of 6 subjects experience a DLT, additional subjects will be enrolled at 
that dose so that a total of 20 subjects will be treated in Cohort 1. If at any time ≥ 2 of 
6 subjects experience a DLT, the dosing regimen will be modified by either reducing 
the dose of vofatamab to 20 mg/kg and/or reducing the dose of docetaxel to 55 mg/m2. 
The dose modification decision will be made based upon the nature of the DLT, e.g., if 
it is clearly related to one or the other drug, or upon discussion with the participating 


Protocol Number: B-701-U21 
CONFIDENTIAL 
Amendment 6 
BioClin Therapeutics, Inc. 
 
31 July 2018 
11 
principal investigators (see Section 5.1.2 for details). A new set of 3 to 6 subjects will 
be enrolled and treated with the modified dose of vofatamab and/or docetaxel. If at any 
time, a dose of vofatamab of 20 or 25 mg/kg or a dose of docetaxel of at least 55 mg/m2 
are deemed not tolerable (i.e., ≥ 2 of 6 subjects at the same dose level who have 
experienced DLTs), enrollment will cease and the study will be stopped until further 
analysis of the combination regimen can be performed. Should a subject discontinue 
dosing with docetaxel at any time during the study, dosing with vofatamab will 
continue until disease progression, unacceptable toxicity, death, or study exit, including 
withdrawal of patient consent or study termination. 
Phase 2:  
Phase 2 of the study is divided in the following 2 cohorts: 
• Cohort 2: Up to 20 subjects with Stage IV, locally advanced or metastatic UCC 
positive for FGFR3 mutation and/or fusion; who are ineligible for or who have 
relapsed after or are refractory to an immune checkpoint inhibitor and at least one prior 
line of chemotherapy which has not included a taxane. All subjects in this cohort will 
receive both vofatamab plus docetaxel. 
• Cohort 3: Up to 20 subjects with Stage IV, locally advanced or metastatic UCC 
positive for FGFR3 mutation and/or fusion; who are ineligible for or who have 
relapsed after or are refractory to an immune checkpoint inhibitor and at least one prior 
line of chemotherapy. All subjects in this cohort will receive vofatamab only. 
Cohort 2 of Phase 2: 
Enrollment in Cohort 2 will commence after the 16th subject is enrolled in Cohort 1 of 
Phase 1b. On Day 1 of each 21-day cycle, subjects in Cohort 2 of Phase 2 will be 
treated with a combination regimen consisting of an intravenous (IV) infusion of 
docetaxel (75 mg/m2) followed by an IV infusion of vofatamab (25 mg/kg). An 
additional dose of vofatamab (25 mg/kg) only will be given on approximately Day 8 of 
Cycle 1 only. Dosing with docetaxel and vofatamab will continue in each subject until 
disease progression, unacceptable toxicity, death, or study exit, including withdrawal of 
patient consent or study termination. Should a subject discontinue dosing with 
docetaxel at any time during the study, dosing with vofatamab will continue until 
disease progression, unacceptable toxicity, death, or study exit, including withdrawal of 
patient consent or study termination. 
Cohort 3 of Phase 2: 
Enrollment in Cohort 3 of Phase 2 will commence after the 16th subject is enrolled in 
Cohort 1 of Phase 1b. On Day 1 of each 21-day cycle, subjects in Cohort 3 of Phase 2 
will receive one IV infusion of vofatamab (25 mg/kg). An additional dose of vofatamab 
(25 mg/kg) will be given on approximately Day 8 of Cycle 1 only. Dosing of 
vofatamab will continue in each subject until disease progression, unacceptable 
toxicity, death, or study exit, including withdrawal of patient consent or study 
termination. 


Protocol Number: B-701-U21 
CONFIDENTIAL 
Amendment 6 
BioClin Therapeutics, Inc. 
 
31 July 2018 
12 
Phase 2b: 
Phase 2b Monotherapy Expansion: 
Enrollment to Monotherapy Expansion will commence once Phase 2 has completed 
enrollment. The Monotherapy Expansion Phase will enroll up to 80 subjects with Stage 
IV, locally advanced or metastatic UCC positive for FGFR3 mutation and/or fusion; 
who are ineligible for or who have relapsed after, or are refractory to an immune 
checkpoint inhibitor and at least one prior line of chemotherapy. (If a checkpoint 
inhibitor is not an approved or available therapy for UCC, then this criterion does not 
apply). 
On Day 1 of each 21-day cycle, subjects in the Monotherapy Expansion Phase will 
receive one IV infusion of vofatamab (25 mg/kg). An additional dose of vofatamab 
(25 mg/kg) will be given on approximately Day 8 of Cycle 1 only. Dosing of 
vofatamab will continue in each subject until disease progression, unacceptable 
toxicity, death, or study exit, including withdrawal of patient consent or study 
termination. 
Pharmacokinetic Sub-study: up to 10 subjects at designated centers in Monotherapy 
Expansion who provide separate informed consent will participate in a PK Sub-study 
and will have intensive PK sample collection (samples obtained before and 30 minutes 
post-dosing) performed on Day 1 of Cycles 1, 2, 3, 5, 6, 10, and end of treatment 
following the initiation of vofatamab dosing. In addition, for Cycle 1, samples will be 
collected on Day 2 and 4, and on Day 8 before and 30 minutes post-dosing. In Cycle 5, 
samples will be collected on Day 2, Day 8, Day 15, and Day 21.  
Phase 2b Randomized Phase: 
Enrollment to the Randomized Phase will commence after a review of the safety and 
efficacy data observed in the Cohort 2 of Phase 2. The review will be conducted by the 
Sponsor and the Safety Oversight Committee (SOC) once the last subject in Cohort 2 
of Phase 2 has completed at least 6 months of follow-up on study, to evaluate the 
potential safety and efficacy benefit of the addition of vofatamab to docetaxel 
chemotherapy. Subjects with Stage IV, locally advanced or metastatic UCC positive for 
FGFR3 mutation and/or fusion; who are ineligible for or who have relapsed after, or are 
refractory to an immune checkpoint inhibitor and at least one prior line of 
chemotherapy which has not included a taxane will be enrolled. (If a checkpoint 
inhibitor is not an approved or available therapy for UCC, then this criterion does not 
apply). 
Subjects will be randomly assigned in a 2:1 ratio to receive therapy with either 
vofatamab plus docetaxel (Arm A, experimental arm) or placebo plus docetaxel 
(Arm B, control arm). Random assignment will be stratified by visceral metastasis 
(presence vs. absence). 
Arm A (vofatamab plus docetaxel): On Day 1 of each 21-day cycle, subjects will 
receive one IV infusion of docetaxel followed by one IV infusion of vofatamab, using 
the MTD identified in Cohort 1. An additional dose of vofatamab (without docetaxel, 


Protocol Number: B-701-U21 
CONFIDENTIAL 
Amendment 6 
BioClin Therapeutics, Inc. 
 
31 July 2018 
13 
and at the dose identified in Cohort 1) will be given on approximately Day 8 of Cycle 1 
only. 
Arm B (placebo plus docetaxel): On Day 1 of each 21-day cycle, subjects will receive 
one IV infusion of docetaxel, using the MTD identified in Cohort 1, followed by one 
IV infusion of placebo. An additional placebo infusion (without docetaxel) will be 
given on approximately Day 8 of Cycle 1 only. 
Crossover from Arm A to Arm B and vice versa will not be allowed. 
Phase 2b Randomized Phase will enroll approximately 160 subjects.  
Phase 1, Phase 2, and Phase 2b Assessements 
Clinical response assessments will be performed every 9 weeks ± 1 week (i.e., every third 
cycle beginning at the Screening visit) until disease progression or lack of tolerability. 
Response assessments will be reported by the investigator and reviewed by the Medical 
Monitor.  
Dosing of vofatamab will continue in each subject until disease progression, unacceptable 
toxicity, death, or study exit, including withdrawal of patient consent or study termination. 
Docetaxel treatment beyond 12 cycles of therapy may be considered at the discretion of the 
treating investigator and Medical Monitor, and after a careful assessment and discussion of 
risk versus benefit with the subject. Study activities are summarized in Table 1. 
Number of Subjects Planned: 
Approximately 300 subjects will be enrolled in the study (approximately 20 in Phase 1b, 
40 in Phase 2 [20 subjects per cohort], and 240 in Phase 2b [up to 80 subjects in 
Monotherapy Expansion, and 160 subjects in Randomized Phase]. 
Diagnosis and Criteria for Inclusion and Exclusion: 
Disease Specific Inclusion Criteria: 
1. Stage IV, locally advanced or metastatic (T4b, any N; or any T, N2-3) urothelial 
bladder cancer or transitional cell carcinoma (TCC) arising in another location of the 
urinary tract, including urethra, ureter, and renal pelvis 
2. Histological or cytological diagnosis of UCC. Mixed histologies are permitted as long 
as TCC is the major component (i.e., > 50% of the pathologic specimen). Pure or 
predominant squamous cell carcinomas or adenocarcinomas are not permitted 
3. Relapsed after or are refractory to at least one prior line of chemotherapy which have 
not included a taxane (with the exception of Cohort 3 of Phase 2 and Phase 2b 
Monotherapy Expansion which will allow the enrollment of subjects with prior 
treatment with a taxane) 
4. Subjects must have received at least one prior chemotherapeutic regimen (at least one 
cycle each) for advanced or metastatic/recurrent disease, of which at least one regimen 
included a platinum agent. If a platinum agent is contraindicated for a subject (e.g., due 
to pre-existing renal impairment such as creatinine clearance < 60 mL/min, 
myelosuppression, hearing impairment, or history of allergic reaction to platinum-


Protocol Number: B-701-U21 
CONFIDENTIAL 
Amendment 6 
BioClin Therapeutics, Inc. 
 
31 July 2018 
14 
containing compounds), the prior regimen(s) need not have included a platinum agent. 
Reason for platinum contraindication will be collected in the eCRFs   
5. Prior neoadjuvant or adjuvant chemotherapy (without a taxane, except Cohort 3 of 
Phase 2 and Monotherapy Expansion of Phase 2b which will allow the enrollment of 
subjects with prior treatment with a taxane) is permitted and will not be counted as 
first-line chemotherapy, as long as the subject has not progressed within 12 months of 
the last dose. However, if the patient progressed within 12 months of the last dose of 
prior neoadjuvant or adjuvant chemotherapy, then this regimen of neoadjuvant or 
adjuvant chemotherapy will be counted as first-line chemotherapy 
6. Measurable disease according to Response Evaluation Criteria in Solid Tumors 
Version 1.1 (RECIST v1.1; see Appendix 3). If possible, sites of measurable disease 
should not be within a previously irradiated site. However, if all sites of measurable 
disease have been irradiated, at least one site must have demonstrated growth after 
irradiation 
7. Subjects must be anticipated to have a PFS of at least 4 weeks from the time of 
randomization (i.e., tumor progression per RECIST v1.1 is not anticipated within the 
first 4 weeks after randomization) 
Phase 2 and Phase 2b Specific Inclusion Criteria: 
1. Tumor shown to have at least one of the following FGFR3 mutations: R248C, S249C, 
G370/2C, S371/3C, Y373/5C, G380/82R, F384/6L, K650/2X (X=E,T or M) or 
FGFR3-TACC3 fusion, as shown by tests performed by a CAP or CLIA certified 
laboratory (or equivalent outside of the US) such as Foundation Medicine, Ashion 
Analytics, or Paradigm Diagnostics on samples that were obtained at or after the time 
when the subject was found to have muscle invasive disease or high grade papillary 
non-muscle invasive disease. In the absence of pre-existing genetic test results, 
subjects can submit archival tissue (obtained at or after the time subject was found to 
have muscle invasive disease) for genetic testing. When such archival tissue is not 
immediately available, a blood sample may be submitted for initial determination of 
FGFR3 mutation and/or fusion status. In all cases, subsequent to subject enrollment, 
previous test results that were not provided by Foundation Medicine will be verified 
using archival tissue (if not available for Randomized Phase, a core biopsy may be 
obtained). Blood samples will be obtained on Cycle 1 Day 1 to verify results observed 
in archival tissues or core biopsies.  
2. Relapsed after or are refractory to an immune checkpoint inhibitor (such as 
atezolizumab, pembrolizumab, nivolumab, avelumab, or durvalumab). This inclusion 
criterion does not apply if the checkpoint inhibitor is contraindicated. Reason for 
checkpoint inhibitor contraindication will be collected in the eCRFs. If a checkpoint 
inhibitor is not an approved or available therapy for UCC, then this inclusion criterion 
does not apply. 
General Inclusion Criteria: 
1. Signed informed consent form, including: 
a. Consent to provide tumor tissue and blood samples for genetic testing 


Protocol Number: B-701-U21 
CONFIDENTIAL 
Amendment 6 
BioClin Therapeutics, Inc. 
 
31 July 2018 
15 
b. Consent to provide metastatic tumor tissue during the study, if available, or at 
autopsy for testing of FGFR3 status, as well as other potential biomarkers 
c. Consent to provide survival information after completion of study drug dosing 
2. For Cohort 1, archival tumor samples must be available for retrospective sequencing of 
cancer-related genes, including FGFR3, by NGS. For Cohorts 2 and 3 of Phase 2 and 
all subjects in Monotherapy Expansion and (Randomized Phase, subjects must be 
confirmed to have a FGFR3 genomic alteration at the time of documentation of 
advanced disease. Available tissue that was obtained at or after the time the subject was 
found to have muscle invasive disease and is of suitable quality and quantity (as 
outlined in the Sponsor’s Laboratory Instructions) should be used to assess the FGFR3 
status by genetic testing. A blood sample to assess the FGFR3 status of circulating 
tumor DNA by genetic sequencing must also be provided. (described in Section 6.2.2). 
In case no archival tissue sample is available or tissue testing was not informative, a 
blood sample to assess the FGFR3 status by circulating tumor DNA (ctDNA) can be 
submitted and if positive will be considered adequate for inclusion. For subjects 
participating in Phase 2b Monotherapy Expansion Phase and Phase 2b Randomized 
Phase, if suitable archival tissue is unavailable and ctDNA is not informative, then a 
core biopsy of tumor tissue (metastatic or primary from any anatomical location except 
the bone, lung or brain) can be obtained to determine FGFR3 status.  
3. Age ≥ 18 years (≥ 20 years in Taiwan) 
4. Life expectancy ≥ 12 weeks  
5. Presence of less than 3 of the following 3 poor prognostic factors:   
a. Eastern Cooperative Oncology Group (ECOG) performance status (PS) ≥1,  
b. hemoglobin <10 g/dL, and  
c. presence of liver metastasis  
(Note: presence of all 3 poor prognostic factors correlates with rapid progression and a 
median survival of 1.7 months (Bellmunt 2010; see also Figure 1) 
6. ECOG PS of 0 or 1 (see Appendix 1) 
7. Adequate hematologic and end organ function defined by the following laboratory 
results obtained within two weeks prior to the first dose of study treatment: 
a. Absolute neutrophil count ≥ 1500/µL 
b. Platelet count ≥ 100,000/µL 
c. Hemoglobin ≥ 9.0 g/dL without transfusion 
d. Albumin ≥ 2.5 g/dL 
e. Total bilirubin ≤ upper limit of normal (ULN) (without exception, as stated in the 
docetaxel package insert) 
f. Aspartate aminotransferase (AST), alanine aminotransferase (ALT), and alkaline 
phosphatase (ALP) ≤ 2.5 × ULN, with the following exceptions: 


Protocol Number: B-701-U21 
CONFIDENTIAL 
Amendment 6 
BioClin Therapeutics, Inc. 
 
31 July 2018 
16 
− Subjects with documented bone metastases: ALP ≤ 5 × ULN 
− Note: Subjects with AST and/or ALT > 1.5 x ULN concomitant with 
alkaline phosphatase > 2.5 x ULN will not be allowed to enroll, regardless 
of presence of liver or bone metastases, as stated in the docetaxel package 
insert 
g. Creatinine clearance ≥ 30 mL/min on the basis of the Cockroft-Gault glomerular 
filtration rate estimation: 
(140 −𝑎𝑔𝑒) × (𝑤𝑒𝑖𝑔ℎ𝑡 𝑖𝑛 𝑘𝑔) × (0.85 𝑖𝑓 𝑓𝑒𝑚𝑎𝑙𝑒) 
72 × (𝑠𝑒𝑟𝑢𝑚 𝑐𝑟𝑒𝑎𝑡𝑖𝑛𝑖𝑛𝑒 𝑖𝑛 𝑚𝑔/𝑑𝐿)
 
h. Prothrombin time/international normalized ratio (PT/INR) and partial 
thromboplastin time (PTT) must be ≤ 1.5 × ULN 
8. Willingness to avoid pregnancy or fathering children based on the criteria below: 
a. Women of non-childbearing potential (i.e., surgically sterile with a hysterectomy 
and/or bilateral oophorectomy OR chemically sterile OR ≥ 12 months of 
amenorrhea in the absence of chemotherapy, anti-estrogens, or ovarian 
suppression). Women of non-childbearing potential need not undergo pregnancy 
testing 
b. Women of childbearing potential who have a negative urine or serum pregnancy 
test at Screening and before the first dose of study drug on Cycle 1, Day 1, and who 
agree to take appropriate precautions to avoid pregnancy (with approximately 99% 
certainty) from Screening through 90 days after the last dose of study drug. 
Permitted methods of contraception that are approximately 99% effective in 
preventing pregnancy are described in Appendix 6, should be communicated to the 
subject, and the subject’s understanding confirmed  
c. Men who agree to take appropriate precautions to avoid fathering children (with at 
least 99% certainty) from Screening through 90 days after the last dose of study 
drug. Permitted methods of contraception that are approximately 99% effective in 
preventing pregnancy are described in Appendix 6, should be communicated to the 
subject, and the subject’s understanding confirmed 
9. Negative urine or serum pregnancy test within 3 days prior to randomization in women 
of childbearing potential 
10. Absence of any psychological, familial, sociological, or geographical condition 
potentially hampering compliance with the study protocol and follow-up schedule 
(such conditions should be discussed with the subject before study entry) 
Exclusion Criteria: 
1. Prior use of any other investigational drug (i.e., monoclonal antibody or experimental 
therapy) within 2 weeks before Cycle 1, Day 1 
2. Palliative radiotherapy within 2 weeks prior to Cycle 1, Day 1 


Protocol Number: B-701-U21 
CONFIDENTIAL 
Amendment 6 
BioClin Therapeutics, Inc. 
 
31 July 2018 
17 
3. Prior anti-cancer therapy (e.g. biologic or other targeted therapy, chemotherapy or 
hormonal therapy) within 2 weeks prior to Cycle 1, Day 1 
a. A washout of less than 14 days may be allowed after discussion with the Medical 
Monitor, provided that the subject has recovered from any clinically relevant 
toxicity (Exception: participants with neuropathy of Grade 1 will be allowed study 
entry) 
b. Clinical AEs, except for alopecia, from any previous treatments must have resolved 
to ≤ Grade 1 
c. Laboratory AEs from any previous treatments must have resolved to ≤ Grade 1 or 
to within 10% of baseline prior to Cycle 1, Day 1 
4. Prior treatment with an inhibitor that is targeted primarily to FGFRs 
5. History of severe allergic or anaphylactic reactions to monoclonal antibody therapy (or 
recombinant antibody-related fusion proteins) 
6. Inability to be pre-medicated with a corticosteroid when treated with docetaxel 
7. Evidence of significant, uncontrolled concomitant diseases which could affect 
compliance with the protocol or interpretation of results, including significant 
cardiovascular disease (such as New York Heart Association (NYHA) Class III or IV 
cardiac disease (see Appendix 2), myocardial infarction or stroke within the last 6 
months, unstable arrhythmias, or unstable angina) or pulmonary disease (including 
obstructive pulmonary disease and history of bronchospasm) 
8. History of major bleeding (requiring a blood transfusion ≥ 2 units) not related to a 
tumor within the past 12 months 
9. History of clinically significant coagulation or platelet disorder in the past 12 months  
10. Currently receiving anticoagulation treatment  
11. Incomplete healing from wounds from prior surgery; wound is larger than 2 cm in 
length 28 days prior to randomization 
12. Known active bacterial, viral, fungal, mycobacterial, parasitic, or other infection 
(excluding fungal infections of nail beds) at screening. Any major episode of infection 
requiring treatment with IV antibiotics or hospitalization must be resolved (including 
the completion of the course of antibiotics) prior to Cycle 1, Day 1 
13. History of other malignancy which could affect compliance with the protocol or 
interpretation of results 
14. Subjects with a history of curatively treated basal or squamous cell carcinoma of the 
skin or in situ carcinoma of the cervix are allowed 
15. Subjects with a malignancy that has been treated with curative intent will also be 
allowed if the malignancy has been in remission without treatment for ≥ 2 years prior 
to Cycle 1, Day 1 
16. Subjects with localized prostate cancer that has been treated with curative intent will be 
allowed 


Protocol Number: B-701-U21 
CONFIDENTIAL 
Amendment 6 
BioClin Therapeutics, Inc. 
 
31 July 2018 
18 
17. Presence of positive test results for Hepatitis B (Hepatitis B surface antigen [HBsAg] 
and/or total Hepatitis B core antibody [anti-HB-c]) or Hepatitis C (Hepatitis C virus 
[HCV] antibody serology testing) 
Subjects positive for anti HB-c are eligible only if polymerase chain reaction (PCR) is 
negative for Hepatitis B viral (HBV) deoxyribonucleic acid (DNA) 
18. Known history of human immunodeficiency virus (HIV) seropositive status 
19. Primary central nervous system (CNS) malignancy, or CNS metastases  
20. Pregnancy (positive pregnancy test), lactation or breastfeeding 
21. Inability to comply with study and follow up procedures 
22. Any other diseases, metabolic dysfunction, physical examination finding, or clinical 
laboratory finding giving reasonable suspicion of a disease or condition that 
contraindicates the use of an investigational drug or that may affect the interpretation 
of the results or render the subject at high risk from treatment complications 


Protocol Number: B-701-U21 
CONFIDENTIAL 
Amendment 6 
BioClin Therapeutics, Inc. 
 
31 July 2018 
19 
Experimental Arm, Dose, and Mode of Administration: 
Vofatamab will be provided as a sterile lyophilized powder in 20-mL single-use vials. 
Vofatamab will be reconstituted with sterile water for injection, and the drug product will 
be delivered at a final concentration of at least 3 mg/mL. Phase 2b sterile liquid 
formulation of vofatamab in 20-mL single use vials is currently in development with 
planned concentration of approximately 50 mg/mL. Details will follow in the 
Investigational Medicinal Product Dossier (IMPD) and pharmacy manual at time of 
introduction of this new formulation. 
Phase 1b 
• Cohort 1: Subjects will receive one IV infusion of docetaxel, 75 mg/m², over 
approximately 60 minutes; followed by one IV infusion of vofatamab, 25 mg/kg, on 
Day 1 of each 21-day cycle. The vofatamab infusion should begin approximately 
30 minutes after completion of the docetaxel infusion, and should be administered over 
90 (± 15) minutes to well-hydrated subjects. An IV loading dose of vofatamab, 
25 mg/kg, (without docetaxel) will be given on approximately Day 8 of Cycle 1 only.  
If prior infusions have been well-tolerated, subsequent doses of vofatamab may be 
administered over 30 (± 10) minutes, followed by a 30-minute observation period post 
infusion.  
Phase 2 
• Cohort 2: Subjects will receive one IV infusion of docetaxel, 75 mg/m², over 
approximately 60 minutes; followed by one IV infusion of vofatamab, 25 mg/kg, on 
Day 1 of each 21-day cycle. The vofatamab infusion should begin approximately 
30 minutes after completion of the docetaxel infusion, and should be administered over 
90 (± 15) minutes to well-hydrated subjects. An IV loading dose of vofatamab, 
25 mg/kg, (without docetaxel) will be given on approximately Day 8 of Cycle 1 only. 
If prior infusions have been well-tolerated, subsequent doses of vofatamab may be 
administered over 30 (± 10) minutes, followed by a 30-minute observation period post 
infusion.  
• Cohort 3: Subjects will receive one IV infusion of vofatamab, 25 mg/kg, on Day 1 of 
each 21-day cycle. The vofatamab infusion should be administered over 90 (± 15) 
minutes to well-hydrated subjects. An IV loading dose of vofatamab, 25 mg/kg, will be 
given on approximately Day 8 of Cycle 1 only. If prior infusions have been 
well-tolerated, subsequent doses of vofatamab may be administered over 
30 (± 10) minutes, followed by a 30-minute observation period post infusion.  
Phase 2b 
• Monotherapy Expansion: Subjects will receive one IV infusion of vofatamab, 
25 mg/kg, on Day 1 of each 21-day cycle. The vofatamab infusion should be 
administered over 90 (± 15) minutes to well-hydrated subjects. An IV loading dose of 
vofatamab, 25 mg/kg, will be given on approximately Day 8 of Cycle 1 only. If prior 
infusions have been well-tolerated, subsequent doses of vofatamab may be 


Protocol Number: B-701-U21 
CONFIDENTIAL 
Amendment 6 
BioClin Therapeutics, Inc. 
 
31 July 2018 
20 
administered over 30 (± 10) minutes, followed by a 30-minute observation period post 
infusion.  
• Phase 2b Randomized Phase: Subjects in Arm A will receive one IV infusion of 
docetaxel, over approximately 60 minutes, followed by one IV infusion of vofatamab, 
using the MTD identified in Cohort 1 of the Phase 1b, on Day 1 of each 21-day cycle. 
The vofatamab infusion should begin approximately 30 minutes after completion of the 
docetaxel infusion; and the initial dose of vofatamab will be administered over 
90 (± 15) minutes to well-hydrated subjects. An additional IV loading dose of 
vofatamab, using the dose identified in Cohort 1 of the Phase 1b (without docetaxel) 
will be given on approximately Day 8 of Cycle 1 only. If prior infusions have been 
well-tolerated, subsequent doses of vofatamab may be administered over 
30 (± 10) minutes, followed by a 30-minute observation period post infusion.  
 
Control Arm, Dose, and Mode of Administration: 
Placebo will be provided as a sterile liquid formulation in 20-mL single-use vials in 
identical format to vofatamab.  
Subjects in Arm B of Randomized Phase of Phase 2b will receive one IV infusion of 
docetaxel at a dose based on the MTD identified in Cohort 1 of Phase 1b over 
approximately 60 minutes, followed by one IV infusion of placebo on Day 1 of each 
21-day cycle. The placebo infusion should begin approximately 30 minutes after 
completion of the docetaxel infusion, and the initial infusion of placebo will be 
administered over 90 (± 15) minutes to well-hydrated subjects. If prior infusions have been 
well-tolerated, subsequent infusions of placebo may be administered over 30 (± 10) 
minutes, followed by a 30-minute observation period post infusion.  
An additional IV infusion of placebo (without docetaxel) will be given on approximately 
Day 8 of Cycle 1 only. 
Premedication: 
Premedication with a corticosteriod will be administered according to the site’s 
institutional standard. An acceptable regimen may consist of dexamethasone 8 mg orally, 
twice-a-day, for 3 days, beginning one day prior to docetaxel infusion. Other 
premedications, such as anti-emetics or antihistamines, may be prescribed, as needed, 
based on the investigator's assessment. 
Statistical Methods: 
Phase 1b and Phase 2: 
Descriptive statistics will be utilized to present the MTD, safety, and efficacy results for 
the Phase 1b and Phase 2 by cohort. The remaining subsections will focus on Phase 2b 
Monotherapy Expansion and Randomized Phases. 


Protocol Number: B-701-U21 
CONFIDENTIAL 
Amendment 6 
BioClin Therapeutics, Inc. 
 
31 July 2018 
21 
Phase 2b Monotherapy Expansion Phase: 
The primary efficacy outcome measure will be PFS, defined as the time from 
randomization to first occurrence of disease progression (per RECIST v1.1) or death, 
whichever occurs first. If a subject does not experience progressive disease (PD) or death, 
PFS will be censored at the day of the last adequate tumor assessment. PFS will be 
reported by the Investigator at each site and confirmed by the Medical Monitor.  
The analysis of the primary efficacy endpoint of PFS will be based on subjects who 
received at least one dose of vofatamab. The Kaplan-Meier (KM) curves will be presented 
for Monotherapy Expansion with calculation of median time (months) and its 95% 
confidence limits.  
The analysis method for PFS will be utilized for overall survival (OS), the key secondary 
endpoint. One sample log-rank test for the median OS in the vofatamab versus historical 
median OS of 7 months will be performed. 
In addition, best overall response will be summarized. The number and percentage of 
subjects who had confirmed complete response (CR) or partial response (PR) as assessed 
by the investigator using RECIST 1.1 criteria will be provided for subjects who received at 
least one dose of vofatamab. 
Safety data including ATAs, AEs, changes in key laboratory test results, ECGs, and 
changes in vital signs will be summarized for subjects who received at least one dose of 
vofatamab. 
At participating sites, an intensive PK Sub-study for up to 10 subjects in who provided 
separate informed consent (Appendix 8) will be performed. Plasma concentrations of 
vofatamab over time will be summarized using descriptive statistics. PK parameters (e.g., 
Cmax, AUC, t1/2) may be listed and summarized using descriptive statistics.  
Phase 2b Randomized Phase: 
Primary Efficacy Endpoint Analysis: 
The primary efficacy outcome measure will be PFS, defined as the time from 
randomization to first occurrence of disease progression (per RECIST v1.1) or death, 
whichever occurs first. If a subject does not experience progressive disease (PD) or death, 
PFS will be censored at the day of the last adequate tumor assessment. PFS will be 
reported by the Investigator at each site and reviewed by the Medical Monitor.  
The analysis of the primary efficacy endpoint of PFS will be based on the intent-to-treat 
(ITT) population. The Kaplan-Meier (KM) curves will be presented for each treatment arm 
with calcuation of median time (months) and its 95% confidence limits. 
The hypothesis test of the primary efficacy endpoint will be performed using an overall 
two-sided significance level of 0.025. The stratified log-rank test with a covariate to 
control for the stratification factor of visceral metastasis (present versus absent) will be 
performed on the ITT population to test the superiority of Arm A over Arm B.  
A sensitivity analysis will also be performed on the Efficacy Evaluable (EE) analysis set 
(if applicable). 
 


Protocol Number: B-701-U21 
CONFIDENTIAL 
Amendment 6 
BioClin Therapeutics, Inc. 
 
31 July 2018 
22 
Secondary Efficacy Endpoint Analyses: 
To maintain an upper boundary on the overall experiment-wise type I error rate, 
hypothesis testing of the secondary efficacy endpoints on the ITT population will follow a 
closed testing procedure. Inferential comparisons between treatment groups for one or 
more of the following efficacy endpoints, listed in rank order of importance, will be made 
provided the null hypothesis associated with the final analysis of PFS is rejected at the 
statistical significance level of two-sided 0.025.  
Rank order of efficacy endpoints for analyses: 
1. 
PFS (Primary Endpoint) 
2. 
OS (Key Secondary Endpoint) 
3. 
ORR 
Inferential testing of the secondary efficacy endpoints will proceed in a sequential 
step-down manner, provided the null hypothesis associated with the previously tested 
endpoint is rejected at the pre-defined statistical significance level. Otherwise, no further 
inferential testing will be conducted. 
If formal inferential statistical testing is stopped due to the closed testing procedure, 
inferential statistics may be employed for the remaining secondary efficacy endpoints. 
Definitions of Secondary Endpoints: 
• ORR is defined as the percentage of subjects who have baseline measurable disease 
and who achieve a best response of either complete response (CR) or partial response 
(PR) as assessed by the investigator using RECIST 1.1 criteria. Subjects who do not 
achieve a CR or PR will be counted as a non-responder.  
• OS defined as the time from randomization to death from any cause. For subjects who 
are alive at the time of analysis data cutoff, OS time will be censored at the last date 
the subject was known to be alive. Survival time for subjects with no post-baseline 
survival information will be censored on the date of randomization. 
• Median time to response (TTR) defined as the time to the first occurrence of a 
documented response. 
• Duration of objective response, defined as the first occurrence of a documented, 
objective response until the time of relapse or death from any cause. This will be 
calculated only for subjects who had a confirmed overall response of CR or PR. In the 
absence of confirmation of death or progressive disease, duration of response will be 
censored at the last adequate disease assessment date. 
• DCR defined as the percentage of subjects who achieve either CR or PR or stable 
disease (SD), as assessed by the investigator per RECIST v1.1. 
• DCR (90), defined as the absence of disease progression and death 90 days from the 
time of randomization as assessed by the investigator using RECIST v1.1. 


Protocol Number: B-701-U21 
CONFIDENTIAL 
Amendment 6 
BioClin Therapeutics, Inc. 
 
31 July 2018 
23 
• DCR (150), defined as the absence of disease progression and death 150 days from the 
time of randomization as assessed by the investigator using RECIST v1.1. 
• QOL, as assessed by EORTC QLQ-C30 (in Phase 2b: Cohorts 4 and 5 [Monotherapy 
Expansion and Randomized Phase, respectively]) will be scored per standard 
methodology developed for the survey. Results will be compared between treatment 
groups; changes from baseline will also be calculated. Ad hoc analyses of individual 
questions relevant to side effects from each treatment may also be performed. 
The time-to-event (OS, TTR, DOR) variables will be summarized by the method described 
for PFS except that DOR will be based on responders.  
For categorical response variables (i.e., ORR, DCR), the frequency count, percentage, and 
95% confidence intervals will be summarized for subjects randomized to the two 
treatments. The response rates will be compared between the randomized groups via the 
stratified Cochran-Mantel-Haenszel test based on the ITT population.  
Exploratory Endpoints 
The association between FGFR3 mutations or fusions and other biomarkers and efficacy 
and AE outcomes will be explored. 
Plasma concentrations of vofatamab over time will be summarized using descriptive 
statistics. PK parameters (e.g., Cmax, AUC, t1/2) may be listed and summarized using 
descriptive statistics.  
Safety Endpoint Analysis: 
Safety will be assessed through summaries of AEs, changes in key laboratory test results, 
ECGs, and changes in vital signs. The number and percentage of subjects with confirmed 
positive ATA will be summarized descriptively by scheduled time point.All subjects who 
receive any amount of vofatamab or docetaxel will be included in the safety analysis. 
The safety data will be presented by treatment study arm in individual subject listings and 
summary tables. 
Interim Analyses: 
No formal interim analysis is planned for Phase 2b Monotherapy Expansion and 
Randomized Phases. 
Safety Review: 
Safety analyses will be performed by a vofatamab Safety Oversight Committee (SOC) for 
phase 1b, phase 2 and Monotherapy Expansion of phase 2b and by study-specific Data 
Monitoring Committee (DMC) for Randomized Phase of Phase 2b based on guidelines 
outlined in the SOC and DMC Charters. The safety review will include AE as well as 
laboratory and ECG data. The safety assessments during Phase 1b, Phase 2 and 
Monotherapy Expansion of Phase 2b  will be conducted in an open fashion. The safety 
assessments during the Randomized Phase will be conducted in a blinded fashion on 
treatment arm and aggregate data. Unblinding in the Randomized Phase will only occur if 
deemed necessary by the DMC and then only on an individual subject basis. 


Protocol Number: B-701-U21 
CONFIDENTIAL 
Amendment 6 
BioClin Therapeutics, Inc. 
 
31 July 2018 
24 
Sample Size Determination for All Phases 
Phase 2 has two cohorts of 20 subjects each (Cohorts 2 and 3). At the end of Cohort 3 of 
Phase 2 (N = 20), there is approximately 88% power to detect a difference between a 
median PFS of 5.5 months in vofatamab monotherapy arm versus 2.5 months from 
historical data using one sample log-rank test at one-sided alpha level of 0.025 
(Finkelstein, 2003; Woolson, 1981; Lachin, 1986).  
The planned sample size for Phase 2b Monotherapy Expansion (up to 80 subjects) is 
mainly based on the safety requirement, with the power to detect a difference between a 
median OS of 12.0 months in vofatamab monotherapy arm versus 7.0 months from 
historical data being approximately 97% using a one sample log-rank test at one-sided 
alpha level of 0.025.   
The primary efficacy endpoint of the Phase 2b Randomized Phase is designed to compare 
PFS in subjects with UCC who are treated with vofatamab plus docetaxel versus placebo 
plus docetaxel. The planned sample size of approximately 160 subjects (107 treated with 
vofatamab plus docetaxel and 53 treated with placebo plus docetaxel) will provide 99% 
power to detect a difference between a median PFS of 5.5 months in vofatamab plus 
docetaxel arm versus 2.5 months in the placebo plus docetaxel arm (hazard ratio = 0.46) at 
alpha = 0.025 (one-sided). This also assumes a 24-month accrual period, 12-month 
follow-up, 10% of dropout rate within 2 years, and an exponential distribution of PFS 
event times. In addition, this sample size has approximately 97% power to detect a 
difference between a median OS of 15 months in vofatamab plus docetaxel arm versus 
7.0 months in the placebo plus docetaxel arm (hazard ratio = 0.47). 


Protocol Number: B-701-U21 
CONFIDENTIAL 
Amendment 6 
BioClin Therapeutics, Inc. 
 
31 July 2018 
25 
Table 1 
Schedule of Assessments 
 
Screening 
Phases 1b, 2, and 2b 
End of 
Treatment/
ET Visit a,c 
 
Cycle 1 
(Weeks 1 - 3) a,b 
Cycles 2+ 
(until 
progression) a,b 
 
 
 
Days 
-28 to -1 
Day 1 Day 8 Day 15 
Day 1 (= Day 21 
of Previous 
Cycle) 
 
 
Written informed consent d 
X 
 
 
 
 
 
 
Confirm availability and request archival tumor 
tissue e 
X 
 
 
 
 
 
 
FGFR3 central testing e 
X 
 
 
 
 
 
 
Review inclusion/exclusion criteria f 
X 
 
 
 
 
 
 
Medical history and demographics 
X 
 
 
 
 
 
 
Complete physical examination g 
X 
 
 
 
 
 
 
Targeted physical examination g 
 
X 
 
 
X 
X 
 
Height (screening only) and weight 
X 
X 
X 
 
X 
X 
 
Vital signsh 
X 
X 
X 
 
X 
X 
 
ECOG performance status 
X 
X 
 
 
X 
X 
 
Adverse events i,j, 
 
X 
X i 
 
X 
X j  
 
Concomitant medications 
X 
X 
X 
 
X 
X 
 
Tumor assessment k,l 
X k 
 
 
 
X l 
X l 
 
Hematology m 
X m 
X m 
X m 
X m 
X m  
X 
 
Serum chemistry n 
X 
X 
 
 
X 
X 
 
Electrocardiogram o 
X 
X 
 
 
X o 
X 
 
Coagulation (aPTT, PT/INR, fibrinogen) p 
X 
X 
X 
 
X 
X 
 
Urine or Serum pregnancy test q 
X 
X 
 
 
X 
X 
 
HBV and HCV screening r 
X 
 
 
 
 
 
 
Urinalysis s 
X 
X 
 
 
X 
 
 


Protocol Number: B-701-U21 
CONFIDENTIAL 
Amendment 6 
BioClin Therapeutics, Inc. 
 
31 July 2018 
26 
 
Screening 
Phases 1b, 2, and 2b 
End of 
Treatment/
ET Visit a,c 
 
Cycle 1 
(Weeks 1 - 3) a,b 
Cycles 2+ 
(until 
progression) a,b 
 
 
 
Days 
-28 to -1 
Day 1 Day 8 Day 15 
Day 1 (= Day 21 
of Previous 
Cycle) 
 
 
Urine and blood biomarker sampling t 
 
X 
 
 
X 
X 
 
PK u 
 
X 
X 
 
X 
X 
 
ATA v 
 
X 
 
 
X 
X 
 
PK Sub-Study w 
 
X 
X 
X 
X 
X 
 
PROMIS GPH Short Survey x 
X 
 
 
 
X 
X 
 
EORTC QLQ-C30 y 
X 
 
 
 
X 
X 
 
Survival (via visits or telephone contact)  
 
X 
X 
 
X 
X 
X z 
Study drug infusion  
 
X aa 
X aa 
 
X aa 
 
 
aPTT = activated partial thromboplastin time; ATA = anti-vofatamab antibodies; ECOG = Eastern Cooperative Oncology Group; ET = early 
termination; GPH = Global Physical Health; HBV = hepatitis B virus; HCV = hepatitis C virus; IHC = immunohistochemistry; INR = 
international normalized ratio; NGS = Next Generation Sequencing; PK = pharmacokinetics; PT = prothrombin time. 
 
a 
Study visits may occur ± 3 days from the date scheduled if required for logistical/scheduling reasons.  
b 
Local laboratory assessments (i.e., hematology, coagulation, serum chemistry, viral serology, urine or serum pregnancy testing, and 
urinalysis) may be performed within 72 hours preceding study drug administration unless otherwise specified.  
c 
Perform within 30 days after the last infusion of study drug. 
d 
Informed consent form(s) must be signed by the subject before any study-specific procedures are performed. 
e 
For Cohort 1, archival tumor samples must be available for retrospective sequencing of cancer-related genes, including FGFR3, by NGS. 
For Cohorts 2 and 3 of Phase 2 and all subjects in Monotherapy Expansion and Randomized Phase, subjects must be confirmed to have a 
FGFR3 genomic alteration at the time of documentation of advanced disease. Available tissue that was obtained at or after the time the 
subject was found to have muscle invasive disease and is of suitable quality and quantity (as outlined in the Sponsor’s Laboratory 
Instructions) should be used to assess the FGFR3 status by genetic testing. A blood sample to assess the FGFR3 status of circulating tumor 
DNA by genetic sequencing must also be provided (described in Section 6.2.2). In case no archival tissue sample is available or tissue 
testing was not informative, a blood sample to assess the FGFR3 status by circulating tumor DNA (ctDNA) can be submitted and if 


Protocol Number: B-701-U21 
CONFIDENTIAL 
Amendment 6 
BioClin Therapeutics, Inc. 
 
31 July 2018 
27 
positive will be considered adequate for inclusion. For subjects participating in Phase 2b Monotherapy Expansion and Randomized Phase, 
if suitable archival tissue is unavailable and ctDNA is not informative, then a core biopsy of tumor tissue (metastatic or primary from any 
anatomical location except the bone, lung or brain) can be obtained to determine FGFR3 status.  
f 
The inclusion and exclusion criteria are the same for all subjects enrolled in the study, except Cohort 1 of the Phase 1b will enroll subjects 
with UCC who have relapsed after, or are refractory to at least one prior line of chemotherapy while Cohorts 2 and 3 of Phase 2b and 
Phase 2b Monotherapy Expansion and Randomized Phase of Phase 2b will enroll subjects with UCC positive for FGFR3 mutation and/or 
fusion who are ineligible for or who have relapsed after, or are refractory to an immune checkpoint inhibitor and at least one prior line of 
chemotherapy. 
g 
Complete physical exam includes all systems described in the body of the protocol. The targeted physical exam should only include 
systems of most clinical relevance (i.e., cardiovascular, respiratory, and those associated with clinical signs/symptoms). 
h 
Blood pressure (supine or sitting), pulse rate, and temperature. On Cycle 1 Day 1 and Cycle 1 Day 8, vital signs for vofatamab should be 
assessed pre-infusion, every 15 (± 5) minutes during the infusion, at the end of the infusion, and 30 (± 10) minutes, 60 (± 10) minutes, and 
90 (± 10) minutes post-infusion. On subsequent cycles, vital signs for vofatamab should be assessed pre-infusion and as clinically 
indicated and post-infusion. For infusions with docetaxel, vital signs should be assessed per institutional guidelines, or regional label. Vital 
signs also will be measured at the End of Treatment/ET visit. 
i 
Subjects will be monitored for any untoward effects during study drug infusion, for 90 minutes following completion of the infusion on 
Day 1 of Cycle 1, and for 30 minutes in the absence of infusion-related adverse events (AEs) at subsequent infusions. All AEs will be 
followed until resolution, stabilization, or until it has been determined that the study treatment or participation is not the cause.  
j 
Follow-up for AEs will occur for 30 days after the subject’s last dose of study drug or until initiation of another anti-tumor therapy, 
whichever occurs first. 
k 
All evaluable and measurable disease must be documented at screening and re-assessed at each subsequent tumor evaluation. A 
documented standard-of-care tumor assessment performed within 28 days prior to Cycle 1, Day 1 may be used for the screening 
assessment. For subjects with measurable disease, response will be reported by the investigator per Response Evaluation Criteria in Solid 
Tumors Version 1.1 (RECIST v 1.1; see Appendix 3) and reviewed by the Medical Monitor. Screening assessments must include: (1) 
computerized tomography (CT) scans of the chest, abdomen, and pelvis and all known or suspected sites of disease, and (2) brain scan 
(CT or magnetic resonance imaging [MRI]). At the investigator’s discretion, additional methods of assessment of measurable disease per 
RECIST v1.1 may be used in addition to those listed above. For subsequent tumor assessments, a CT scan of the chest, abdomen, and 
pelvis, and all known or suspected sites of disease must be obtained each time. The same imaging methods used at screening must be used 
throughout the study for each subject. 
l 
Perform tumor assessments every 9 weeks ± 1 week and prior to start of next infusion (i.e., every third cycle beginning at the Screening 
visit) until disease progression or lack of tolerability. Additional tumor assessments may be conducted as clinically indicated during the 
study. Results must be reviewed prior to study drug infusion at next cycle and continuation in the study will be based on the tumor 
assessment results. A tumor assessment scan should be performed if the subject is discontinuing the study early. At the End of 
Treatment/ET visit, subjects will be asked to provide an optional metastatic tumor tissue sample (biopsy) at End of Treatment or at 
autopsy. 


Protocol Number: B-701-U21 
CONFIDENTIAL 
Amendment 6 
BioClin Therapeutics, Inc. 
 
31 July 2018 
28 
m 
Includes complete blood count (hemoglobin, hematocrit, red blood cell [RBC] count, white blood cell [WBC] count), platelet count, and 
percent and absolute differential counts (neutrophils, bands, lymphocytes, eosinophils, monocytes, basophils, and other cells). For the 
Phase 1b, Phase 2 and Phase 2b, CBC will be obtained on Day 1 of each cycle and on Day 8 (+/- 2 days) of Cycle 1. For the Phase 1b and 
Phase 2, CBC will also be obtained on Day 15 (+/- 2 days) of Cycle 1. 
n 
Includes sodium, potassium, chloride, bicarbonate, non-fasting glucose, blood urea nitrogen, creatinine, calcium, phosphate, magnesium, 
total and direct bilirubin, total protein, albumin, alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, lactate 
dehydrogenase, and uric acid.  
o 
Subjects should be resting in a supine or sitting position for ≥ 10 minutes prior to electrocardiogram (ECG) collection. One ECG reading 
should be obtained at each of the following time points: Screening; Cycle 5, Day 1 (prior to infusion with study drug); and at the End of 
Treatment visit. ECGs (at least 3 readings) should be obtained at the following time points: Cycle 1, Day 1 (prior to infusion with study 
drug; 30 (± 15) minutes and 2-hours (± 15 minutes) post infusion with study drug) and Cycle 2, Day 1 (prior to infusion with study drug). 
p 
Coagulation assessments (activated partial thromboplastin time [aPTT], prothrombin time [PT]/international normalization ratio [INR], 
and fibrinogen). 
q 
For women of childbearing potential, a urine or serum pregnancy test must be performed at Screening, prior to administration of study 
drug on Day 1 of each cycle, and at the End of Treatment/ET visit.  
r 
Hepatitis B surface antigen, Hepatitis B core antibody, and Hepatitis C antibody (HBcAb) serology required at Screening (also Hepatitis B 
viral deoxyribonucleic acid [DNA] by polymerase chain reaction [PCR] if the subject is HBcAb positive). 
s 
Urinalysis includes macroscopic analysis (specific gravity, pH, protein, glucose, ketones, blood, bilirubin, leukocyte esterase, 
urobilinogen, and nitrite) and microscopic urinalysis (RBCs, WBCs, epithelial cells, casts, crystals, bacteria, and yeast). 
t 
Urine samples for assessment of biomarkers will be collected pre-dose on Cycle 1, Day 1. Samples will be collected within 60 minutes 
following study drug (vofatamab or placebo) infusion on Day 1 of Cycles 2 and 5. Blood for circulating tumor DNA (ctDNA) will be 
collected at the time of progression. Urine will also be collected for assessment of biomarkers at EOT. 
u 
Serum samples for assessment of vofatamab pharmacokinetics (PK) will be drawn within 30 (± 15) minutes after completion of docetaxel 
infusion and before study drug (vofatamab or placebo) infusion and within 30 (± 15) minutes after the end of study drug (vofatamab or 
placebo) infusion on Days 1 and 8 of Cycle 1, Day 1 of Cycles 2, 5, and 10 and once at the End of Treatment/Early Termination (ET) visit.  
v 
Serum samples for assessment of anti-vofatamab antibodies (ATAs) will be drawn prior to study drug (vofatamab or placebo) infusion on 
Day 1 of Cycles 1, 5 and at the End of Treatment/ET visit.  
w 
Pharmacokinetic Sub-study: up to 10 subjects at designated centers in Phase 2b Monotherapy Expansion who provide separate informed 
consent (Appendix 8) will participate in a PK Sub-study and will have intensive PK sample collection (samples obtained before and 30 
minutes post-dosing) performed on Day 1 of Cycles 1, 2, 3, 5, 6, 10, and end of treatment following the initiation of vofatamab dosing. In 
addition, for Cycle 1, samples will be collected on Day 2 and 4, and on Day 8 before and 30 minutes post-dosing.  In Cycle 5, samples will 
be collected on Day 2, Day 8, Day 15, and Day 21. 
. 


Protocol Number: B-701-U21 
CONFIDENTIAL 
Amendment 6 
BioClin Therapeutics, Inc. 
 
31 July 2018 
29 
x 
Administer the PROMIS GPH Short Survey during Phase 1b (cohort 1) and Phase 2 (cohort 2 and cohort 3) at the Screening visit, at the 
end of every third cycle (i.e., end of Cycles 3, 6, 9, and 12; or Week 9 and every 9 weeks thereafter for up to 36 weeks, before pre-
medication and administration of the next dose) and at the End of Treatment/ET visit. 
y 
The EORTC QLQ-C30 instrument is administered during Cohorts 4 and 5 (Monotherapy Expansion and Randomized Phase, respectively) 
of Phase 2b at the Screening visit, at the end of every third cycle (i.e., end of Cycles 3, 6, 9, and 12; or Week 9 and every 9 weeks 
thereafter for up to 36 weeks, before pre-medication and administration of the next dose) and at the End of Treatment/ET visit. 
z 
All subjects will be followed for survival every 3 months via telephone until death or full withdrawal of consent. The End of Study 
survival assessment should be performed via telephone follow-up. 
aa 
Subjects in Cohorts 1 of Phase 1b and Cohort 2 of Phase 2 will receive one intravenous (IV) infusion of docetaxel followed by one IV 
infusion of vofatamab on Day 1 of each 21-day cycle. Subjects in Cohort 3 of Phase 2 and Phase 2b Monotherapy Expansion of Phase 
2b of the study will receive an IV infusion of vofatamab on Day 1 of each 21-day cycle. Subjects in Randomized Phase of Phase 2b of the 
study will receive one IV infusion of docetaxel followed by one IV infusion of study drug (vofatamab or placebo), using the MTD 
identified in Cohort 1 of Phase 1b, on Day 1 of each 21-day cycle. Docetaxel will be administered over approximately 60 minutes. The 
initial infusion of study drug (vofatamab or placebo) should begin approximately 30 minutes after completion of the docetaxel infusion 
and should be administered over 90 (± 15) minutes to well-hydrated subjects. If prior infusions have been well-tolerated, subsequent doses 
of study drug (vofatamab or placebo) may be administered over 30 (± 10) minutes, followed by a 30-minute observation period post 
infusion. An additional IV dose of study drug (vofatamab in Phase 1b, Phase 2, and Monotherapy Expansion of Phase 2b; vofatamab or 
placebo in Randomized Phase will be given on approximately Day 8 of Cycle 1 only. Doses for Cycle 2 and beyond may be given ± 3 
days from the date scheduled if required for logistical/scheduling reasons. Doses may also be delayed up to 21 days for recovery from 
reversible toxicity.  
 


Protocol Number: B-701-U21 
CONFIDENTIAL 
Amendment 6 
BioClin Therapeutics, Inc. 
 
31 July 2018 
30 
GLOSSARY OF TERMS  
Abbreviation/Acronym 
Definition 
ADCC 
antibody-dependent cell-mediated cytotoxicity 
AE 
adverse event 
ALP 
alkaline phosphatase 
ALT 
alanine aminotransferase 
ANOVA 
analysis of variance 
anti-HB-c 
Hepatitis B core antibody 
aPTT 
activated partial thromboplastin time 
AST 
aspartate aminotransferase 
ATA 
anti-vofatamab antibodies 
ATC 
anatomical therapeutic chemical 
AUC 
area under the concentration curve 
BUN 
blood urea nitrogen 
CBC 
complete blood count  
ctDNA 
circulating tumor deoxyribonucleic acid  
CHO 
Chinese hamster ovary 
CL 
Clearance 
CNS 
central nervous system 
CR 
complete response 
CRO 
clinical research organization 
CT 
computerized tomography 
CTCAE 
Common Terminology Criteria for Adverse Events 
DCR 
disease control rate 
DLT 
dose-limiting toxicity 
DMC 
Data Monitoring Committee 
DNA 
deoxyribonucleic acid 
DOR 
duration of objective response 
DVT 
deep vein thrombosis 
ECG 
Electrocardiogram 
ECOG 
Eastern Cooperative Oncology Group 
eCRF 
electronic case report form 
EDC 
electronic data capture 
EE 
efficacy evaluable 
EORTC QLQ-C30 
European Organization for Research and Treatment Quality of Life 
Questionnaire 
ET 
early termination 
EU 
European Union 


Protocol Number: B-701-U21 
CONFIDENTIAL 
Amendment 6 
BioClin Therapeutics, Inc. 
 
31 July 2018 
31 
Abbreviation/Acronym 
Definition 
FDA 
Food and Drug Administration 
FGFR3 
fibroblast growth factor receptor 3 
GCP 
Good Clinical Practice 
GPH 
Global Physical Health 
HBcAb 
Hepatitis C antibody 
HBsAg 
Hepatitis B surface antigen 
HBV 
Hepatitis B virus 
HCV 
Hepatitis C virus 
HEENT 
head, eye, ear, nose, and throat 
HIPAA 
Health Insurance Portability and Accountability Act 
HIV 
human immunodeficiency virus 
ICF 
Informed Consent Form 
ICH 
International Conference on Harmonisation 
Ig 
immunoglobulin  
IgG1 
immunoglobulin G1 
IHC 
Immunohistochemistry 
IRB/EC 
Institutional Review Board/Ethics Committee 
IRR 
infusion-related reaction 
ITT 
intent-to-treat 
IV 
Intravenous 
IVRS/IWRS 
interactive voice/web response system 
MedDRA 
Medical Dictionary for Regulatory Activities 
MMP-1 
matrix metalloproteinase-1 
MRI 
magnetic resonance imaging 
MTD 
maximum tolerated dose 
NCI  
National Cancer Institute 
NGS 
Next Generation Sequencing 
NYHA 
New York Heart Association 
ORR 
objective response rate 
OS 
overall survival 
PCR 
polymerase chain reaction 
PD 
progressive disease 
PFS 
progression-free survival 
PK 
Pharmacokinetic 
pro-MMP-10 
pro-matrix metalloproteinase-10 
PR 
partial response 


Protocol Number: B-701-U21 
CONFIDENTIAL 
Amendment 6 
BioClin Therapeutics, Inc. 
 
31 July 2018 
32 
Abbreviation/Acronym 
Definition 
PS 
performance status 
PT/INR 
prothrombin time/international normalized ratio 
PTT 
partial thromboplastin time 
QOL 
quality of life 
QW 
Weekly 
RECIST v1.1 
Response Evaluation Criteria in Solid Tumors Version 1.1 
RBC 
red blood cell 
SAE 
serious adverse event 
SD 
stable disease 
SDV 
source data verification 
SOC 
Safety Oversight Committee 
TCC 
transitional cell carcinoma 
TTR 
time to response 
UCB 
urothelial cell carcinoma of the bladder 
UCC 
urothelial cell carcinoma 
ULN 
upper limit of normal 
US 
United States 
vofatamab 
formerly referred to as B-701 and MFGR1877S 
WBC 
white blood cell 
WHO 
World Health Organization 
WT 
wild-type 
 


Protocol Number: B-701-U21 
CONFIDENTIAL 
Amendment 6 
BioClin Therapeutics, Inc. 
 
31 July 2018 
33 
1 
INTRODUCTION 
1.1 
Background on Urothelial Cell Carcinoma 
Urothelial cell carcinoma (UCC; also known as transitional cell carcinoma [TCC]) occurs in the 
urinary system (i.e., kidneys, urinary bladder, and accessory organs) and is the most common 
type of bladder cancer, accounting for 90% of all bladder tumors (Eble 2004). It is the fifth most 
common cancer in the United States (US) (Costantini 2011) and fourth most common cancer in 
Europe (Jemal 2011); with an estimated 74,690 new cases and 15,580 deaths occurring in the US 
in 2014 (Cancer.org), and an estimated 136,000 new cases and 49,000 deaths occurring in 
Europe in 2009 (Bellmunt 2009).  
Clinical and pathological studies have identified two variants of urothelial cell carcinoma of the 
bladder (UCB) which arise via distinct mechanisms, a low-grade papillary variant and an 
invasive tumor variant (Wu 2005, Vallot 2011). The low-grade papillary variant accounts for 
80% of all UCBs and arises from urothelial hyperplasia. The five-year survival for this tumor 
type, when treated with surgery and intravesical immunotherapy, is greater than 90% 
(Cancer.org). The invasive tumor variant, which represents 20% of UCBs, has a poor prognosis, 
despite surgery and systemic therapy, with 50% of patients dying from metastasis within two 
years of diagnosis (Cancer.org). Furthermore, the five-year survival for metastatic bladder cancer 
is only 6%, and the median survival ranges from 8 to 15 months (Cancer.org). Therefore, while 
superficial tumors can be treated effectively with transurethral resection and intravesical therapy, 
there is a significant rate of recurrence and overall poor prognosis for patients with muscle 
invasive disease (Grossman 2003). 
1.1.1 
FGFR3 in Bladder Cancer 
The fibroblast growth factor receptor 3 (FGFR3) belongs to a family of structurally related 
tyrosine kinase receptors encoded by four different genes (FGFR1-4). These receptors regulate 
various biological processes, including proliferation, differentiation, migration and apoptosis.  
Recent studies have shown that UCC tumors often have genetic alterations in FGFR3 (Cancer 
Genome Atlas Research Network 2013, Tomlinson 2007a, Gust 2013). Inappropriate FGFR3 
signaling is implicated in the pathogenesis of the majority of muscle invasive UCC tumors with a 
notable percentage (16%−20%) caused by activating FGFR3 mutations or gene fusions, and a 
significant percentage (~50%) overexpressing the receptor (Gomez-Roman 2005, Tomlinson 
2007a, Gust 2013). Preclinical data from several lines of investigation, including short hairpin 
ribonucleic acid knockdown (Tomlinson 2007b, Qing 2009), antibody targeting (Martinez-
Torrecuadrada 2005, Qing 2009), and small molecule inhibition (Lamont 2011) of FGFR3 in 
bladder cancer cell lines, also demonstrate that FGFR3 is essential for UCC cell growth in vitro 
and in vivo.  
Mutations in two mutually exclusive isoforms of FGFR3, FGFR3-IIIb the main form expressed 
in epithelial cells and FGFR3-IIIc the main form expressed in chondrocytes (Murgue 1994, 
Delezoide 1998), have been identified in hematological cancers, multiple myeloma, and 
carcinomas of the bladder and cervix (Chesi 1997, Cappellen 1999, Richelda 1997). The 


Protocol Number: B-701-U21 
CONFIDENTIAL 
Amendment 6 
BioClin Therapeutics, Inc. 
 
31 July 2018 
34 
transforming properties of mutated FGFR3-IIIc, the main FGFR3 isoform expressed in multiple 
myeloma, are well documented (Chesi 2001, Ronchetti 2001). Additional studies have also 
demonstrated the oncogenic role of FGFR3-IIIb-S249C, the most common mutated form of 
FGFR3 in UCC (Bourdin 1999). In preclinical studies, the introduction of FGFR3-IIIb-S249C 
induced transforming properties characteristic of oncogenes, including anchorage-independent 
growth and tumor formation (Bernard-Pierrot 2005). Treatment with an FGFR kinase inhibitor, 
FGFR3 depletion, and siRNA in both the transformed FGFR3-S249c cells and a UCC cell line 
expressing a mutated form of FGFR3-IIIb, reversed the oncogenic properties of both cell lines; 
demonstrating that mutations in FGFR3-IIIb result in the oncogenic transformation of cells and 
are essential for UCC progression (Bernard-Pierrot 2005). More recently, two fusion forms of 
FGFR3, FGFR3- transforming acidic coiled-coil containing protein 3 (TACC3) and 
FGFR3-BAIAPL2, have been identified in bladder cancer and shown to have transformative 
properties (Williams 2013). 
These data demonstrate the potential of FGFR3 as an important therapeutic target in the 
treatment of UCC of the bladder. 
1.2 
Background on Vofatamab 
Vofatamab is a phage-derived, affinity-matured, human monoclonal antibody specific for 
FGFR3. It is based on a human immunoglobulin G1 (IgG1) framework containing heavy chain 
VHIII and light chain VκI subgroup sequences. The recombinant antibody is produced in Chinese 
hamster ovary (CHO) cells and consists of two heavy chains (456 amino acid residues each) and 
two light chains (214 amino acid residues each) with inter- and intra-chain disulfide bonds that 
are typical of IgG1 antibodies. The CH2 domain of each heavy chain also has a single conserved 
glycosylation site at Asn307. The N-linked oligosaccharides of vofatamab are typical of those 
observed on other CHO-derived monoclonal antibodies. 
Vofatamab can be used to target FGFR3-positive tumors via three possible modes of action: 
(1) the blocking of ligand binding, receptor dimerization and activation, and downstream 
receptor signaling, (2) eliciting effector function such as antibody-dependent cell-mediated 
cytotoxicity (ADCC), and/or (3) antagonizing ligand-independent activating mutations 
(Qing 2009). 
1.2.1 
Nonclinical Data with Vofatamab 
In in vivo studies, vofatamab demonstrated binding to FGFR3 from multiple species, including 
mouse, rat, cynomolgus monkey, and human. Vofatamab also inhibited ligand binding to 
FGFR3, prevented receptor−receptor association, blocked receptor dimerization, and blocked 
downstream signaling from both wild-type (WT) and common mutant variants of FGFR3, as 
well as FGFR3-TACC3 fusions linked with bladder cancer. Vofatamab suppressed FGFR3-
mediated cell proliferation and exerted strong anti-tumor activity in mouse xenograft models of 
both bladder carcinoma and t(4;14)-positive multiple myeloma. Anti-tumor activity was due to 
direct inhibition of FGFR3 signaling and/or engagement of ADCC.  


Protocol Number: B-701-U21 
CONFIDENTIAL 
Amendment 6 
BioClin Therapeutics, Inc. 
 
31 July 2018 
35 
Vofatamab was well-tolerated and resulted in no severe toxicities when administered 
intravenously weekly for 8 weeks (total of nine doses) in either rats or cynomolgus monkeys at 
doses up to the maximum feasible dose of 50 mg/kg. Vofatamab-related effects in the 
repeat-dose toxicity study in rats were limited to microscopic findings of minimal to slight focal 
tubular hypospermatogenesis/atrophy in male rats at the recovery necropsy. These observations 
were limited in distribution and severity, and therefore considered unlikely to result in a 
detectable impact on fertility. Vofatamab-related effects that were observed in cynomolgus 
monkeys included increased spleen weight and minimal/moderate splenic lymphoid hyperplasia 
at terminal necropsy. These effects were reversible and not considered adverse.  
Pharmacokinetic (PK) studies of vofatamab in mice, Sprague-Dawley rats, and cynomolgus 
monkeys demonstrated both non-linear and linear PK characteristics, suggesting that the total 
clearance (CL) of vofatamab consists of contributions of a specific (target-mediated) CL 
component and a non-specific CL component, with the specific CL component having a greater 
contribution at lower doses. In repeat-dose toxicology studies in rats and cynomolgus monkeys, 
drug exposure increased proportionally with weekly (qw) intravenous (IV) doses of 5, 15, and 
50 mg/kg, suggesting limited contribution of saturable target-mediated CL to the overall CL at 
these dose levels. Overall, the PK assessment indicates that vofatamab behaves like a typical 
IgG1, with some contribution of target-mediated clearance indicated by higher total CL estimates 
at the lower doses. 
Additional nonclinical study information is provided in the Investigator’s Brochure. 
1.2.2 
Clinical Data with Vofatamab 
As of April 2013, two Phase 1 clinical studies of vofatamab have been completed, 
Study MFG4991g and Study MFG4809g. As of April 2018, an interim analysis of Cohort 1 in 
the Phase 1b of current study has been completed and is provided in Section 1.2.2.3. Summaries 
of the respective studies are provided below and additional study information is provided in the 
Investigator’s Brochure. 
1.2.2.1 
Study MFG4991g (Phase 1 study in Patients with Advanced Solid Tumors) 
Study MFG4991g was an open-label, multicenter, Phase 1 study in 26 subjects with advanced 
solid tumors, of which 10 subjects had UCC. The safety and PK of escalating doses of vofatamab 
were evaluated following IV infusion of vofatamab to subjects once every 28 days (on Day 1 of 
each cycle), with an additional loading dose on Day 8 of Cycle 1 only. Doses of 2, 4, 8, 15, and 
30 mg/kg of vofatamab were evaluated in 26 subjects. The study was terminated early by the 
Sponsor for reasons unrelated to efficacy or safety. All 26 subjects enrolled were in the dose-
escalation stage, and the maximum tolerated dose was not reached. The maximum administered 
dose was 30 mg/kg on a 28-day schedule, and the median number of doses administered for all 
subjects was 3 (range 1-16).  
Overall, vofatamab administered as an IV infusion at doses up to 30 mg/kg on a 28-day schedule 
was well-tolerated in subjects with advanced solid tumors. Two deaths due to disease 
progression were reported, and no deaths due to treatment-related AEs were reported. Only one 


Protocol Number: B-701-U21 
CONFIDENTIAL 
Amendment 6 
BioClin Therapeutics, Inc. 
 
31 July 2018 
36 
dose-limiting toxicity (DLT) was observed in the study; and was reported by one subject in the 
30 mg/kg cohort (Grade 4 thrombocytopenia which occurred on Day 4 of treatment and was 
attributed by the investigator as possibly due to concomitant treatment with levofloxacin).  
The adverse events (AEs) assessed as related to vofatamab and occurring in ≥ 10% of the 
subjects were fatigue (19.2%) and mucosal inflammation (11.5%). Furthermore, the majority of 
vofatamab-related AEs reported were Grade 1 or 2 in severity. Ten (38.5%) subjects experienced 
Grade ≥ 3 AEs, with 1 (3.8%) having Grade 4 thrombocytopenia and 1 (3.8%) having Grade 3 
white blood cell (WBC) count decreased assessed as related to vofatamab. Eleven serious 
adverse events (SAEs) were reported in 8 (30.8%) subjects, with 1 (3.8%) subject experiencing 
one SAE assessed as related to vofatamab. 
Serum exposure of vofatamab was approximately dose-proportional and increased with dose 
across the dose range of 2−30 mg/kg.  
All 26 subjects enrolled in the study had evaluable anti-vofatamab antibodies (ATA) samples 
after treatment, and all tested negative for antibodies to vofatamab. 
A total of 10 subjects (38%) had stable disease (SD) as their best clinical response on study. 
Furthermore, a post-hoc analysis comparing progression-free survival (PFS) of high-dose 
vofatamab (30 mg/kg) vs. low doses of vofatamab (< 30 mg/kg) showed greater PFS in the high-
dose subjects (Figure 1). This finding was most notable in the evaluable UCC subpopulation, 
which had a median PFS of 5.7 months for the high-dose group (n = 5) compared with a median 
PFS of 1.7 months in the low-dose group (n = 3). Two subjects with UCC were not considered 
evaluable and were not included in this analysis. 


Protocol Number: B-701-U21 
CONFIDENTIAL 
Amendment 6 
BioClin Therapeutics, Inc. 
 
31 July 2018 
37 
Figure 1 
Progression-Free Survival in Subjects with UCC (Study MFG4991g) 
 
Note: This data set excludes one subject who received escalating doses of vofatamab (anti-FGFR3), 4 mg/kg up to 
30 mg/kg, and a 2nd subject dosed at 30 mg/kg who died after Day 4 of the study due to disease progression 
^ Subject had a single dose of vofatamab (anti-FGFR3) and dropped out of the study due to thrombocytopenia, 
possibly related to levofloxacin. 
 
1.2.2.2 
Study MFG4809g (Phase 1 Study in Patients with Multiple Myeloma) 
Study MFG4809g was an open-label, multicenter, Phase 1 study in subjects with relapsed or 
refractory t(4;14)-positive multiple myeloma. The safety and PK of escalating doses of 
vofatamab were evaluated following IV infusion of vofatamab to subjects weekly for 3 weeks 
(Days 1, 8, and 15 of a 28-day cycle), followed by a single infusion of the same dose on Day 1 of 
the subsequent cycles. Doses of 1, 2, 4, 8, and 15 mg/kg of vofatamab were evaluated in 14 
subjects. The median number of cycles administered was 1.5 and the median number of doses 
administered was 3.5. The study was terminated early by the Sponsor due to unsatisfactory 
enrollment.  
All subjects had discontinued from the study at the time of study termination for the following 
reasons: 10 (71.4%) subjects due to disease progression, 3 (21.4%) subjects died (including 2 
subjects who died due to disease progression and 1 subject who died due to disease progression 
with Grade 5 intracranial hemorrhage), and 1 (7.1%) subject due to subject/legal guardian 
decision to withdraw. All 14 subjects experienced at least one AE. The most common AEs 
irrespective of study drug attribution were fatigue experienced by 6 (42.9%) subjects; anemia 
and nausea experienced by 4 (28.6%) subjects each; diarrhea, dyspnea, headache, and 
thrombocytopenia experienced by 3 (21.4%) subjects each; and confusional state, cough, 
decreased appetite, hypercalcemia, neutropenia, peripheral edema, platelet count decreased, 
pyrexia, and urinary tract infection experienced by 2 (14.3%) subjects each. A total of 6 subjects 


Protocol Number: B-701-U21 
CONFIDENTIAL 
Amendment 6 
BioClin Therapeutics, Inc. 
 
31 July 2018 
38 
experienced 9 SAEs between Cycle 1 Day 1 and 90 days after the last administration of 
vofatamab, including one SAE of Grade 5 intracranial hemorrhage and one SAE of Grade 2 
pyrexia, which was deemed related to vofatamab. All other SAEs were considered unrelated to 
vofatamab. There were no AEs of special interest, and there were no additional AEs of interest 
identified during the conduct of the study. Furthermore, no events were identified as a DLT and 
the maximum tolerated dose (MTD) was not reached prior to the Sponsor’s decision to stop 
enrollment.  
Given the small sample size, no definitive conclusions regarding anti-tumor activity could be 
drawn. The best overall response achieved was that of SD, which was reported in 7 of 
14 subjects. 
Exposure to vofatamab increased with increasing dose. Increases in exposure were non-dose 
proportional in the lower dose groups of 1 and 2 mg/kg, and approximately dose proportional at 
all other dose groups (i.e., 4, 8, and 15 mg/kg). FGFR3 levels did not appreciably change upon 
vofatamab treatment, regardless of dose. 
1.2.2.3 
Study B-701-U21 (Phase 1/2(b) Study in Patients with Stage IV, Locally 
Advanced or Metastatic Urothelial Cell Carcinoma) 
Interim safety and efficacy data from the Phase 1b Cohort 1 of the current study (Study 
B-701-U21) are available for subjects with locally advanced or metastatic UCC who received 
vofatamab plus docetaxel, which evaluated the maximum tolerated dose of vofatamab using the 
3 + 3 study design described in Section 3.1.1.1. On Day 1 of each 21-day cycle, subjects were 
treated with a combination regimen consisting of an intravenous (IV) infusion of docetaxel (75 
mg/m2) followed by an IV infusion of vofatamab (25 mg/kg). An additional dose of vofatamab 
(25 mg/kg) only was given on approximately Day 8 of Cycle 1 only. Dosing with docetaxel and 
vofatamab continued in each subject until disease progression, unacceptable toxicity, death, or 
study exit, including withdrawal of patient consent or study termination. Of 20 subjects enrolled 
in Cohort 1 of Phase 1b, 19 subjects were treated (1 subject progressed prior to treatment) and 
were included in the interim analysis.  
Overall, vofatamab combined with standard-dose docetaxel was well tolerated. No protocol 
defined dose-limiting toxicities (DLT) were observed. A total of 5 subjects experienced 
15 treatment-related AEs which led to vofatamab dose interruption or modification. A total of 
4 subjects had docetaxel dose reductions and 1 subject discontinued treatment due to AE (due to 
disseminated intravascular coagulation). As of June 2018, 15 subject’s deaths were reported on 
study, including 11 due to disease progression, 2 due to adverse events (AEs) (of disseminated 
intravascular coagulation that was considered possibly related to vofatamab and intracranial 
hemorrhage that was considered unrelated to vofatamab), and 2 due to unknown causes. 
Table 2 presents the June 2018 analysis of the AEs in Cohort 1. All 19 subjects (100.0%) 
experienced at least 1 AE, with 15 subjects (78.9%) experiencing AEs assessed as related to 
vofatamab. The most frequent AEs (≥ 15% of subjects) assessed as related to vofatamab were 
diarrhea (31.6%), fatigue (21.1%), neutrophil count decreased (21.1%), alopecia (15.8%), and 


Protocol Number: B-701-U21 
CONFIDENTIAL 
Amendment 6 
BioClin Therapeutics, Inc. 
 
31 July 2018 
39 
nausea (15.8%). A total of 13 subjects (68.4%) and 11 subjects (57.9%) experienced serious AEs 
and Grade ≥ 3 AEs, respectively.   
Table 2. 
B-701-U21:  Summary of Adverse Events in Cohort 1 
 
Cohort 1 
(N = 19) 
Treatment-Emergent Adverse Events (TEAEs) 
 
Any TEAEs 
10 (100.0) 
Vofatamab-Related TEAEs 
15 (78.9) 
Serious TEAEs 
 
Any Serious TEAEs 
11 (57.9) 
Vofatamab-Related Serious TEAEs 
4 (21.1) 
Grade 3/4/5 TEAEs 
 
Any Grade 3/4/5 TEAEs 
13 (68.4) 
Grade 5 
 
Disseminated intravascular coagulation 
1 (5.3) 
Grade 4 
 
Neutrophil count decreased 
4 (21.1) 
Thrombocytopenia 
1 (5.3) 
Grade 3 
 
Fatigue 
3 (15.8) 
White blood cell count decreased 
3 (15.8) 
Asthenia 
1 (5.3) 
Clostridium difficile infection 
1 (5.3) 
Colitis 
1 (5.3) 
Diarrhea 
1 (5.3) 
Hyponatremia 
1 (5.3) 
Lymphocyte count decreased 
1 (5.3) 
Percentage is calculated using the number of subjects in the column heading as the denominator. 
Treatment-emergent adverse events (TEAEs) are defined as AEs that start on or after the first administration 
of study drug (vofatamab or docetaxel). 
Source: Tables 14.3.1.1 and 14.3.1.14; run date: 25Jun2018; data cut-off date: 22Jun2018 
 
A total of 3 subjects (15.8%) had either complete response (5.3%) or partial response (10.5%) as 
their best clinical response on study. Subjects with FGFR3 mutation or fusions experienced 
prolonged progression-free survival and the median survival was not reached after 20 months of 
follow up. Table 3 presents the disease control rate, progression-free survival, and overall 


Protocol Number: B-701-U21 
CONFIDENTIAL 
Amendment 6 
BioClin Therapeutics, Inc. 
 
31 July 2018 
40 
survival for these subjects overall and for subjects with and without FGFR3 gene mutation or 
fusion. 
Table 3. 
B-701-U21:  Summary of Best Overall Response, Disease Control Rate, 
Progression-Free Survival, and Overall Survival in Cohort 1 
 
Total 
(N = 19) 
Wild Type 
(N = 13) 
FGFR3 Mut/Fus 
(N = 6) 
Best Response of CR or PR 
1 CR, 2 PR 
1 PR 
1 CR, 1 PR 
Median Disease control rate, % (95% 
CI) 
63.2 (39.2, 74.5) 
53.8 (25.1, 80.8) 
83.3 (35.9, 99.6) 
Median Progression-free survival, 
months (95% CI) 
3.25 (1.9, 5.2) 
2.37 (1.6, 3.7) 
6.56 (1.9, 17.3) 
Median Overall survival, months 
(95% CI) 
6.87 (4.01, 11.30) 
5.32 (3.25, 7.3) 
Not Reached at 20 mo 
follow-up 
CR = complete response; PR = partial response 
Bellmunt J ASCO Poster 2018. Data cut-off date: 18April2018 
 


Protocol Number: B-701-U21 
CONFIDENTIAL 
Amendment 6 
BioClin Therapeutics, Inc. 
 
31 July 2018 
41 
2 
OBJECTIVES 
2.1 
Phase 1b (Cohort 1) 
2.1.1 
Primary Objective 
• To determine an acceptable maximum tolerated dose (MTD) of vofatamab plus docetaxel in 
subjects with Stage IV, locally advanced or metastatic UCC who have relapsed after, or are 
refractory to at least one prior line of chemotherapy. 
2.2 
Phase 2 (Cohorts 2 and 3) 
2.2.1 
Primary Objective 
• To evaluate the initial safety and efficacy of vofatamab in combination with docetaxel and 
vofatamab monotherapy in advanced UCC with FGFR3 genomic aberrations. 
2.3 
Phase 2b Monotherapy Expansion and Randomized Phase 
2.3.1 
Phase 2b Monotherapy Expansion Primary Objective 
• To evaluate the efficacy of vofatamab in the treatment of subjects with Stage IV, locally 
advanced or metastatic UCC who have relapsed after, or are refractory to at least one prior 
line of chemotherapy, as measured by progression-free survival (PFS). 
2.3.2 
Secondary Objectives 
• To evaluate overall survival (OS) of vofatamab in the treatment of subjects with UCC. 
• To evaluate the efficacy of vofatamab in the treatment of subjects with UCC as measured by 
objective response rate (ORR), disease control rate (DCR), duration of objective response 
(DOR), time to response (TTR), and quality of life (QOL). 
• To evaluate the safety and tolerability of vofatamab in the treatment of subjects with UCC as 
measured by anti-vofatamab antibodies (ATA), adverse events (AEs), physical examination, 
laboratory, and other clinically relevant results. 
2.3.3 
Exploratory Objective 
• To evaluate the pharmacokinetics (PK) of vofatamab in advanced UCC 
 
2.4 
Phase 2b Randomized Phase 
2.4.1 
Primary Objective 
• To evaluate the efficacy of vofatamab plus docetaxel compared with placebo plus docetaxel 
in the treatment of subjects with Stage IV, locally advanced or metastatic UCC who have 


Protocol Number: B-701-U21 
CONFIDENTIAL 
Amendment 6 
BioClin Therapeutics, Inc. 
 
31 July 2018 
42 
relapsed after, or are refractory to at least one prior line of chemotherapy which has not 
included a taxane, as measured by progression-free survival (PFS). 
2.4.2 
Secondary Objectives 
• To evaluate overall survival (OS) of vofatamab plus docetaxel compared with placebo plus 
docetaxel in the treatment of subjects with UCC. 
• To evaluate the efficacy of vofatamab plus docetaxel compared with placebo plus docetaxel 
in the treatment of subjects with UCC as measured by objective response rate (ORR), disease 
control rate (DCR), duration of objective response (DOR), time to response (TTR), and 
quality of life (QOL). 
• To evaluate the safety and tolerability of vofatamab plus docetaxel compared with placebo 
plus docetaxel in the treatment of subjects with UCC as measured by ATAs, adverse events 
(AEs), physical examination, laboratory, and other clinically relevant results. 
2.4.3 
Exploratory Objectives 
• To study the association between the level of FGFR3 expression, the presence of FGFR3 
mutations or fusions, as well as other potential biomarkers (e.g., genetic alterations in other 
cancer-related genes), in primary tumors or metastases, with efficacy and/or adverse event 
(AE) outcomes. 
• To evaluate the pharmacokinetics (PK) of vofatamab monotherapy and vofatamab in 
combination with docetaxel in advanced UCC. 
 
 


Protocol Number: B-701-U21 
CONFIDENTIAL 
Amendment 6 
BioClin Therapeutics, Inc. 
 
31 July 2018 
43 
3 
STUDY DESIGN 
3.1 
Overall Study Design 
This is a Phase 1/2(b), sequential, dose escalation, open-label and randomized, expansion 
multicenter, efficacy and safety study of vofatamab alone or in combination with docetaxel in 
subjects with Stage IV, locally advanced or metastatic UCC who have relapsed after, or are 
refractory to at least one prior line of chemotherapy.  
This study is divided into 3 phases: Phase 1b (Cohort 1), Phase 2 (Cohorts 2 and 3) and Phase 2b 
Phase 2b Monotherapy Expansion and Randomized Phase). 
3.1.1 
Phase 1b 
The clinical trial will commence with an open-label dose escalation Phase 1b. Phase 1b consists 
of Cohort 1  
• Cohort 1: Approximately 20 subjects with Stage IV, locally advanced or metastatic UCC 
who have relapsed after, or are refractory to at least one prior line of chemotherapy which 
has not included a taxane. All subjects in this cohort will receive both  vofatamab plus 
docetaxel.  
3.1.1.1 
Cohort 1 of the Phase 1b 
Cohort 1 of the study will utilize the following 3 + 3 design: 
Initially, one subject will be enrolled in Cohort 1. On Day 1 of Cycle 1, the initial subject in this 
cohort will be treated with a combination regimen consisting of an IV infusion of docetaxel 
(75 mg/m2) followed by an IV infusion of vofatamab (25 mg/kg). On Day 8 of Cycle 1, the 
subject will be treated with an IV infusion of vofatamab (25 mg/kg) alone. If the subject 
experiences a DLT during the DLT observation period (defined as the first 21-day cycle), then 
additional subjects will be enrolled at the same dose until 6 subjects are enrolled or until ≥ 2 
subjects have experienced DLTs. If no DLT is observed through Day 21, an additional 2 subjects 
will be treated, on different days, with the same regimen. If a DLT is observed in 1 of the 
3 subjects during the DLT observation period, then additional subjects will be enrolled until at 
least 6 subjects are enrolled or until ≥ 2 subjects have experienced DLT (i.e., with docetaxel 75 
mg/m2 and vofatamab 25 mg/kg). If 0 of 3 subjects or ≤ 1 of 6 subjects experience a DLT, 
additional subjects will be enrolled at that dose so that a total of 20 subjects will be treated in 
Cohort 1. If at any time, ≥2 of 6 subjects experience a DLT, the dosing regimen will be modified, 
by either reducing the dose of vofatamab to 20 mg/kg and/or reducing the dose of docetaxel to 
55 mg/m2. The dose modification decision will be made based upon the nature of the DLT, e.g., 
if it is clearly related to one or the other drug, or upon discussion with the participating principal 
investigators (see Section 5.1.2 for details). A new set of 3 to 6 subjects will be enrolled and 
treated with the modified dose of vofatamab and/or docetaxel. If at any time, a dose of 
vofatamab of 20 or 25 mg/kg or a dose of docetaxel of at least 55 mg/m2 are deemed not 
tolerable (i.e., ≥ 2 of 6 subjects at the same dose level who have experienced DLTs), enrollment 
will cease and the study will be stopped until further analysis of the combination regimen can be 


Protocol Number: B-701-U21 
CONFIDENTIAL 
Amendment 6 
BioClin Therapeutics, Inc. 
 
31 July 2018 
44 
performed. Should a subject discontinue dosing with docetaxel at any time during the study, 
dosing with  vofatamab will continue until disease progression, unacceptable toxicity, death, or 
study exit, including withdrawal of patient consent or study termination. 
3.1.2 
Phase 2 
Phase 2 of the study is divided in the following 2 cohorts: 
• Cohort 2: Up to 20 subjects with Stage IV, locally advanced or metastatic UCC positive for 
FGFR3 mutation and/or fusion; who are ineligible for or who have relapsed after, or are 
refractory to an immune checkpoint inhibitor and at least one prior line of chemotherapy 
which has not included a taxane. All subjects in this cohort will receive both vofatamab plus 
docetaxel. 
• Cohort 3: Up to 20 subjects with Stage IV, locally advanced or metastatic UCC positive for 
FGFR3 mutation and/or fusion; who are ineligible for or who have relapsed after, or are 
refractory to an immune checkpoint inhibitor and at least one prior line of chemotherapy. All 
subjects in this cohort will receive vofatamab  only.   
3.1.2.1 
Cohort 2 in Phase 2  
Enrollment in Cohort 2 will commence after the 16th subject is enrolled in Cohort 1 of the Phase 
1b. On Day 1 of each 21-day cycle, subjects in Cohort 2 will be treated with a combination 
regimen consisting of an intravenous (IV) infusion of docetaxel (75 mg/m2) followed by an IV 
infusion of vofatamab (25 mg/kg). An additional dose of vofatamab (25 mg/kg) only will be 
given on approximately Day 8 of Cycle 1 only. Dosing with docetaxel and vofatamab will 
continue in each subject until disease progression, unacceptable toxicity, death, or study exit, 
including withdrawal of patient consent or study termination. Should a subject discontinue 
dosing with docetaxel at any time during the study, dosing with vofatamab will continue until 
disease progression, unacceptable toxicity, death, or study exit, including withdrawal of patient 
consent or study termination. 
3.1.2.2 
Cohort 3 in Phase 2  
Enrollment in Cohort 3 will commence after the 16th subject is enrolled in Cohort 1 of the 
Phase 1b. On Day 1 of each 21-day cycle, subjects in Cohort 3 will receive one IV infusion of 
vofatamab (25 mg/kg). An additional dose of vofatamab (25 mg/kg) will be given on 
approximately Day 8 of Cycle 1 only. Dosing of vofatamab will continue in each subject until 
disease progression, unacceptable toxicity, death, or study exit, including withdrawal of patient 
consent or study termination. 
3.1.3 
Phase 2b 
3.1.3.1 
Phase 2b Monotherapy Expansion 
Enrollment to the Phase 2b Monotherapy Expansion will commence once Phase 2 has completed 
enrollment. The Phase 2b Monotherapy Expansion will enroll up to 80 subjects with Stage IV, 


Protocol Number: B-701-U21 
CONFIDENTIAL 
Amendment 6 
BioClin Therapeutics, Inc. 
 
31 July 2018 
45 
locally advanced or metastatic UCC positive for FGFR3 mutation and/or fusion; who are 
ineligible for or who have relapsed after, or are refractory to an immune checkpoint inhibitor and 
at least one prior line of chemotherapy. (If a checkpoint inhibitor is not an approved or available 
therapy for UCC, then this criterion does not apply).  
On Day 1 of each 21-day cycle, subjects in the Phase 2b Monotherapy Expansion will receive 
one IV infusion of vofatamab (25 mg/kg). An additional dose of vofatamab (25 mg/kg) will be 
given on approximately Day 8 of Cycle 1 only. Dosing of vofatamab will continue in each 
subject until disease progression, unacceptable toxicity, death, or study exit, including 
withdrawal of patient consent or study termination. 
3.1.3.1.1 
Pharmacokinetic Sub-Study 
Up to 10 subjects at designated centers in Phase 2b Monotherapy Expansion (Appendix 8) who 
provide separate informed consent will participate in a PK Sub-study and will have intensive PK 
sample collection (samples obtained before and 30 minutes post-dosing) performed on Day 1 of 
Cycles 1, 2, 3, 5, 6, 10, and end of treatment following the initiation of vofatamab dosing. In 
addition, for Cycle 1, samples will be collected on Day 2 and 4 , and on Day 8 before and 30 
minutes post-dosing. In Cycle 5, samples will be collected on Day 2, Day 8, Day 15, and Day 21. 
3.1.3.2 
Phase 2b Randomized Phase 
Enrollment to Randomized Phase in Phase 2b will commence after a review of the safety and 
efficacy data observed in Cohort 2 of Phase 2. The review will be conducted by the Sponsor and 
the Safety Oversight Committee (SOC) once the last subject in Cohort 2 of Phase 2 has 
completed at least 6 months of follow-up on study, to evaluate the potential safety and efficacy 
benefit of the addition of vofatamab to docetaxel chemotherapy. Subjects with Stage IV, locally 
advanced or metastatic UCC positive for FGFR3 mutation and/or fusion; who are ineligible for 
or who have relapsed after, or are refractory to an immune checkpoint inhibitor and at least one 
prior line of chemotherapy which has not included a taxane will be enrolled. (If a checkpoint 
inhibitor is not an approved or available therapy for UCC, then this criterion does not apply.) 
Subjects will be randomly assigned in a 2:1 ratio to receive therapy with either vofatamab plus 
docetaxel (Arm A, experimental arm) or placebo plus docetaxel (Arm B, control arm). Random 
assignment will be stratified by visceral metastasis (presence vs. absence). 
Arm A (vofatamab plus docetaxel): On Day 1 of each 21-day cycle, subjects will receive one 
IV infusion of docetaxel followed by one IV infusion of vofatamab, using the MTD identified in 
Cohort 1. An additional dose of vofatamab, (without docetaxel; and at the dose identified in 
Cohort 1) will be given on approximately Day 8 of Cycle 1 only. 
Arm B (placebo plus docetaxel): On Day 1 of each 21-day cycle, subjects will receive one IV 
infusion of docetaxel, using the MTD identified in Cohort 1, followed by one IV infusion of 
placebo. An additional dose of placebo (without docetaxel) will be given on approximately Day 
8 of Cycle 1 only. 


Protocol Number: B-701-U21 
CONFIDENTIAL 
Amendment 6 
BioClin Therapeutics, Inc. 
 
31 July 2018 
46 
Crossover from Arm A to Arm B and vice versa will not be allowed. 
Phase 2b Randomized Phase will enroll approximately 160 subjects.  
3.1.4 
Phase 1b, Phase 2, and Phase 2b Assessments 
Clinical response assessments will be performed every 9 weeks ± 1 week (i.e., every third cycle 
beginning at the Screening visit) until disease progression or lack of tolerability. Response 
assessments will be reported by the investigator and reviewed by the Medical Monitor.  
Dosing of vofatamab will continue in each subject until disease progression, unacceptable 
toxicity, death, or study exit, including withdrawal of patient consent or study termination. 
Docetaxel treatment beyond 12 cycles of therapy may be considered at the discretion of the 
treating investigator and Medical Monitor, and after a careful assessment and discussion of risk 
versus benefit with the subject. 
The study design is summarized in Figure 2. 


Protocol Number: B-701-U21 
CONFIDENTIAL 
Amendment 5 
 
BioClin Therapeutics, Inc. 
 
31 July 2018 
47 
Figure 2 
Study Design 
  
 
 


Protocol Number: B-701-U21 
CONFIDENTIAL 
Amendment 6 
 
BioClin Therapeutics, Inc. 
 
31 July 2018 
48 
3.2 
Discussion of Study Design 
3.2.1 
Selection of Dose and Dosing Schedule  
The combination regimen of vofatamab plus docetaxel was selected based on preclinical 
data, which demonstrated that the combination of vofatamab plus a taxane was highly 
effective in suppressing tumor growth in a mouse xenograft model of bladder cancer 
(Figure 3). Similar to previously observed results with gemcitabine, the combination of 
vofatamab plus paclitaxel, at of doses of either 10 mg/kg qw × 2 / 40mg/kg qw × 2 or 
20 mg/kg qw × 4, resulted in greater tumor suppression than either agent alone (Figure 3). 
These data support the clinical testing of vofatamab in combination with a taxane, such as 
docetaxel. 
Figure 3 
Tumor Suppression Following Vofatamab Treatment in a Bladder 
Cancer Xenograft Model (UMUC-1) 
 
 
The dosing regimen of vofatamab at 25 mg/kg every 21 days was selected since it is 
estimated to provide a steady-state area under the concentration curve (AUC) comparable to 


Protocol Number: B-701-U21 
CONFIDENTIAL 
Amendment 6 
 
BioClin Therapeutics, Inc. 
 
31 July 2018 
49 
30 mg/kg every 28 days, a dose and regimen that was administered and found to be generally 
safe and well-tolerated in the completed Phase 1 study in advanced solid tumors. From an 
efficacy perspective, this dose is anticipated to be sufficient based on extrapolation from 
preclinical PK/pharmacodynamic analyses.  
Lower and higher dose levels than 25 mg/kg every 21 days are not tested in this study 
because: 
1. Dose levels lower than 25 mg/kg every 21 days are predicted to provide less efficacy 
based on extrapolation from preclinical PK/pharmacodynamic analyses. Given the 
excellent safety and tolerability of vofatamab at 30 mg/kg every 28 days from the 
solid tumor Phase 1 study, and given the severity of the target disease of advanced, 
relapsed or refractory UCC, the potential benefit-risk of a lower dose level is deemed 
less favorable than 25 mg/kg every 21 days and thus will not tested in this study.  
2. The MTD was not established in the solid tumor Phase 1 study and thus higher doses 
of vofatamab could theoretically be explored. However, dose levels higher than 25 
mg/kg every 21 days would be an extraordinary amount of a monoclonal antibody to 
be administered, and is not likely to provide additional benefit-risk. Thus, a dose level 
higher than 25 mg/kg every 21 days will not be tested in this study.  
Similar to the completed Phase 1 study, to achieve steady state exposure and potential 
clinical benefit as quickly as possible, an additional loading dose of 25 mg/kg of vofatamab 
will be administered on approximately Day 8 of Cycle 1 only. From a safety perspective, the 
loading doses of 25 mg/kg on Days 1 and 8 are slightly lower than the loading doses of 
30 mg/kg on Days 1 and 8 that were administered in the previous Phase 1 advanced solid 
tumor study. 
The following information provides further details: 
• Preclinical studies in mice produced data from which it was estimated that a steady-state 
AUC of 850 day × µg/mL on a weekly basis, or 3400 day × µg/mL with administration 
every 4 weeks was needed for efficacy. Using compartmental PK analysis, it was 
determined that IV administration of 20 mg/kg and 30 mg/kg of vofatamab every 21 days 
are expected to have steady-state AUC of 3529 day × µg/mL and 5293 day × µg/mL, 
respectively. Thus, 25 mg/kg every 21 days is predicted to provide adequate doses for 
efficacy and that lower doses would be inadequate.  
• Results from Study MFG4991g demonstrated the following: 
o Administration of vofatamab across the dose range of 2 to 30 mg/kg every 28-days 
was well-tolerated in subjects with advanced solid tumors. 
o Serum exposure of vofatamab was approximately dose-proportional and increased 
with dose across the dose range of 2−30 mg/kg tested.  
o Six of the 10 subjects who had SD as their best clinical response on study were 
treated with 30 mg/kg vofatamab every 28-days. 


Protocol Number: B-701-U21 
CONFIDENTIAL 
Amendment 6 
 
BioClin Therapeutics, Inc. 
 
31 July 2018 
50 
o Based on a population PK analysis of the data from Study MFG4991g, the post-hoc 
estimate of steady-state AUC for 30 mg/kg every 28-days was 5021 day × µg/mL. 
Studies MFG4991g and MFG4809g had loading doses in Cycle 1. In Study MFG4809g, 
doses were given on Days 1, 8 and 15 of Cycle 1, and then Day 1 of each subsequent 28-day 
cycle. In Study MFG4991g, doses were given on Days 1 and 8 in Cycle 1, and then on Day 1 
of each subsequent 28-day. 
3.2.2 
Selection of Control 
3.2.2.1 
Docetaxel 
To date, several Food and Drug Administration (FDA)-approved second-line therapies for 
the treatment of bladder cancer exist. However, the National Comprehensive Cancer 
Network Guidelines on Bladder Cancer (2014) recommend the use of docetaxel, paclitaxel, 
or gemcitabine as control agents in bladder cancer trials (NCCN 2014). Since gemcitabine is 
typically a first-line treatment, second-line treatment usually consists of a taxane (e.g., 
docetaxel or paclitaxel [Galsky 2005; McCaffrey 1997; Papamichael 1997; Vaughn 1999]). 
In a poll of 11 key opinion leaders, a taxane was the most widely used second-line therapy, 
and a majority favored docetaxel 75 mg/m2 every 21 days over paclitaxel due to a better 
tolerability profile.  
3.2.2.2 
Placebo 
The use of placebo will enable Randomized Phase in Phase 2b of the study to be 
double-blind, which is necessary since the primary endpoint, PFS, may be influenced if 
subjects or investigators are unblinded to the treatment assignment. Knowledge of the 
treatment assignment could: (1) result in different patterns of requests for unscheduled 
computerized tomography (CT) scans, which could bias the PFS results; and (2) result in 
more drop-outs of subjects in the placebo arm, which could also bias PFS results due to 
differential drop-out patterns between the two treatment arms.  
3.2.3 
Selection of Study Population 
This study will be conducted in subjects with Stage IV, locally advanced or metastatic 
relapsed/refractory UCC (Cohort 1) and Stage IV, locally advanced or metastatic UCC 
positive for FGFR3 mutation and/or fusion; who are ineligible for or who have relapsed after, 
or are refractory to an immune checkpoint inhibitor and at least one prior line of 
chemotherapy (Cohorts 2 and 3 of Phase 2, and Phase 2b Monotherapy Expansion and 
Randomized Phase of Phase 2b). 
Preclinical data indicate that antibody targeting of FGFR3 may be a valuable clinical strategy 
in the treatment of UCC. In addition, an analysis of metastatic tumor tissue in UCC subjects 
demonstrates that approximately 74% of subjects with UCC have high FGFR3 expression 
(Du 2011). Results from Study MFG4991g, in subjects with advanced solid tumors, also 
showed that the greatest increase in PFS following treatment with vofatamab, was in subjects 
with UCC (see Section 1.2.2.1). Thus, this population was chosen on the basis of high unmet 


Protocol Number: B-701-U21 
CONFIDENTIAL 
Amendment 6 
 
BioClin Therapeutics, Inc. 
 
31 July 2018 
51 
need, together with preclinical and clinical evidence that vofatamab has promising 
therapeutic potential in this indication.  
3.2.3.1 
Rationale for FGFR3 Expression Criterion 
Because vofatamab is a highly selective agent, targeting the FGFR3 receptor, only those 
subjects who express the target are likely to benefit from treatment. Therefore, subjects in 
Cohort 1 of the Phase 1b will be retrospectively tested using an immunohistochemistry (IHC) 
assay for FGFR3, and only subjects with confirmed FGFR3 mutation and/or fusion will be 
enrolled in Cohorts 2 and 3 of Phase 2 and Phase 2b Monotherapy Expansion and 
Randomized Phase of Phase 2b. Additional analyses will be performed to determine whether 
a threshold level of FGFR3 expression is associated with vofatamab efficacy. 
3.2.4 
Duration of Subject Participation 
Subjects will participate in the study for approximately 36 months, including a 28-day 
screening period, 21-day cycles of treatment, and follow-up to monitor survival. 
3.2.4.1 
Definition of End of Study 
The end of the study (i.e., the last visit) will occur when the last subject completes the End of 
Study visit. 
 


Protocol Number: B-701-U21 
CONFIDENTIAL 
Amendment 6 
 
BioClin Therapeutics, Inc. 
 
31 July 2018 
52 
4 
STUDY POPULATION AND WITHDRAWAL 
4.1 
Inclusion Criteria 
Individuals eligible to participate in this study must meet all of the following criteria listed in 
Sections 4.1.1 through 4.1.3. 
4.1.1 
Disease Specific Inclusion Criteria 
1. Stage IV, locally advanced or metastatic (T4b, any N; or any T, N2-3) urothelial bladder 
cancer or TCC arising in another location of the urinary tract, including urethra, ureter, 
and renal pelvis 
2. Histological or cytological diagnosis of UCC. Mixed histologies are permitted as long as 
TCC is the major component (i.e., > 50% of the pathologic specimen). Pure or 
predominant squamous cell carcinomas or adenocarcinomas are not permitted 
3. Relapsed after or are refractory to at least one prior line of chemotherapy which has not 
included a taxane (with the exception of Cohort 3 of Phase 2 and Phase 2b Monotherapy 
Expansion of Phase 2b which will allow the enrollment of subjects with prior treatment 
with a taxane) 
4. Subjects must have received at least one prior chemotherapeutic regimen (at least one 
cycle each) for advanced or metastatic/recurrent disease, of which at least one regimen 
included a platinum agent. If a platinum agent is contraindicated for a subject (e.g., due to 
pre-existing renal impairment such as creatinine clearance < 60 mL/min, 
myelosuppression, hearing impairment, or history of allergic reaction to 
platinum-containing compounds), the prior regimen(s) need not have included a platinum 
agent. Reason for platinum contraindication will be collected in the eCRFs 
5. Prior neoadjuvant or adjuvant chemotherapy (without a taxane, except Cohort 3 of 
Phase 2 and Phase 2b Monotherapy Expansion, which will allow the enrollment of 
subjects with prior treatment with a taxane) is permitted and will not be counted as first-
line chemotherapy, as long as the subject has not progressed within 12 months of the last 
dose. However, if the patient progressed within 12 months of the last dose of prior 
neoadjuvant or adjuvant chemotherapy, then this regimen of neoadjuvant or adjuvant 
chemotherapy will be counted as first-line chemotherapy  
6. Measurable disease according to Response Evaluation Criteria in Solid Tumors 
Version 1.1 (RECIST v1.1; see Appendix 3). If possible, sites of measurable disease 
should not be within a previously irradiated site. However, if all sites of measurable 
disease have been irradiated, at least one site must have demonstrated growth after 
irradiation 
7. Subjects must be anticipated to have a PFS of at least 4 weeks from the time of 
randomization (i.e., tumor progression per RECIST v1.1 is not anticipated within the first 
4 weeks after randomization) 


Protocol Number: B-701-U21 
CONFIDENTIAL 
Amendment 6 
 
BioClin Therapeutics, Inc. 
 
31 July 2018 
53 
4.1.2 
Phase 2 and Phase 2b Specific Inclusion Criteria 
1. Tumor shown to have at least one of the following FGFR3 mutations: R248C, S249C, 
G370/2C, S371/3C, Y373/5C, G380/82R, F384/6L, K650/2X (X=E,T or M) or 
FGFR3-TACC3 fusion, as shown by tests performed by a CAP or CLIA certified 
laboratory (or equivalent outside of the US) such as Foundation Medicine, Ashion 
Analytics, or Paradigm Diagnostics on samples that were obtained at or after the time 
when the subject was found to have muscle invasive disease or high grade papillary non-
muscle invasive disease. In the absence of pre-existing genetic test results, subjects can 
submit archival tissue (obtained at or after the time subject was found to have muscle 
invasive disease) for genetic testing. When such archival tissue is not immediately 
available, a blood sample may be submitted for initial determination of FGFR3 mutation 
and/or fusion status. In all cases, subsequent to subject enrollment, previous test results 
that were not provided by Foundation Medicine will be verified using archival tissue (if 
not available for Randomized Phase, a core biopsy may be obtained). Blood samples will 
be obtained on Cycle 1 Day 1 to verify results observed in archival tissues or core 
biopsies.  
2. Relapsed after or are refractory to an immune checkpoint inhibitor (such as atezolizumab, 
pembrolizumab, nivolumab, avelumab, or durvalumab). This inclusion criterion does not 
apply if the checkpoint inhibitor is contraindicated. Reason for checkpoint inhibitor 
contraindication will be collected in the eCRFs. If a checkpoint inhibitor is not an 
approved or available therapy for UCC, then this inclusion criterion does not apply. 
4.1.3 
General Inclusion Criteria 
1. Signed informed consent form, including: 
a. Consent to provide tumor tissue and blood samples for genetic testing 
b. Consent to provide metastatic tumor tissue during the study, if available, or at autopsy 
for testing of FGFR3 status, as well as other potential biomarkers 
c. Consent to provide survival information after completion of study drug dosing 
2. For Cohort 1, archival tumor samples must be available for retrospective sequencing 
of cancer-related genes, including FGFR3, by NGS. For Cohorts 2 and 3 of Phase 2 
and all subjects in Phase 2b Monotherapy Expansion and Randomized Phase, subjects 
must be confirmed to have a FGFR3 genomic alteration at the time of documentation 
of advanced disease. Available tissue that was obtained at or after the time the subject 
was found to have muscle invasive disease and is of suitable quality and quantity (as 
outlined in the Sponsor’s Laboratory Instructions) should be used to assess the 
FGFR3 status by genetic testing. A blood sample to assess the FGFR3 status of 
circulating tumor DNA by genetic sequencing must also be provided (described in 
Section 6.2.2). In case no archival tissue sample is available or tissue testing was not 
informative, a blood sample to assess the FGFR3 status by circulating tumor DNA 
(ctDNA) can be submitted and if positive will be considered adequate for inclusion. 
For subjects participating in Phase 2b Monotherapy Expansion and Randomized 
Phase, if suitable archival tissue is unavailable and ctDNA is not informative, then a 


Protocol Number: B-701-U21 
CONFIDENTIAL 
Amendment 6 
 
BioClin Therapeutics, Inc. 
 
31 July 2018 
54 
core biopsy of tumor tissue (metastatic or primary from any anatomical location 
except the bone, lung or brain) can be obtained to determine FGFR3 status.  
3. Age ≥ 18 years (≥ 20 years in Taiwan) 
4. Life expectancy ≥ 12 weeks  
5. Presence of less than 3 of the following 3 poor prognostic factors:   
a. Eastern Cooperative Oncology Group (ECOG) performance status (PS) ≥ 1,  
b. hemoglobin <10 g/dL, and  
c. presence of liver metastasis  
(Note: presence of all 3 poor prognostic factors correlates with rapid progression and a 
median survival of 1.7 months (Bellmunt 2010; see also Figure 1) 
6. ECOG PS of 0 or 1 (see Appendix 1) 
7. Adequate hematologic and end organ function defined by the following laboratory results 
obtained within two weeks prior to the first dose of study treatment: 
a. Absolute neutrophil count ≥ 1500/µL 
b. Platelet count ≥ 100,000/µL 
c. Hemoglobin ≥ 9.0 g/dL without transfusion 
d. Albumin ≥ 2.5 g/dL 
e. Total bilirubin ≤ upper limit of normal (ULN) (without exception, as stated in the 
docetaxel package insert) 
f. Aspartate aminotransferase (AST), alanine aminotransferase (ALT), and alkaline 
phosphatase (ALP) ≤ 2.5 × ULN, with the following exceptions: 
− Subjects with documented bone metastases: ALP ≤ 5 × ULN 
− Note:  Subjects with AST and/or ALT > 1.5 x ULN concomitant with alkaline 
phosphatase > 2.5 x ULN will not be allowed to enroll, regardless of presence 
of liver or bone metastases, as stated in the docetaxel package insert 
g. Creatinine clearance ≥ 30 mL/min on the basis of the Cockroft-Gault glomerular 
filtration rate estimation: 
(140 −𝑎𝑔𝑒) × (𝑤𝑒𝑖𝑔ℎ𝑡 𝑖𝑛 𝑘𝑔) × (0.85 𝑖𝑓 𝑓𝑒𝑚𝑎𝑙𝑒) 
72 × (𝑠𝑒𝑟𝑢𝑚 𝑐𝑟𝑒𝑎𝑡𝑖𝑛𝑖𝑛𝑒 𝑖𝑛 𝑚𝑔/𝑑𝐿)
 
h. Prothrombin time/international normalized ratio (PT/INR) and partial thromboplastin 
time (PTT) must be ≤ 1.5 × ULN 
8. Willingness to avoid pregnancy or fathering children based on the criteria below: 
a. Women of non-childbearing potential (i.e., surgically sterile with a hysterectomy 
and/or bilateral oophorectomy OR chemically sterile OR ≥ 12 months of amenorrhea 
in the absence of chemotherapy, anti-estrogens, or ovarian suppression). Women of 
non-childbearing potential need not undergo pregnancy testing  


Protocol Number: B-701-U21 
CONFIDENTIAL 
Amendment 6 
 
BioClin Therapeutics, Inc. 
 
31 July 2018 
55 
b. Women of childbearing potential who have a negative urine or serum pregnancy test 
at Screening and before the first dose of study drug on Cycle 1, Day 1, and who agree 
to take appropriate precautions to avoid pregnancy (with approximately 99% 
certainty) from Screening through 90 days after the last dose of study drug. Permitted 
methods of contraception that are approximately 99% effective in preventing 
pregnancy are described in Appendix 6, should be communicated to the subject, and 
the subject’s understanding confirmed  
c. Men who agree to take appropriate precautions to avoid fathering children (with at 
least 99% certainty) from Screening through 90 days after the last dose of study drug. 
Permitted methods of contraception that are approximately 99% effective in 
preventing pregnancy are described in Appendix 6, should be communicated to the 
subject, and the subject’s understanding confirmed 
9. Negative urine or serum pregnancy test within 3 days prior to randomization in women of 
childbearing potential 
10. Absence of any psychological, familial, sociological, or geographical condition 
potentially hampering compliance with the study protocol and follow-up schedule (such 
conditions should be discussed with the subject before study entry) 
4.2 
Exclusion Criteria 
Individuals who meet any of the following exclusion criteria will not be eligible to participate 
in the study: 
1. Prior use of any other investigational drug (i.e., monoclonal antibody or experimental 
therapy) within 2 weeks before Cycle 1, Day 1 
2. Palliative radiotherapy within 2 weeks prior to Cycle 1, Day 1 
3. Prior anti-cancer therapy (e.g. biologic or other targeted therapy, chemotherapy or 
hormonal therapy) within 2 weeks prior to Cycle 1, Day 1 
a. A washout of less than 14 days may be allowed after discussion with the Medical 
Monitor, provided that the subject has recovered from any clinically relevant toxicity 
(Exception: participants with neuropathy of Grade 1 will be allowed study entry) 
b. Clinical AEs, except for alopecia, from any previous treatments must have resolved to 
≤ Grade 1 
c. Laboratory AEs from any previous treatments must have resolved to ≤ Grade 1 or to 
within 10% of baseline prior to Cycle 1, Day 1 
4. Prior treatment with an inhibitor that is targeted primarily to FGFRs  
5. History of severe allergic or anaphylactic reactions to monoclonal antibody therapy (or 
recombinant antibody-related fusion proteins) 
6. Inability to be pre-medicated with a corticosteroid when treated with docetaxel 
7. Evidence of significant, uncontrolled concomitant diseases which could affect 
compliance with the protocol or interpretation of results, including significant 
cardiovascular disease (such as New York Heart Association (NYHA) Class III or IV 


Protocol Number: B-701-U21 
CONFIDENTIAL 
Amendment 6 
 
BioClin Therapeutics, Inc. 
 
31 July 2018 
56 
cardiac disease (see Appendix 2), myocardial infarction or stroke within the last 6 
months, unstable arrhythmias, or unstable angina) or pulmonary disease (including 
obstructive pulmonary disease and history of bronchospasm) 
8. History of major bleeding (requiring a blood transfusion ≥ 2 units) not related to a tumor 
within the past 12 months 
9. History of clinically significant coagulation or platelet disorder in the past 12 months  
10. Currently receiving anticoagulation treatment 
11. Incomplete healing from wounds from prior surgery; wound is larger than 2 cm in length 
28 days prior to randomization 
12. Known active bacterial, viral, fungal, mycobacterial, parasitic, or other infection 
(excluding fungal infections of nail beds) at screening. Any major episode of infection 
requiring treatment with IV antibiotics or hospitalization must be resolved (including the 
completion of the course of antibiotics) prior to Cycle 1, Day 1 
13. History of other malignancy which could affect compliance with the protocol or 
interpretation of results 
14. Subjects with a history of curatively treated basal or squamous cell carcinoma of the skin 
or in situ carcinoma of the cervix are allowed 
15. Subjects with a malignancy that has been treated with curative intent will also be allowed 
if the malignancy has been in remission without treatment for ≥ 2 years prior to Cycle 1, 
Day 1 
16. Subjects with localized prostate cancer that has been treated with curative intent will be 
allowed 
17. Presence of positive test results for Hepatitis B (Hepatitis B surface antigen [HBsAg] 
and/or total Hepatitis B core antibody [anti-HB-c]) or Hepatitis C (Hepatitis C virus 
[HCV] antibody serology testing) 
Subjects positive for anti-HB-c are eligible only if polymerase chain reaction (PCR) is 
negative for Hepatitis B viral (HBV) deoxyribonucleic acid (DNA) 
18. Known history of human immunodeficiency virus (HIV) seropositive status 
19. Primary central nervous system (CNS) malignancy, or CNS metastases  
20. Pregnancy (positive pregnancy test), lactation or breastfeeding 
21. Inability to comply with study and follow up procedures 
22. Any other diseases, metabolic dysfunction, physical examination finding, or clinical 
laboratory finding giving reasonable suspicion of a disease or condition that 
contraindicates the use of an investigational drug or that may affect the interpretation of 
the results or render the subject at high risk from treatment complications 


Protocol Number: B-701-U21 
CONFIDENTIAL 
Amendment 6 
 
BioClin Therapeutics, Inc. 
 
31 July 2018 
57 
4.3 
Discontinuation Criteria 
4.3.1 
Subject Discontinuation  
Subjects must be withdrawn from the study if they experience disease progression (defined 
using RECIST v1.1 in Appendix 3). Subjects may continue vofatamab and/or docetaxel 
therapy beyond progression based on the clinical judgement of the investigator that the 
subject is experiencing clinical benefit and with subject re-consent. A written request 
explaining the clinical benefit and patient assent to continuing treatment should be sent to the 
medical monitor with a request for consultation. Following consultation and, if needed, 
discussion with the medical monitor, the subject may continue on treatment as long as they 
are experiencing clinical benefit until the next scheduled evaluation at which time the case 
will need to be re-discussed with the medical monitor team. 
Subjects may discontinue study drug treatment early (i.e., for reasons other than disease 
progression) for reasons such as subject/investigator choice or unacceptable toxicity 
(or DLT). The reasons for early discontinuation of treatment must be documented on the 
appropriate electronic case report form (eCRF). 
Subjects who discontinue study treatment early due to toxicity (or DLT) should continue to 
be followed for resolution or stabilization of toxicity as scheduled. 
Subjects must be withdrawn from the study if they become pregnant. 
The investigator has the right to discontinue a subject from the study for any medical 
condition that the investigator determines may jeopardize the subject’s safety if he or she 
continues in the study, for reasons of noncompliance (e.g., missed doses [≥ 2 doses], visits), 
or if the investigator determines it is in the best interest of the subject. 
The End of Treatment/Early Termination (ET) visit assessments should be performed on 
subjects who prematurely withdraw from the study during the treatment period. Subjects 
should be followed for safety outcomes for 30 days following the subject’s last dose of study 
drug or until the subject receives another anti-cancer therapy, whichever occurs first.  
4.3.1.1 
Subject Replacement 
Subjects who discontinue the study early will not be replaced. 
4.3.2 
Study Discontinuation 
BioClin (hereafter referred to as the “Sponsor”) has the right to terminate this study at any 
time. Reasons for terminating the study may include, but are not limited to, the following: 
• The incidence or severity of AEs in this or other studies indicates a potential health 
hazard to subjects. 
• Subject enrollment is unsatisfactory. 


Protocol Number: B-701-U21 
CONFIDENTIAL 
Amendment 6 
 
BioClin Therapeutics, Inc. 
 
31 July 2018 
58 
• Data recording is inaccurate or incomplete. 


Protocol Number: B-701-U21 
CONFIDENTIAL 
Amendment 6 
 
BioClin Therapeutics, Inc. 
 
31 July 2018 
59 
5 
TREATMENT OF SUBJECTS 
5.1 
Treatment Regimen 
5.1.1 
Premedication 
Premedication with a corticosteroid will be administered according to the site’s institutional 
standard. An acceptable regimen may consist of dexamethasone 8 mg orally, twice-a-day, for 
3 days, beginning one day prior to docetaxel infusion. Other premedications, such as 
anti-emetics or antihistamines, may be prescribed, as needed, based on the investigator's 
assessment.  
5.1.2 
Cohort 1 of Phase 1b 
Initially, one subject will be enrolled in Cohort 1. On Day 1 of Cycle 1, the initial subject in 
this cohort will be treated with a combination regimen consisting of an IV infusion of 
docetaxel (75 mg/m2) followed by an IV infusion of vofatamab (25 mg/kg). On Day 8 of 
Cycle 1, the subject will be treated with an IV infusion of vofatamab (25 mg/kg) alone. If the 
subject experiences a DLT during the DLT observation period (defined as the first 21-day 
cycle), then additional subjects will be enrolled at the same dose until 6 subjects are enrolled 
or until ≥ 2 subjects have experienced DLTs. If no DLT is observed through Day 21, an 
additional 2 subjects will be treated, on different days, with the same regimen. If a DLT is 
observed in 1 of the 3 subjects during the DLT observation period, then additional subjects 
will be enrolled until at least 6 subjects are enrolled or until ≥ 2 subjects have experienced 
DLT (i.e., with docetaxel 75 mg/m2 and vofatamab (25 mg/kg). If 0 of 3 subjects or ≤ 1 of 
6 subjects experience a DLT, additional subjects will be enrolled at that dose so that a total of 
20 subjects will be treated in Cohort 1 of the Phase 1b. If at any time, ≥ 2 subjects experience 
a DLT, the dosing regimen will be modified, by either reducing the dose of vofatamab to 
20 mg/kg and/or reducing the dose of docetaxel to 55 mg/m2. The dose modification decision 
will be made based upon the nature of the DLT, e.g., if it is clearly related (i.e., possibly, 
probably or definitely related) to one or the other drug, or upon discussion with the 
participating principal investigators. Please see Sections 5.1.2.1 and 5.1.6.2.1 for details on 
the nature of DLTs.  
Briefly, if 2 or more of up to 6 subjects had DLTs that were deemed by the investigators to 
be possibly, probably or definitely related to vofatamab and definitely not or unlikely related 
to docetaxel, then only the vofatamab dose level would be reduced while the docetaxel dose 
level would remain unchanged.  
If 2 or more of up to 6 subjects had DLTs that were deemed by the investigators to be 
possibly, probably or definitely related to docetaxel and definitely not related or unlikely 
related to vofatamab, then only the docetaxel dose level would be reduced while the 
vofatamab dose level would remain unchanged.  
If 2 or more of up to 6 subjects had DLTs that were considered by investigators to be 
possibly, probably or definitely related to both vofatamab and docetaxel, then both the 
docetaxel dose level and vofatamab dose levels would be reduced.  


Protocol Number: B-701-U21 
CONFIDENTIAL 
Amendment 6 
 
BioClin Therapeutics, Inc. 
 
31 July 2018 
60 
When DLTs are analyzed by investigators as to relatedness to vofatamab or docetaxel, 
investigators should consider that the following AEs could be considered more likely due to 
docetaxel than vofatamab (anemia, neuropathy, dysgeusia, dyspnea, constipation, nail 
disorders, fluid retention, pain, alopecia, skin reactions, and myalgia). The following AEs 
may be attributed to either docetaxel, vofatamab, or to both, such that, for these AEs, 
modification of the doses for either or both docetaxel and vofatamab should be considered; 
allergic or non-allergic infusion reaction (fever, chills/rigors, nausea, vomiting, pruritus, 
headache, rhinitis, rash, hypotension, hypersensitivity, anaphylaxis, dyspnea, wheezing, 
bronchospasm, tachycardia, reduced oxygen saturation, or respiratory distress), mucositis, 
thrombocytopenia, neutropenia, leukopenia, infections, hypersensitivity, diarrhea, anorexia, 
asthenia/fatigue, flushing, pain and headache. All other AEs not listed in the prior paragraph 
above may also be attributed to either docetaxel, vofatamab, or to both.  
After dose modification, a new set of 3 to 6 subjects will be enrolled and treated with the 
modified dose of vofatamab and/or docetaxel. If at any time, a dose of cofatamab of 20 or 
25 mg/kg or a dose of docetaxel of at least 55 mg/m2 are deemed not tolerable (i.e., 
≥ 2 subjects at the same dose level who have experienced DLTs), enrollment will cease and 
the study will be stopped until further analysis of the combination regimen can be performed. 
Should a subject discontinue dosing with docetaxel at any time during the study, dosing with 
vofatamab will continue until disease progression, unacceptable toxicity, death, or study exit, 
including withdrawal of patient consent or study termination. 
5.1.2.1 
Dose-Limiting Toxicity Evaluation and Follow-Up 
A DLT will be defined as any of the following AEs considered by the investigator to be 
(i.e., possibly, probably or definitely related) related to vofatamab occurring during the DLT 
assessment window (Cohort 1, Days 1−21 of the Phase 1b). All AEs should be considered to 
be possibly, probably or definitely related to vofatamab, unless such a relationship clearly 
can be excluded. All AEs, including DLTs, are to be reported according to instructions in 
Section 8.6.1 and graded according to the NCI CTCAE, v4.0. 
• Grade 3/4 hematologic toxicity deemed to be possibly, probably, or definitely related to 
vofatamab, meeting the following criteria: 
o Grade 4 neutropenia > 5 days in the absence of fever 
o Grade 3 or 4 neutropenia with fever 
o Any Grade 4 thrombocytopenia 
o Grade 3 thrombocytopenia with hemorrhage 
• Grade ≥ 3 non-hematologic, except for the following: 
o Grade 3 nausea or vomiting (in the absence of premedication) that resolves to 
Grade ≤ 1 within 72 hours with appropriate supportive therapy 
o Grade 3 diarrhea that resolves to Grade ≤ 1 within 72 hours with appropriate 
supportive therapy 


Protocol Number: B-701-U21 
CONFIDENTIAL 
Amendment 6 
 
BioClin Therapeutics, Inc. 
 
31 July 2018 
61 
o Grade 3 fatigue that resolves to Grade ≤ 1 within 72 hours with appropriate 
supportive therapy 
• Grade 3 elevation of total bilirubin, hepatic transaminases (ALT or AST), or ALP, with 
the following exceptions: 
o For subjects with Grade 2 hepatic transaminase levels at baseline (≤ 5 × ULN) as a 
result of liver metastases, only a hepatic transaminase level > 10 × ULN 
(NCI CTCAE v4.0 Grade 3 is > 5.0 to 20.0 × ULN) will be considered a DLT 
o For subjects with Grade 2 ALP levels at baseline as a result of liver or bone 
metastases, only an ALP level > 10 × ULN (NCI CTCAE v4.0 Grade 3 is > 5.0 to 
20.0 × ULN) will be considered a DLT 
o Note: Subjects who develop Grade ≥ 3 AST or ALT and Grade ≥ 2 bilirubin elevation 
with ALP ≤ 2 x ULN (i.e. Hy’s Law criteria) will be considered to have DLT, 
irrespective of baseline LFTs 
• Adverse events which prevent the administration of study drug on Cycle 1 Day 8 or 
which delay, by > 2 weeks, administration of study drug on Cycle 1 Day 8 will be 
considered DLT 
If a subject experiences a DLT, he or she will be treated according to clinical practice. 
Vofatamab will be withheld until the toxicity resolves to Grade 1 or baseline or, in the case 
of laboratory abnormalities, returns to Grade 1 or to within 10% of the baseline value within 
21 days.  
5.1.3 
Cohort 2 of Phase 2 
On Day 1 of each 21-day cycle, subjects will receive one IV infusion of docetaxel, 75 mg/m², 
over approximately 60 minutes; followed by one IV infusion of vofatamab, 25 mg/kg. The 
initial dose of vofatamab will be administered 30 minutes after completion of the docetaxel 
infusion and will be administered over 90 (± 15) minutes to well-hydrated subjects. If prior 
infusions have been well-tolerated, subsequent doses of vofatamab may be administered over 
30 (± 10) minutes, followed by a 30-minute observation period post infusion. An additional 
dose of study drug (vofatamab 25 mg/kg) will be given on Day 8 of Cycle 1 only.  
Dosing with docetaxel and vofatamab will continue in each subject until disease progression, 
unacceptable toxicity, death, or study exit, including withdrawal of patient consent or study 
termination. Should a subject discontinue dosing with docetaxel at any time during the study, 
dosing with vofatamab will continue until disease progression, unacceptable toxicity, death, 
or study exit, including withdrawal of patient consent or study termination. The rules for 
continued dosing are provided in Section 5.1.6.1, and dose modification instructions are 
provided in Section 5.1.6.2. Additional drug administration details are provided in the 
Sponsor’s Pharmacy Instructions. 
5.1.4 
Cohort 3 of Phase 2 
On Day 1 of each 21-day cycle, subjects will receive one IV infusion of vofatamab, 
25 mg/kg. The initial dose of vofatamab will be administered over 90 (± 15) minutes to 


Protocol Number: B-701-U21 
CONFIDENTIAL 
Amendment 6 
 
BioClin Therapeutics, Inc. 
 
31 July 2018 
62 
well hydrated subjects. If prior infusions have been well-tolerated, subsequent doses of 
vofatamab may be administered over 30 (± 10) minutes, followed by a 30-minute observation 
period post infusion. An additional dose of study drug (vofatamab 25 mg/kg) will be given 
on Day 8 of Cycle 1 only.  
Dosing of vofatamab will continue in each subject until disease progression, unacceptable 
toxicity, death, or study exit, including withdrawal of patient consent or study termination. 
The rules for continued dosing are provided in Section 5.1.6.1, and dose modification 
instructions are provided in Section 5.1.6.2. Additional drug administration details are 
provided in the Sponsor’s Pharmacy Instructions. 
5.1.5 
Phase 2b Monotherapy Expansion  
On Day 1 of each 21-day cycle, subjects will receive one IV infusion of vofatamab, 
25 mg/kg. The initial dose of vofatamab will be administered over 90 (± 15) minutes to 
well-hydrated subjects. If prior infusions have been well-tolerated, subsequent doses of 
vofatamab may be administered over 30 (± 10) minutes, followed by a 30-minute observation 
period post infusion. An additional dose of study drug (vofatamab 25 mg/kg) will be given 
on Day 8 of Cycle 1 only.  
Dosing of vofatamab will continue in each subject until disease progression, unacceptable 
toxicity, death, or study exit, including withdrawal of patient consent or study termination. 
The rules for continued dosing are provided in Section 5.1.6.1, and dose modification 
instructions are provided in Section 5.1.6.2. Additional drug administration details are 
provided in the Sponsor’s Pharmacy Instructions. 
5.1.6 
Phase 2b Randomized Phase 
On Day 1 of each 21-day cycle, subjects will receive one IV infusion of docetaxel over 
approximately 60 minutes, followed by one IV infusion of study drug (vofatamab in Arm A 
or placebo in Arm B), using the MTD identified in Cohort 1 of the Phase 1b in Section 5.1.2. 
The initial dose of study drug (vofatamab  or placebo) will be administered 30 minutes after 
completion of the docetaxel infusion and will be administered over 90 (± 15) minutes to 
well-hydrated subjects. If prior infusions have been well-tolerated, subsequent doses of study 
drug (vofatamab  or placebo) may be administered over 30 (± 10) minutes, followed by a 
30-minute observation period post infusion. An additional dose of study drug (vofatamab  
25 mg/kg or placebo) will be given on Day 8 of Cycle 1 only.  
 
Dosing will continue in each subject until disease progression, unacceptable toxicity, death, 
or study exit, including withdrawal of patient consent or termination. The rules for continued 
dosing are provided in Section 5.1.6.1, and dose modification instructions are provided in 
Section 5.1.6.2. Additional drug administration details are provided in the Sponsor’s 
Pharmacy Instructions. 


Protocol Number: B-701-U21 
CONFIDENTIAL 
Amendment 6 
 
BioClin Therapeutics, Inc. 
 
31 July 2018 
63 
5.1.6.1 
Guidelines for Continued Dosing  
To be eligible to receive additional infusions of study drug, subjects must meet the following 
criteria for ongoing clinical benefit and acceptable toxicity: 
• Ongoing clinical benefit: Subjects must have no signs or symptoms of progressive 
disease (PD). Subjects will be clinically assessed for disease progression on Day 1 of 
each cycle. Subjects with PD (as defined by RECIST v1.1 in Appendix 3), will be 
ineligible to receive further treatment with study drug.  
• Acceptable toxicity: All study drug–related (i.e., possibly, probably or definitely related) 
AEs from prior infusions must have decreased to Grade 1 or baseline grade on or before 
the day of the next infusion. Exceptions on the basis of ongoing clinical benefit may be 
allowed after a careful assessment and discussion of risk versus benefit with the subject 
by the investigator and approval from the Medical Monitor, with the option of dosing 
study drug (vofatamab or placebo) at the full dose of 25 mg/kg or reducing the dose of 
study drug (vofatamab or placebo) to 20 mg/kg. In addition, delay of therapy due to 
toxicities not attributed to study drug (i.e., definitely not related or unlikely related) may 
not require discontinuation and must be discussed with the Medical Monitor.  
5.1.6.2 
Dose Modification 
The following AEs are more likely to be attributed to docetaxel and not to vofatamab such 
that, for these AEs, modification of the dose of docetaxel and not vofatamab should be 
considered:  anemia, neuropathy, dysgeusia, constipation, nail disorders, fluid retention, 
alopecia, skin reactions, and myalgia.  
The following AEs may be attributed to either docetaxel or vofatamab or both such that, for 
these AEs, modification of the dose of either or both docetaxel and vofatamab should be 
considered:  allergic or non-allergic infusion reaction (fever, chills/rigors, nausea, vomiting, 
pruritus, headache, rhinitis, rash, hypotension, hypersensitivity, anaphylaxis, dyspnea, 
wheezing, bronchospasm, tachycardia, reduced oxygen saturation, or respiratory distress), 
mucositis, thrombocytopenia, neutropenia, leukopenia, infections, hypersensitivity, diarrhea, 
anorexia, asthenia/fatigue, flushing, pain and headache. All other AEs not listed in the prior 
paragraph above may also be attributed to either docetaxel or vofatamab or both.  
There are currently no AEs that are more likely attributed to vofatamab and not docetaxel. 
Subjects will be closely monitored for platelets and coagulation factors including, aPTT, 
PT/INR, and fibrinogen (see Table 1 for the timing of assessments). If either aPTT or 
PT/INR exceeds 1.5 × ULN, all study drug treatment should be held until these factors return 
to baseline levels before redosing. Exceptions may be allowed upon discussion with the 
Sponsor and Investigator. 
5.1.6.2.1 
Vofatamab Dose Modification 
During Cycle 1, if the Day 8 dose is not completed within the 3-day visit window (i.e., by 
Day 11) for toxicity issues, the next dose should be withheld until the Day 21 (Cycle 2, 


Protocol Number: B-701-U21 
CONFIDENTIAL 
Amendment 6 
 
BioClin Therapeutics, Inc. 
 
31 July 2018 
64 
Day 1) administration. Subjects in whom toxicities have not reversed sufficiently by the 
scheduled day of infusion (for Cycle 2 and beyond) may have their dose of study drug 
(vofatamab or placebo) delayed by up to 21 days. If all study drug–related (i.e., possibly, 
probably or definitely related) toxicities have reversed sufficiently and the additional criteria 
described in Section 5.1.6.1 have been met, then the subject may receive the subsequent dose 
of study drug (vofatamab or placebo).  
Subjects who do not fulfill the criteria for dosing after 21 days have elapsed will be 
discontinued from study treatment, will undergo End of Treatment/ET visit assessments, and 
will be followed for safety outcomes for 30 days following the subject’s last dose of study 
drug (vofatamab or placebo) or until the subject receives another anti-cancer therapy, 
whichever occurs first. Exceptions on the basis of ongoing clinical benefit may be allowed 
following a careful assessment and discussion of risk versus benefit with the subject by the 
investigator and approval from the Medical Monitor, with the option of dosing study drug 
(vofatamab or placebo) at the full dose of 25 mg/kg or reducing the dose of study drug 
(vofatamab or placebo) to 20 mg/kg. In addition, delay of therapy because of toxicities not 
attributed to study drug (i.e., definitely not related or unlikely related) may not require 
discontinuation and will be discussed with the Medical Monitor. 
5.1.6.2.2 
Docetaxel Dose Modification 
Subjects who experience either febrile neutropenia, neutrophils < 500 cells/mm3 for more 
than one week, severe or cumulative cutaneous reactions, or other Grade 3/4 
non-hematological toxicities during docetaxel treatment should have study drug (vofatamab 
or placebo) and docetaxel treatment withheld until resolution of the toxicity. Once the 
toxicity resolves, subjects should resume treatment with (vofatamab or placebo) and 
docetaxel according to the site’s institutional standard if the AE is deemed by the investigator 
to be most likely due to docetaxel treatment. An acceptable dose modification regimen is to 
reduce the dose of docetaxel to 55 mg/m2. Subjects who develop Grade 3 peripheral 
neuropathy should have docetaxel treatment discontinued entirely (note: subjects who 
discontinue docetaxel due to lack of tolerability should continue to receive vofatamab as a 
single-agent until disease progression, unacceptable toxicity, death, or study exit, including 
withdrawal of patient consent or study termination). 
5.1.7 
Post-Study Access to Study Drug 
The Sponsor does not have any plans to provide vofatamab or other study interventions to 
subjects after the conclusion of the study or any earlier withdrawal. The Sponsor will 
evaluate the appropriateness of continuing to provide vofatamab to study subjects after 
evaluating the primary efficacy outcome measure and safety data gathered in the study. 
5.2 
Preparation, Administration, and Storage of Study Drug 
Once a subject is enrolled into Randomized Phase of Phase 2b of the study, the pharmacist 
will obtain the randomization number and treatment assignment for the subject from the 
interactive voice/web response system (IVRS/IWRS).  


Protocol Number: B-701-U21 
CONFIDENTIAL 
Amendment 6 
 
BioClin Therapeutics, Inc. 
 
31 July 2018 
65 
Using the IVRS/IWRS treatment assignment, the pharmacist will then prepare and 
reconstitute the study drug as appropriate. The pharmacist will also maintain records for drug 
accountability. 
5.2.1 
Vofatamab 
5.2.1.1 
Preparation and Administration 
Vofatamab is provided as a sterile lyophilized powder and contains no preservatives. After 
reconstitution with sterile water for injection, the drug product is formulated as 10 mg/mL 
vofatamab in 200 mM arginine succinate, 0.02% polysorbate 20, pH 5.5. Phase 2b sterile 
liquid formulation of vofatamab in 20-mL single use vials is currently in development with a 
planned concentration of approximately 50 mg/mL. Details will follow in the IMPD and 
pharmacy manual at time of introduction of this new formulation. 
Compatibility testing has shown that vofatamab as a sterile lyophilized powder is stable 
when diluted to a concentration at or above 3 mg/mL in 0.45% sodium chloride diluent. 
Therefore, delivery will be carried out either with or without dilution of the drug product, 
depending upon the amount of drug administered. When administered undiluted, drug 
product will be delivered using standard medical syringes, and syringe pump or using IV 
bags and pump. When diluted, the drug product will be delivered by dilution in 0.45% 
sodium chloride IV bags with a final vofatamab concentration of 3 mg/mL or higher. In both 
cases, delivery will be carried out with a 0.22 μm in-line filter, on either the syringe-pump 
extension set or the IV infusion set.  
The initial dose of vofatamab will be administered over 90 (± 15) minutes to well-hydrated 
subjects. The infusion may be slowed or interrupted for subjects experiencing 
infusion-associated symptoms. Following the initial dose, subjects will be observed for 
90 minutes for fever, chills, rigors, hypotension, nausea, or other infusion-associated 
symptoms. If prior infusions have been well-tolerated, subsequent doses of vofatamab may 
be administered over 30 (± 10) minutes, followed by a 30-minute observation period 
post-infusion. Additional instructions on study drug preparation and administration are 
provided in the Sponsor’s Pharmacy Instructions. 
5.2.1.2 
Storage 
Vofatamab vials must be refrigerated at 2ºC–8ºC (36ºF-46ºF) upon receipt until use. 
Vofatamab should not be used beyond the expiration date provided by the manufacturer. The 
lyophilized vofatamab vials should be reconstituted with  water for injection the day of use. 
Vial contents should not be frozen or shaken and should be protected from direct sunlight. If 
not diluted immediately, the reconstituted drug may be stored at 2ºC–8ºC (36ºF-46ºF) for 
24 hours. Once diluted using half normal saline (0.5 NS; 0.45% sodium chloride), vofatamab 
solutions may be stored at refrigerated (2-8ºC) for 24 hours or at room temperatures (25ºC 
[77ºF]) for up to 8 hours prior to use, total time at both temperatures not to exceed 24 hours. 
Additional vofatamab dosage, administration, and storage instructions are provided in the 
Sponsor’s Pharmacy Instructions. 


Protocol Number: B-701-U21 
CONFIDENTIAL 
Amendment 6 
 
BioClin Therapeutics, Inc. 
 
31 July 2018 
66 
5.2.1.3 
Precautions 
Mild infusion reactions have been reported with vofatamab in subjects dosed up to 30 mg/kg 
vofatamab. Though these reactions were mild, administration of vofatamab will be 
performed in a setting with access to emergency equipment and staff who are trained to 
monitor and respond to medical emergencies. Subjects will be monitored during and after 
each vofatamab infusion for 90 minutes after the first infusion and for 30 minutes after 
subsequent infusions in the absence of infusion-related AEs. Subjects who experience 
infusion-related symptoms should be managed as directed in Table 4 below. 
Table 4 
Management of Infusion-Related Symptoms (e.g., fever, chills/rigors, 
nausea, vomiting, pruritus, headache, rhinitis, rash, hypotension, 
hypersensitivity, anaphylaxis, dyspnea, wheezing, bronchospasm, 
tachycardia, reduced oxygen saturation, or respiratory distress) 
Infusion-Related Symptoms a 
Guidance 
Grade 1−2 
• 
Slow or hold infusion. 
• 
Give supportive treatment b. 
• 
Upon symptom resolution, may resume infusion rate escalation at the 
investigator’s discretion c. 
Grade 3-4 
• 
Discontinue infusion immediately, treat symptoms aggressively, and do 
not restart drug. 
a 
Refer to National Cancer Institute Common Terminology Criteria for Adverse Events, v4.0, 
for the grading of symptoms. This table does not refer to management of IgE-mediated allergic reactions, 
which should be managed as directed in text following this table. 
b 
Supportive treatment: Subjects should be treated with acetaminophen/paracetamol and an antihistamine 
such as diphenhydramine if they have not been received in the last 4 hours. Intravenous saline may be 
indicated. For bronchospasm, urticaria, or dyspnea, subjects may require antihistamines, oxygen, 
corticosteroids (e.g., 100 mg IV prednisolone or equivalent), and/or bronchodilators. For hypotension, 
subjects may require vasopressors. 
c 
Infusion rate escalation after re-initiation: Upon complete resolution of symptoms, the infusion may be 
resumed at 50% of the rate achieved prior to interruption. In the absence of infusion-related symptoms, the 
rate of infusion may be escalated in increments of 50 mg/hr every 30 minutes. 
 
Subjects who experience vofatamab infusion-related temperature elevations of  38.5C or 
other minor infusion-related symptoms may be treated symptomatically with acetaminophen 
(≥ 500 mg) and/or H1 and H2 histamine-receptor antagonists (e.g., diphenhydramine, 
ranitidine). Serious infusion-related events manifested by dyspnea, hypotension, wheezing, 
bronchospasm, tachycardia, reduced oxygen saturation, or respiratory distress should be 
managed with additional supportive therapies (e.g., supplemental oxygen, 2-agonists, and/or 
corticosteroids) as clinically indicated according to standard clinical practice. Infusion-
related reaction (IRR) prophylaxis with medications (e.g., acetaminophen, antihistamines, 
and/or corticosteroids) may be instituted at any point in the study that it is determined to be 
in the best interest of subjects due to the observation of IRRs in a significant number of 
subjects. 
In the event of a life-threatening infusion-related reaction (which may include pulmonary or 
cardiac events) or immunoglobulin (Ig) E-mediated anaphylactic reaction, vofatamab should 


Protocol Number: B-701-U21 
CONFIDENTIAL 
Amendment 6 
 
BioClin Therapeutics, Inc. 
 
31 July 2018 
67 
be discontinued and no additional vofatamab should be administered. Subjects who 
experience these reactions should receive aggressive symptomatic treatment and should be 
discontinued from study treatment. 
Precautions and procedures for suspected anaphylactic reaction during study drug infusions 
are provided in Appendix 4. Prophylactic administration with acetaminophen and 
antihistamine may be used at investigator discretion. 
5.2.2 
Docetaxel 
Premedication with a corticosteroid will be administered according to the site’s institutional 
standard. An acceptable regimen may consist of dexamethasone 8 mg orally, twice-a-day, for 
3 days, beginning one day prior to docetaxel infusion. Other pre-medications, such as 
anti-emetics or antihistamines, may be prescribed, as needed, based on the investigator's 
assessment.  
Complete preparation, administration, and storage instructions for docetaxel are provided in 
the Sponsor’s Pharmacy Instructions. 
5.2.3 
Placebo 
The placebo will be provided as a sterile liquid formulation in 20-mL single-use vials in 
identical format to vofatamab  
5.3 
Study Drug Accounting 
5.3.1 
Receipt of Drug Supplies 
Upon receipt of the study treatment supplies, an inventory must be performed and a drug 
receipt log filled out and signed by the person accepting the shipment. It is important that the 
designated study staff counts and verifies that the shipment contains all the items noted in the 
shipment inventory. Any damaged or unusable study drug in a given shipment (active drug or 
comparator) will be documented in the study files. The investigator must notify study 
sponsor of any damaged or unusable study treatments that were supplied to the investigator’s 
site. 
5.3.2 
Return or Destruction of Study Drug 
At the end of the study, there will be a final reconciliation of drug shipped, drug consumed, 
and drug remaining. This reconciliation will be logged on the drug reconciliation form, 
signed and dated. Any discrepancies noted will be investigated, resolved, and documented 
prior to return or destruction of unused study drug. Drug returned or destroyed on site during 
the study or at completion of the study, will be documented in the study files. 


Protocol Number: B-701-U21 
CONFIDENTIAL 
Amendment 6 
 
BioClin Therapeutics, Inc. 
 
31 July 2018 
68 
5.4 
Method of Assigning Subjects to Treatment Groups 
5.4.1 
Phase 1b (Cohort 1) 
Subjects will be enrolled into Phase 1b as described in Section 3.1.1 
5.4.2 
Phase 2 (Cohorts 2 and 3) 
Subjects will be enrolled into Phase 2 as described in Section 3.1.2. 
Phase 2b Monotherapy Expansion Subjects will be enrolled into the Phase 2b Monotherapy 
Expansion as described in Section 3.1.3.1. 
5.4.3 
Phase 2b Randomized Phase 
After written informed consent has been obtained and preliminary eligibility has been 
established, the study site will submit documentation supporting eligibility to the Sponsor via 
facsimile or email of a scanned copy, and obtain the Sponsor’s approval to enroll the subject. 
Once the Sponsor reviews and approves the subject for enrollment, the Sponsor will inform 
the site and the pharmacist will obtain the subject’s randomization number and treatment 
assignment from the IVRS/IWRS. 
Subjects will be assigned in a 2:1 ratio to either Arm A or Arm B by IVRS/IWRS, and the 
central randomization schedule will have subjects stratified by visceral metastasis (present 
versus absent). 
5.5 
Blinding of Study Drug 
The subjects and/or legal guardians, Investigators, and all Sponsor personnel and designees 
involved in the conduct of the study will be blinded to the identity of the study infusions 
during the Randomized Phase of Phase 2b. The following precautions will be taken to ensure 
the integrity of the study blind during the Randomized Phase: 
• Treatment will not be unblinded for an individual subject, until all subjects have 
completed the Randomized Phase of the study. By exception, treatment may be unblinded 
for an individual subject in the event of a medical emergency (Section 5.5.1). 
5.5.1 
Unblinding 
The unblinding of an individual subject may only occur in the event of a medical emergency, 
where knowledge of the study drug administered to the subject is essential for medical 
management of the subject. In the event of a medical emergency requiring unblinding, the 
Investigator must notify the Medical Monitor immediately. 
Emergency unblinding will be managed through IVRS/IWRS. If unblinding should occur, 
the reason for the unblinding will be recorded in the eCRF. 
If a subject’s treatment assignment is formally unblinded for any reason, the subject must be 
discontinued from the double-blind treatment period. 


Protocol Number: B-701-U21 
CONFIDENTIAL 
Amendment 6 
 
BioClin Therapeutics, Inc. 
 
31 July 2018 
69 
5.6 
Treatment Compliance 
Subject compliance with treatment is not applicable, since study site personnel will 
administer study drug. 
5.7 
Concomitant and Prohibited Therapies 
5.7.1 
Concomitant Therapy 
Concomitant therapy includes any prescription medications or over-the-counter preparations 
used by a subject between the screening evaluation and the end of study visits. All 
concomitant medications should be reported to the investigator and recorded on the 
appropriate eCRF. 
Subjects who use oral contraceptives, hormone-replacement therapy, or other maintenance 
therapy should continue their use. Concomitant use of hematopoietic growth factors is 
allowed in accordance with instructions provided in the package inserts. 
Patients receiving an anticoagulant at Screening are excluded. However, treatment with an 
anticoagulant(s) is permitted for subjects who are on study and receiving vofatamab, if 
deemed clinically necessary following discussion with the Sponsor and Investigator.  
5.7.2 
Prohibited Therapy 
Use of the following therapies is prohibited during the study: 
• Cytotoxic chemotherapy 
• Radiotherapy (unless for palliative care of solitary lesions) 
• Immunotherapy 
• Hormone therapy (other than contraceptives, hormone-replacement therapy, or megestrol 
acetate) 
• Biologic agents (other than hematopoietic growth factors, which are allowed if clinically 
indicated and used in accordance with instructions provided in the package inserts) 
• Any therapies intended for the treatment of UCC, whether approved by local regulatory 
authorities or investigational 
Subjects who require the use of any of these agents will be discontinued from treatment with 
study drug. See Section 6.1.3 for assessments that are to be performed for subjects who 
discontinue from the study early. 


Protocol Number: B-701-U21 
CONFIDENTIAL 
Amendment 6 
 
BioClin Therapeutics, Inc. 
 
31 July 2018 
70 
6 
STUDY ASSESSMENTS AND PROCEDURES 
The Schedule of Assessments, Screening through End of Study, is presented in Table 1.  
6.1 
Assessments by Study Visit 
6.1.1 
Screening 
The following Screening evaluations will be performed within 28 days preceding Cycle 1, 
Day 1 of Phase 1b, Phase 2, and Phase 2b (defined as the day of the first dose of study drug), 
unless otherwise specified.  
• Written informed consent must be signed before any study-specific procedures are 
performed (described in Section 6.2.1)  
• A separate informed consent form must be signed for subjects in Phase 2b Monotherapy 
Expansion participating in the PK Sub-study (Appendix 8). 
• For Cohort 1, archival tumor samples must be available for retrospective sequencing of 
cancer-related genes, including FGFR3, by NGS. 
• For Cohorts 2 and 3 of Phase 2 and all subjects in Phase 2b Monotherapy Expansion and 
Phase 2b Randomized Phase, subjects must be confirmed to have a FGFR3 genomic 
alteration at the time of documentation of advanced disease. Available tissue that was 
obtained at or after the time the subject was found to have muscle invasive disease and is 
of suitable quality and quantity (as outlined in the Sponsor’s Laboratory Instructions) 
should be used to assess the FGFR3 status by genetic testing. A blood sample to assess 
the FGFR3 status of circulating tumor DNA by genetic sequencing must also be 
provided. (described in Section 6.2.2). In case no archival tissue sample is available or 
tissue testing was not informative, a blood sample to assess the FGFR3 status by 
circulating tumor DNA (ctDNA) can be submitted and if positive will be considered 
adequate for inclusion. For subjects participating in Phase 2b Monotherapy Expansion 
and Phase 2b Randomized Phase, if suitable archival tissue is unavailable and ctDNA is 
not informative, then a core biopsy of tumor tissue (metastatic or primary from any 
anatomical location except the bone, lung or brain) can be obtained to determine FGFR3 
status.  
• Review inclusion/exclusion criteria (described in Section 6.2.3) 
• Medical history and demographics (described in Section 6.2.4) 
• Complete physical examination (described in Section 6.2.5) 
• Height and weight 
• Vital signs (described in Section 6.2.6) 
• ECOG PS 
• Concomitant medications 


Protocol Number: B-701-U21 
CONFIDENTIAL 
Amendment 6 
 
BioClin Therapeutics, Inc. 
 
31 July 2018 
71 
• Tumor assessment: A documented standard-of-care tumor assessment performed within 
28 days prior to Cycle 1, Day 1 may be used for the screening assessment (described in 
Section 6.2.8 and Appendix 3) 
• CT or MRI of the brain 
• Hematology (described in Section 6.2.9.2) 
• Serum chemistry (described in Section 6.2.9.2) 
• ECG (described in Section 6.2.10) 
• Coagulation (i.e., aPTT, PT/INR, fibrinogen)  
• Urine or serum pregnancy test (described in Section 6.2.9.2) 
• HBV and HCV screening (described in Section 6.2.9.2) 
• Urinalysis (described in Section 6.2.9.2) 
• In Cohort 1 (Phase 1b) and Cohorts 2 and 3 (Phase 2): PROMIS Global Physical Health 
(GPH) Short Survey (described in Section 6.2.11 and Appendix 5) 
• In Phase 2b Monotherapy Expansion and Phase 2b Randomized Phase: European 
Organization for Research and Treatment Quality of Life Questionnaire 
(EORTC QLQ-C30; described in Section 6.2.12 and Appendix 7) 
 
6.1.2 
Phase 1b, Phase 2 and Phase 2b (Cycle 1 Through Cycle 12 and Beyond: 
Week 1 Through Week 36 and Beyond) 
All screening evaluations must be completed and reviewed by the Medical Monitor to 
confirm that subjects meet all eligibility criteria and are approved for enrollment before the 
first infusion of study drug. Procedures and assessments are summarized in the Schedule of 
Assessments (Table 1). Study treatment with vofatamab and docetaxel or vofatamab alone 
may continue until disease progression, unacceptable toxicity, death, or study exit, including 
withdrawal of patient consent or study termination. 
All visits should occur on the scheduled days. However, visits may occur ± 3 days from the 
scheduled date, if a change is required for logistical/scheduling reasons. Assessments 
scheduled on the day of study drug administration (Day 1) of each cycle should be performed 
prior to study drug infusion, unless otherwise noted.  
Local laboratory assessments may be performed within 72 hours preceding study drug 
administration on Day 1 of each cycle, unless otherwise specified. Results must be reviewed 
and the review documented prior to study drug administration. 
Up to 10 subjects at designated centers in Phase 2b Monotherapy Expansion (Appendix 8) 
who provide separate informed consent will participate in a PK Sub-study and will have 


Protocol Number: B-701-U21 
CONFIDENTIAL 
Amendment 6 
 
BioClin Therapeutics, Inc. 
 
31 July 2018 
72 
intensive PK sample collection (samples obtained before and 30 minutes post-dosing) 
performed on Day 1 of Cycles 1, 2, 3, 5, 6, 10 and end of treatment following the initiation of 
vofatamab dosing. In addition, for Cycle 1, samples will be collected on Day 2 and 4, and on 
Day 8 before and 30 minutes post-dosing. In Cycle 5, samples will be collected on Day 2, 
Day 8, Day 15, and Day 21.  
6.1.2.1 
Cycle 1, Day 1 
The following assessments should be performed prior to study drug infusion: 
• Targeted physical examination (described in Section 6.2.5) 
• Weight 
• Vital signs (described in Section 6.2.6) 
• ECOG PS 
• Concomitant medications 
• Hematology (described in Section 6.2.9.2) 
• Serum chemistry (described in Section 6.2.9.2) 
• ECGs (described in Section 6.2.10) 
• If the subject enrolled in the study based on genetic testing of solid tumor (archival or 
biopsy), a blood sample for genetic testing of circulating tumor DNA will be obtained to 
verify the results  
• Coagulation (i.e., aPTT, PT/INR, fibrinogen)  
• Urine or serum pregnancy test (described in Section 6.2.9.2) 
• Urinalysis (described in Section 6.2.9.2) 
• Urine biomarker sample collection (described in Section 6.2.9.1) 
• ATA samples will be drawn predose on Day 1 of Cycle 1 (described in Section 6.2.9.1) 
Study drug administration: 
• Subjects should be well-hydrated prior to study drug administration.  
o Subjects in Cohorts 1 (Phase 1b), 2 (Phase 2), and Phase 2b Randomized Phase: 
Subjects will receive one IV infusion of docetaxel, over approximately 60 minutes, 
followed by one IV infusion of study drug (vofatamab for Cohorts 1 and 2 and 
blinded vofatamab [Arm A] or placebo [Arm B] in Phase 2b Randomized Phase. The 
study drug (vofatamab or placebo) IV infusion will begin approximately 30 minutes 
after completion of the docetaxel infusion and will be conducted over 90 (± 15) 


Protocol Number: B-701-U21 
CONFIDENTIAL 
Amendment 6 
 
BioClin Therapeutics, Inc. 
 
31 July 2018 
73 
minutes. Infusions will be followed by a 90-minute observation period (described in 
Section 5.2) 
o Subjects in Cohort 3 (Phase 2) and Phase 2b Monotherapy Expansion: Subjects will 
receive one IV infusion of vofatamab over 90 (± 15) minutes. Infusions will be 
followed by a 90-minute observation period (described in Section 5.2) 
• PK samples for the assessment of vofatamab will be collected within 30 (± 15) minutes 
after completion of docetaxel infusion and before study drug (vofatamab or placebo) 
infusion (described in Section 6.2.9.1).  
• Vital signs should be assessed every 15 (± 5) minutes during the study drug infusion, and 
at the end of the infusion (described in Section 6.2.6) 
• AEs should be collected and recorded while the subject is receiving study drug 
The following assessment(s) should be performed after study drug infusion has been 
completed: 
• ECGs should be collected 30 (± 15) minutes and 2-hours (± 15 minutes) post infusion 
with study drug (described in Section 6.2.10) 
• Vital signs should be assessed every 30 (± 10) minutes for 90 minutes post-infusion 
(described in Section 6.2.6) 
• PK samples for vofatamab will be collected within 30 (± 15) minutes after completion of 
study drug (vofatamab or placebo) infusion (described in Section 6.2.9.1)  
• AEs: Subjects should be monitored for 90 minutes following completion of the infusion 
• Survival  
6.1.2.2 
Cycle 1, Day 8 
The following assessments should be performed prior to study drug infusion: 
• Weight 
• Vital signs (described in Section 6.2.6) 
• Hematology (described in Section 6.2.9.2) 
• Coagulation (i.e., aPTT, PT/INR, fibrinogen)  
• AEs since the previous visit 
• Concomitant medications 


Protocol Number: B-701-U21 
CONFIDENTIAL 
Amendment 6 
 
BioClin Therapeutics, Inc. 
 
31 July 2018 
74 
Study drug administration: 
• Subjects should be well-hydrated prior to study drug administration. Subjects in 
Cohorts 1 to 3, Phase 2b Monotherapy Expansion, and Phase 2b Randomized Phase Arm 
A will receive one IV infusion of vofatamab, 25 mg/kg, over 90 (± 15) minutes. Subjects 
in Phase 2b Randomized Phase Arm B will receive one IV infusion of placebo over 
90 (± 15) minutes. (Note: If the prior study drug (vofatamab or placebo) infusion was 
well-tolerated, the infusion on Day 8 may be administered over 30 [± 10] minutes). 
Infusions will be followed by a 30-minute observation period (described in Section 5.2). 
• PK samples for the assessment of vofatamab will be collected before study drug 
(vofatamab or placebo) infusion (described in Section 6.2.9.1). 
• Vital signs should be assessed every 15 (± 5) minutes during the infusion, and at the end 
of the infusion (described in Section 6.2.6) 
• AEs should be collected and recorded while the subject is receiving study drug 
The following assessment(s) should be performed after study drug infusion has been 
completed: 
• Vital signs should be assessed every 30 (± 10) minutes (described in Section 6.2.6) 
• PK samples will be collected within 30 (± 15) minutes after completion of study drug 
(vofatamab or placebo) infusion (described in Section 6.2.9.1) 
• AEs: Subjects should be monitored for 30 minutes following completion of the infusion 
• Survival  
6.1.2.3 
Cycle 1, Day 15 (Phase 1 and 2 only) 
• CBC (described in Section 6.2.9.2) 
6.1.2.4 
Cycles 2-12 and Beyond, Day1  
Prior tumor assessment results must be reviewed before study drug infusion. Continuation in 
the study will be based on the tumor assessment results. 
The following assessments should be performed prior to study drug infusion: 
• Targeted physical examination (described in Section 6.2.5) 
• Weight 
• Vital signs (described in Section 6.2.6) 
• ECOG PS 
• AEs since the previous visit 


Protocol Number: B-701-U21 
CONFIDENTIAL 
Amendment 6 
 
BioClin Therapeutics, Inc. 
 
31 July 2018 
75 
• Concomitant medications 
• Tumor assessments should be performed every 9 weeks ± 1 week and prior to start of 
next infusion (i.e., every third cycle beginning at the Screening visit; described in 
Section 6.2.8) 
• Hematology (described in Section 6.2.9.2) 
• Serum chemistry (described in Section 6.2.9.2) 
• Coagulation (i.e., aPTT, PT/INR, fibrinogen)  
• Urine or serum pregnancy test (described in Section 6.2.9.2) 
• Urinalysis (described in Section 6.2.9.2) 
• ECG (described in Section 6.2.10) 
• ATA samples will be drawn predose on Day 1 of Cycle 5 only  
• In Cohort 1 (Phase 1b) and Cohorts 2 and 3 (Phase 2): PROMIS GPH Short Survey 
should be performed at the end of every third cycle (i.e., end of Cycles 3, 6, 9, and 12; or 
Week 9 and every 9 weeks thereafter for up to 36 weeks; described in Section 6.2.11) 
• In Phase 2b Monotherapy Expansion and Phase 2b Randomized Phase: the EORTC 
QLQ-C30 instrument should be performed at the end of every third cycle (i.e., end of Cycles 
3, 6, 9, and 12; or Week 9 and every 9 weeks thereafter for up to 36 weeks, described in 
Section 6.2.12). 
Study drug administration: 
• Subjects should be well-hydrated prior to study drug administration.  
o Subjects in Cohort 1 of Phase 1b, Cohort 2 of Phase 2, and all subjects in Phase 2b 
Randomized Phase: Subjects will receive one IV infusion of docetaxel, over 
approximately 60 minutes, followed by one IV infusion of study drug (vofatamab in 
Cohorts 1 and 2 and blinded vofatamab [Arm A] or placebo [Arm B] in Randomized 
Phase) The study drug (vofatamab or placebo) infusion will begin approximately 30 
minutes after completion of the docetaxel infusion and will be conducted over 
90 (± 15) minutes. (Note: If prior study drug (vofatamab or placebo) infusions have 
been well-tolerated, doses of study drug (vofatamab or placebo) during Cycles 2-12 
and beyond may be administered over 30 [± 10 minutes]). Infusions will be followed 
by a 30-minute observation period (described in Section 5.2) 
o Subjects in Cohort 3 of Phase 2 and in Phase 2b Monotherapy Expansion of Phase 2b: 
Subjects will receive one IV infusion of vofatamab. (Note: If prior vofatamab 
infusions have been well-tolerated, doses of vofatamab during Cycles 2-12 and 
beyond may be administered over 30 [± 10 minutes]). Infusions will be followed by a 
30-minute observation period (described in Section 5.2) 


Protocol Number: B-701-U21 
CONFIDENTIAL 
Amendment 6 
 
BioClin Therapeutics, Inc. 
 
31 July 2018 
76 
• PK samples for the assessment of vofatamab will be collected within 30 (±15) minutes 
after completion of docetaxel infusion and before study drug (vofatamab or placebo) 
infusion on Day 1 of Cycles 2, 5, and 10.  
• Vital signs should be assessed every 15 (± 5) minutes during the infusion, and at the end 
of the infusion (described in Section 6.2.6) 
• ECGs should be collected on Day 1 of Cycles 2 and 5 (described in Section 6.2.10) 
• AEs should be collected and recorded while the subject is receiving study drug 
The following assessment(s) should be performed after study drug infusion has been 
completed: 
• Vital signs should be assessed every 30 (± 10) minutes post-infusion (described in 
Section 6.2.6) 
• Urine biomarker sample collection within 60 minutes post-infusion on Day 1 of Cycles 2 
and 5 (described in Section 6.2.9.1) 
• PK samples will be collected within 30 (± 15) minutes after completion of study drug 
(vofatamab or placebo) infusion on Day 1 of Cycles 2, 5 and 10. 
• AEs: Subjects should be monitored for 30 (± 10) minutes following completion of the 
infusion 
• Survival  
6.1.3 
End of Treatment/Early Termination 
Subjects who complete the study or discontinue from the study early will be asked to return 
to the clinic within 30 days after the last study drug infusion for an End of Treatment/ET 
visit. The visit at which response assessment shows progressive disease may be used as the 
End of Treatment/ET visit. 
The following assessments should be performed: 
• Targeted physical examination (described in Section 6.2.5) 
• Weight 
• Vital signs (described in Section 6.2.6) 
• ECOG PS 
• Adverse events  
• Concomitant medications 


Protocol Number: B-701-U21 
CONFIDENTIAL 
Amendment 6 
 
BioClin Therapeutics, Inc. 
 
31 July 2018 
77 
• Tumor assessment; subjects will also be asked to provide an optional metastatic tumor 
tissue sample (biopsy) at End of Treatment or at autopsy (described in Section 6.2.8). 
• Hematology (described in Section 6.2.9.2) 
• Serum chemistry (described in Section 6.2.9.2) 
• ECG (described in Section 6.2.10) 
• Coagulation (i.e., aPTT, PT/INR, fibrinogen)  
• Urine or serum pregnancy test (described in Section 6.2.9.2) 
• Urine biomarker sample collection (described in Section 6.2.9.1) 
• PK (described in Section 6.2.9.1) 
• ATA (described in Section 6.2.9.1) 
• Blood for circulating tumor DNA (ctDNA) will be collected at the time of progression. 
• In Cohort 1 (Phase 1b) and Cohorts 2 and 3 (Phase 2): PROMIS GPH Short Survey 
(described in Section 6.2.11) 
• In Phase 2b Monotherapy Expansion and Phase 2b Randomized Phase: EORTC QLQ-
C30 (described in Section 6.2.12) 
• Survival 
6.1.4 
End of Study 
All subjects will be monitored for survival every 3 months via telephone follow-up from the 
investigator until death or full withdrawal of consent. 
6.2 
Description of Assessments and Procedures 
6.2.1 
Informed Consent 
The potential subject or legal guardian of a potential subject will be given a verbal 
explanation of the study and the procedures involved and will have all questions addressed. 
The subject or legal guardian must sign and date a consent form that has been approved by 
the appropriate Institutional Review Board/Ethic Committee (IRB/EC) before any 
study-specific procedures are initiated. The subject’s or legal guardian will be given a copy 
of the signed and dated informed consent form.  
Informed Consent Forms for subjects who are not subsequently enrolled will be maintained 
at the study site. 
 


Protocol Number: B-701-U21 
CONFIDENTIAL 
Amendment 6 
 
BioClin Therapeutics, Inc. 
 
31 July 2018 
78 
6.2.2 
Archival Tissue Collection 
For Phase 1b (cohort 1), all subjects in this study must consent to submit archival tumor 
tissue. Availability of archival tumor tissue should be confirmed prior to study entry, 
requested from the appropriate institution after study entry, and sent to the appropriate 
laboratory as soon after the administration of the first dose as possible. Archival tissue 
specimens will be analyzed for FGFR3 expression, mutations and FGFR3-TACC3 fusions. 
Testing will be completed after study entry.  
For Cohorts 2 and 3 of Phase 2 and all subjects in Phase 2b Monotherapy Expansion and 
Phase 2b Randomized Phase, subjects must be confirmed to have a FGFR3 genomic 
alteration at the time of documentation of advanced disease. Available tissue that was 
obtained at or after the time the subject was found to have muscle invasive disease and is of 
suitable quality and quantity (as outlined in the Sponsor’s Laboratory Instructions) should be 
used to assess the FGFR3 status by genetic testing. A blood sample to assess the FGFR3 
status of circulating tumor DNA by genetic sequencing must also be provided. (described in 
Section 6.2.2). In case no archival tissue sample is available or tissue testing was not 
informative, a blood sample to assess the FGFR3 status by circulating tumor DNA (ctDNA) 
can be submitted and if positive will be considered adequate for inclusion. For subjects 
participating in Phase 2b Monotherapy Expansion and Phase 2b Randomized Phase, if 
suitable archival tissue is unavailable and ctDNA is not informative, then a core biopsy of 
tumor tissue (metastatic or primary from any anatomical location except the bone, lung or 
brain) can be obtained to determine FGFR3 status. Other exploratory studies (e.g., 
determining whether genetic alterations in FGFR3 or other cancer-related genes that may act 
cooperatively with FGFR3 in promoting tumor growth and invasion are present) may also be 
conducted on these samples by the Sponsor or a central laboratory. 
After analysis, any remaining tissue blocks from archival biopsies will be returned to the 
facility from which they were obtained. 
Detailed instructions will be provided in the Sponsor’s Laboratory Instructions. 
6.2.3 
Subject Eligibility 
During the Screening visit, all subjects will be assessed for eligibility against the inclusion 
and exclusion criteria described in Section 4.1 and Section 4.2. 
6.2.4 
Medical History and Demographics 
Complete medical history will be recorded at the Screening visit. 
6.2.5 
Physical Examination, Height, and Weight 
Complete physical examinations should include the evaluation of head, eye, ear, nose, and 
throat (HEENT), cardiovascular, dermatological, musculoskeletal, respiratory, 
gastrointestinal, and neurological systems.  


Protocol Number: B-701-U21 
CONFIDENTIAL 
Amendment 6 
 
BioClin Therapeutics, Inc. 
 
31 July 2018 
79 
Targeted physical examinations should be limited to systems of primary relevance (i.e., 
cardiovascular, respiratory, those systems associated with symptoms, and any system that 
might be associated with tumor assessment). 
Changes from baseline for all targeted physical examinations should be recorded at each 
subsequent physical examination. New or worsened abnormalities should be recorded as AEs 
if appropriate. 
Height should be measured only at the Screening visit and weight should be measured at the 
Screening visit and on Day 1 of each cycle.  
6.2.6 
Vital Signs 
Vital signs will be measured while the subject is in a supine or sitting position and will 
include measurements of systolic and diastolic blood pressure, pulse rate, and body 
temperature. Ensure the same method for each subject during the study period.  
On Cycle 1 Day 1 and Cycle Day 8, vital signs for vofatamab should be assessed pre-
infusion, every 15 (± 5) minutes during the infusion, at the end of the infusion, and 30 (± 10) 
minutes, 60 (± 10) minutes, and 90 (± 10) minutes post-infusion. On subsequent cycles, vital 
signs for vofatamab should be assessed pre-infusion as clinically indicated, and post infusion. 
For infusions with docetaxel, vital signs should be assessed per institutional guidelines, or 
regional label.  Vital signs also will be measured at the End of Treatment/ET visit. 
6.2.7 
Adverse Events 
Safety assessments will consist of monitoring and recording protocol-defined AEs and SAEs; 
measurement of protocol-specified hematology, clinical chemistry, vital signs, and other 
protocol-specified tests that are deemed critical to the safety evaluation of the study drug. 
Subjects will be monitored for any untoward effects during study drug infusion and for 
90 minutes following completion of the first infusion on Day 1 of Cycle 1, and for 
30 minutes in the absence of infusion-related AEs at subsequent infusions. All AEs will be 
followed until resolution, stabilization, or until it has been determined that the study 
treatment or participation is not the cause. 
Follow-up for AEs will occur for 30 days after the subject’s last dose of study drug or until 
initiation of another anti-tumor therapy, whichever occurs first. 
Safety assessment guidelines are described in Section 8. 
6.2.8 
Tumor and Response Assessments 
For subjects with measurable disease, response will be reported by the investigator per 
RECIST v1.1 (see Appendix 3) and reviewed by the Medical Monitor. 
• All evaluable and measurable disease must be documented at the Screening visit and 
re-assessed every 9 weeks ± 1 week until disease progression or lack of tolerability; and 


Protocol Number: B-701-U21 
CONFIDENTIAL 
Amendment 6 
 
BioClin Therapeutics, Inc. 
 
31 July 2018 
80 
will include the following measures CT scans of the chest, abdomen, and pelvis, and all 
known or suspected sites of disease  
• Brain scan (CT or magnetic resonance imaging [MRI]) (Screening only) 
• Bone scans (CT or MRI), if clinically indicated 
Additional methods of assessment of measurable disease per RECIST v1.1 may be used in 
addition to those listed above. The same imaging methods used at screening must be used 
throughout the study for each subject. Additional tumor assessments may be conducted as 
clinically indicated during the study. Results must be reviewed prior to study drug infusion at 
the next cycle to assess whether a subject is eligible to continue treatment. A tumor 
assessment scan should be performed if the subject is discontinuing the study early. 
At the End of Treatment/ET visit, subjects will be asked to provide any optional metastatic 
tumor tissue samples collected during the study or at autopsy. 
6.2.9 
Laboratory Assessments 
Local laboratory assessments may be performed within 72 hours preceding study drug 
administration on Day 1 of each cycle, unless otherwise specified. Results must be reviewed 
and the review documented prior to study drug administration. 
Instruction manuals and supply kits will be provided for all central laboratory assessments. 
Detailed sample collection instructions will be provided in the Sponsor’s Laboratory 
Instructions. 
6.2.9.1 
Central Laboratory Assessments 
At select sites, samples for biomarkers, anti-vofatamab and PK assays will be collected and 
will be sent to one or more laboratories for analyses. 
• Urine or blood biomarker assessments: Biomarkers will be assessed for all subjects. 
Urine samples will be obtained from all subjects before the administration of study drug 
(vofatamab or placebo) on Day 1 of Cycle 1, after the administration of study drug 
(vofatamab or placebo) on Day 1 of Cycles 2, and 5. Blood for circulating tumor DNA 
(ctDNA) will be collected at the time of progression. Urine will also be collected for 
assessment of biomarkers at EOT. (Table 1). 
Biomarker urine and blood sample collection instructions are described in the Sponsor’s 
Laboratory Instructions. 
• ATA assessments: As expected with any recombinant antibody, vofatamab may elicit an 
immune response and subjects may develop antibodies against vofatamab. Although 
ATAs directed against vofatamab are not expected to result in significant clinical 
consequence, subjects will be monitored for any potential immune response to vofatamab 
in this clinical study. Blood samples from all subjects treated will be obtained prior to 


Protocol Number: B-701-U21 
CONFIDENTIAL 
Amendment 6 
 
BioClin Therapeutics, Inc. 
 
31 July 2018 
81 
study drug (vofatamab or placebo) infusion on Day 1 of Cycles 1, 5 and at the End of 
Treatment/ET Visit.  
Serum samples will be analyzed using a validated assay for the determination of 
antibodies to vofatamab in human serum. Additional details are provided in the Sponsor’s 
Laboratory Instructions. 
• PK assessments: PK will be assessed for vofatamab for all subjects. Blood samples will 
be obtained from all subjects 30 (± 15) minutes before study drug (vofatamab or placebo) 
infusion, and within 30 (± 15) minutes after the end of study drug (vofatamab or placebo) 
infusion on Days 1 and 8 of Cycle 1, Day 1 of Cycles 2, 5, and 10 and once at the End of 
Treatment/ET visit (Table 1).  
Subjects in Phase 2b Monotherapy Expansion of Phase 2b that consented to the optional 
PK Sub-study will have intensive PK sample collection (Appendix 8). 
Serum samples will be analyzed for the quantitative determination of vofatamab in human 
serum. Additional details are provided in the Sponsor’s Laboratory Instructions. 
6.2.9.2 
Local Laboratory Assessments 
Samples for hematology, serum chemistry, pregnancy, and urinalysis will be analyzed at the 
study site’s local laboratory. 
• Hematology: complete blood count (complete blood count [CBC]; including hemoglobin, 
hematocrit, red blood cell [RBC], WBC), platelet count, and percent and absolute 
differential count (neutrophils, bands, lymphocytes, eosinophils, monocytes, basophils, 
and other cells) 
• Coagulation: activated partial thromboplastin time (aPTT), PT/INR, fibrinogen 
• Serum chemistry: sodium, potassium, chloride, bicarbonate, non-fasting glucose, blood 
urea nitrogen (BUN), creatinine, calcium, phosphate, magnesium, total and direct 
bilirubin, total protein, albumin, ALT, AST, ALP, lactate dehydrogenase, and uric acid 
• Viral serology and detection: Hepatitis B (HBsAg and HBcAb; also HBV DNA by PCR 
if the subject is HBcAb positive), HCV antibody at Screening 
• Urine or serum pregnancy test: For women of childbearing potential, a urine or serum 
pregnancy test must be performed at Screening, prior to administration of study drug on 
Day 1 of each cycle, and at the End of Treatment/ET visit.  
• Urinalysis: 
o Macroscopic examination: specific gravity, pH, protein, glucose, ketones, blood, 
bilirubin, leukocyte esterase, urobilinogen, and nitrite 
o Microscopic examination: RBCs, WBCs, epithelial cells, casts, crystals, bacteria, and 
yeast 


Protocol Number: B-701-U21 
CONFIDENTIAL 
Amendment 6 
 
BioClin Therapeutics, Inc. 
 
31 July 2018 
82 
6.2.10 
Electrocardiogram Assessments 
ECG measurements must be obtained from subjects who have been resting in a supine or 
sitting position for at least 10 minutes, either before or after drawing blood samples. One 
ECG reading should be obtained at each of the following time points:  Screening; Cycle 5, 
Day 1 (prior to infusion with study drug); and at the End of Treatment Visit. ECGs (at least 
3 readings) should be obtained at the following time points:  Cycle 1, Day 1 (prior to infusion 
with study drug; 30 (± 15) minutes and 2 hours (± 15 minutes) post infusion with study 
drug); and Cycle 2, Day 1 (prior to infusion with study drug) (described in Section 6.1 and 
Table 1).  
6.2.11 
PROMIS Global Physical Health Short Survey 
 In Cohort 1 (Phase 1b) and Cohorts 2 and 3 (Phase 2), the PROMIS GPH Short Survey is a 
self-administered, 4 question, survey which assesses overall physical health, physical 
function, pain, and fatigue (Hays 2009). The GPH Short Survey will be administered at the 
Screening visit, at the end of every third cycle (i.e., end of Cycles 3, 6, 9, and 12; or Week 9 
and every 9 weeks thereafter for up to 36 weeks, before pre-medication and administration of 
the next dose) and at the End of Treatment/ET visit. The survey is provided in Appendix 5. 
6.2.12 
European Organization for Research and Treatment Quality of Life 
Questionnaire 
In Phase 2b Monotherapy Expansion and Phase 2b Randomized Phase, the EORTC 
QLQ-C30 assesses the quality of life (disease and treatment-related symptoms, physical, 
psychological, and social functioning) of cancer patients using a self-reported questionnaire. 
The EORTC QLQ-C30 will be assessed at the Screening visit, at the end of every third cycle 
(i.e., end of Cycles 3, 6, 9, and 12; or Week 9 and every 9 weeks thereafter for up to 
36 weeks, before pre-medication and administration of the next dose) and at the End of 
Treatment/ET visit. The survey is provided in Appendix 7. 
6.2.13 
Survival 
Upon discontinuation of study treatment, subjects will be followed for overall survival every 
3 months via telephone until death or full withdrawal of consent. 
The End of Study visit assessment should be performed by telephone call. 
6.3 
Appropriateness of Measurements 
The efficacy and safety assessments for this study are standard, widely used, and generally 
recognized as reliable, accurate, and relevant. 


Protocol Number: B-701-U21 
CONFIDENTIAL 
Amendment 6 
 
BioClin Therapeutics, Inc. 
 
31 July 2018 
83 
7 
STATISTICAL PLAN 
This section will outline the planned analysis for this study. Analysis will be done for the 
Phase 1b, Phase 2, Phase 2b Monotherapy Expansion, and Phase 2b Randomized Phase 
separately. 
In general, continuous variables will be summarized by the non-missing sample size (n), 
mean, standard deviation, median, first and third quartiles, minimum, and maximum. 
Categorical variables will be summarized by the n and percentage in each category. 
Complete details of the prospective analyses and procedures for handling missing/spurious 
data handling will be provided in the Statistical Analysis Plan. 
The final analysis will occur once 160 subjects have enrolled in Phase 2b Randomized Phase 
and followed for 12 months. All summaries will be presented by assigned treatment arm. 
7.1 
Sample Size Determination for All Phases 
Phase 2 has two cohorts of 20 subjects each (Cohorts 2 and 3). At the end of Cohort 3 of 
Phase 2 (N = 20), there is approximately 88% power to detect a difference between a median 
PFS of 5.5 months in vofatamab monotherapy arm versus 2.5 months from historical data 
using one sample log-rank test at one-sided alpha level of 0.025 (Finkelstein, 2003; 
Woolson, 1981; Lachin, 1986).  
The planned sample size for Phase 2b Monotherapy Expansion (up to 80 subjects) is mainly 
based on the safety requirement, with the power to detect a difference between a median OS 
of 12.0 months in vofatamab monotherapy arm versus 7.0 months from historical data being 
approximately 97% using a one sample log-rank test at one-sided alpha level of 0.025.   
The primary efficacy endpoint of the Phase 2b Randomized Phase is designed to compare 
PFS in subjects with UCC who are treated with vofatamab plus docetaxel versus placebo plus 
docetaxel. The planned sample size of approximately 160 subjects (107 treated with 
vofatamab plus docetaxel and 53 treated with placebo plus docetaxel) will provide 99% 
power to detect a difference between a median PFS of 5.5 months in vofatamab plus 
docetaxel arm versus 2.5 months in the placebo plus docetaxel arm (hazard ratio = 0.46) at 
alpha = 0.025 (one-sided). This also assumes a 24-month accrual period, 12-month 
follow-up, 10% of dropout rate within 2 years, and an exponential distribution of PFS event 
times. In addition, this sample size has approximately 97% power to detect a difference 
between a median OS of 15 months in vofatamab plus docetaxel arm versus 7.0 months in 
the placebo plus docetaxel arm (hazard ratio = 0.47). 
7.2 
Phase 1b and Phase 2  
Descriptive statistics will be utilized to present the MTD, safety, and efficacy results for 
Cohort 1 (Phase 1b) and Cohorts 2 and 3 (Phase 2), as appropriate. The remaining 
subsections will focus on Phase 2b Monotherapy Expansion and Phase 2b Randomized 
Phase.  


Protocol Number: B-701-U21 
CONFIDENTIAL 
Amendment 6 
 
BioClin Therapeutics, Inc. 
 
31 July 2018 
84 
7.3 
Phase 2b Monotherapy Expansion  
Disposition, demographic, and baseline characteristics will be summarized with descriptive 
statistics, including sample size, mean, median, standard deviation, and range for continuous 
variables and frequency counts and percentages for categorical data.   
The primary efficacy outcome measure will be PFS, defined as the time from randomization 
to first occurrence of disease progression (per RECIST v1.1) or death, whichever occurs first. 
If a subject does not experience progressive disease (PD) or death, PFS will be censored at 
the day of the last adequate tumor assessment. PFS will be reported by the Investigator at 
each site and reviewed by the Medical Monitor. 
The analysis of the primary efficacy endpoint of PFS will be based on subjects who received 
at least 1 dose of vofatamab. The Kaplan-Meier (KM) curves will be presented with 
calculation of median time (months) and its 95% confidence limits. One sample log-rank test 
for the median PFS in the vofatamab versus historical median PFS of 2.5 months will be 
performed. 
The analysis method for PFS will be repeated for overall survival (OS), the key secondary 
endpoint. One sample log-rank test for the median OS in the vofatamab versus historical 
median OS of 7 months will be performed. 
In addition, best overall response will be summarized. The number and percentage of 
subjects who had confirmed complete response (CR) or partial response (PR) as assessed by 
the investigator using RECIST 1.1 criteria will be provided for subjects who received at least 
1 dose of vofatamab. 
Safety data including ATAs, AEs, changes in key laboratory test results, ECGs, and changes 
in vital signs will be summarized for subjects who received at least 1 dose of vofatamab. 
7.3.1 
Pharmacokinetic Sub-Study  
For PK, plasma concentrations of vofatamab over time will be summarized using descriptive 
statistics. PK parameters (e.g., Cmax, AUC, t1/2) may be listed and summarized using 
descriptive statistics. Details of an integrated population PK analysis will be provided in the 
PK reporting and analysis plan. 
7.4 
Phase 2b Randomized Phase 
7.5 
Efficacy Analysis 
7.5.1 
Primary Efficacy Endpoint 
The primary efficacy outcome measure will be PFS, defined as the time from randomization 
to first occurrence of disease progression (per RECIST v1.1) or death, whichever occurs first. 
If a subject does not experience PD or death, PFS will be censored at the day of the last 
adequate tumor assessment. PFS will be reported by the investigator and reviewed by the 
Medical Monitor.  


Protocol Number: B-701-U21 
CONFIDENTIAL 
Amendment 6 
 
BioClin Therapeutics, Inc. 
 
31 July 2018 
85 
The analysis of the primary efficacy endpoint of PFS will be based on the ITT population.  
PFS will be summarized with hazard ratios, Kaplan-Meier (KM) curves, KM proportions at 
select time points, KM quartiles (when estimable), the number of subjects with events, the 
number of subjects censored, and the pattern of censoring. Point estimates for efficacy 
endpoints will be accompanied by 2-sided 95% confidence intervals including estimates of 
KM quartiles (Brookmeyer and Crowley, 1982), KM proportions 
(Kalbfleisch and Prentice, 1980), and binomial proportions (Clopper and Pearson, 1934). 
The hypothesis test of the primary efficacy endpoint will be performed using an overall 
one-sided significance level of 0.025. The stratified log-rank test with a covariate to control 
for the stratification factor of visceral metastasis (present versus absent) will be performed on 
the ITT population to test the superiority of Arm A over Arm B.  
A sensitivity analysis will also be performed on the EE analysis set (if applicable).  
7.5.2 
Secondary Efficacy Endpoints 
To maintain an upper boundary on the overall experiment-wise type I error rate, hypothesis 
testing of the secondary efficacy endpoints on the ITT population will follow a closed testing 
procedure. Inferential comparisons between treatment groups for one or more of the 
following efficacy endpoints, listed in rank order of importance, will be made provided the 
null hypothesis associated with the final analysis of PFS is rejected at the statistical 
significance level of one-sided 0.025.  
Rank order of efficacy endpoints for analyses: 
1. PFS (Primary Endpoint) 
2. OS (Key Secondary Endpoint) 
3. ORR 
Inferential testing of the secondary efficacy endpoints will proceed in a sequential step-down 
manner, provided the null hypothesis associated with the previously tested endpoint is 
rejected at the pre-defined statistical significance level. Otherwise, no further inferential 
testing will be conducted. 
If formal inferential statistical testing is stopped due to the closed testing procedure, 
inferential statistics may be employed for the remaining secondary efficacy endpoints. 
Definitions of Secondary Endpoints: 
• ORR is defined as the percentage of subjects who have baseline measurable disease and 
who achieve a best response of either complete response (CR) or partial response (PR) as 
assessed by the investigator using RECIST 1.1 criteria. Subjects who do not achieve a CR 
or PR will be counted as a non-responder. Estimate and exact 95% CI will be provided 
for ORR by treatment arms. 


Protocol Number: B-701-U21 
CONFIDENTIAL 
Amendment 6 
 
BioClin Therapeutics, Inc. 
 
31 July 2018 
86 
• OS defined as the time from randomization to death from any cause. For subjects who are 
alive at the time of analysis data cutoff, OS time will be censored at the last date the 
subject was known to be alive. Survival time for subjects with no post-baseline survival 
information will be censored on the date of randomization. 
• Medical time to response (TTR) defined as the time to the first occurrence of a 
documented response. 
• DOR, defined as the first occurrence of a documented, objective response until the time 
of relapse or death from any cause. This will be calculated only for subjects who had a 
confirmed overall response of CR or PR. In the absence of confirmation of death or 
progressive disease, duration of response will be censored at the last adequate disease 
assessment date. 
• DCR defined as the percentage of subjects who achieve either CR or PR or SD, as 
assessed by the investigator per RECIST v1.1. 
• DCR (90), defined as the absence of disease progression and death 90 days from the time 
of randomization as assessed by the investigator using RECIST v1.1. 
• DCR (150), defined as the absence of disease progression and death 150 days from the 
time of randomization as assessed by the investigator using RECIST v1.1. 
• QOL, as assessed by EORTC QLQ-C30 (in Phase 2b Monotherapy Expansion and 
Phase 2b Randomized Phase) will be scored per standard methodology developed for the 
survey. Results will be compared between treatment groups; changes from baseline will 
also be calculated. Ad hoc analyses of individual questions relevant to side effects from 
each treatment may also be performed. 
The time-to-event (OS, TTR, DOR) variables will be summarized by the method described 
for PFS except that DOR will be based on responders. 
For categorical response variables (i.e., ORR, DCR), the frequency count, percentage, and 
exact 95% confidence intervals will be summarized for subjects randomized to the two 
treatments. The response rates will be compared between the randomized groups via the 
stratified Cochran-Mantel-Haenszel test based on the ITT population.  
7.6 
Exploratory Endpoints 
The association between FGFR3 mutations or fusions and other biomarkers and efficacy and 
AE outcomes will be explored. 
Plasma concentrations of vofatamab over time will be summarized using descriptive 
statistics. PK parameters (e.g., Cmax, AUC, t1/2) may be listed and summarized using 
descriptive statistics.  
 


Protocol Number: B-701-U21 
CONFIDENTIAL 
Amendment 6 
 
BioClin Therapeutics, Inc. 
 
31 July 2018 
87 
7.7 
Safety 
Safety will be assessed through summaries of AEs, changes in key laboratory test results, 
ECGs, and changes in vital signs. The number and percentage of subjects with confirmed 
positive ATA will be summarized descriptively by scheduled time point. All subjects who 
receive any amount of vofatamab or docetaxel will be included in the safety analysis. 
The safety data will be presented by treatment study arm in individual subject listings and 
summary tables.  
7.7.1 
Adverse Events 
Overall incidences of all AEs occurring on or after treatment on Day 1 will be summarized 
by Medical Dictionary for Regulatory Activities (MedDRA) system organ class, MedDRA 
preferred term, and NCI CTCAE v4.0 toxicity grade for both study treatment groups. Each 
subject will be counted only once within a system organ class or a preferred term by using 
the AEs with the highest severity (per CTCAE v4.0) within each category. AEs will also be 
summarized by system organ class, preferred term, toxicity grade (including ≥Grade 3), and 
relationship to treatment. AE onset will be shown relative (in number of days) to the day of 
the first study treatment. 
All information pertaining to AEs noted during the study will be listed per subject, detailing 
verbatim, MedDRA preferred term, MedDRA system organ class, start date, stop date, 
toxicity grade, and relationship to study treatment. Additionally, all dose modifications and 
treatment delays and associated AEs will be summarized in a listing. 
Subjects who discontinued treatment due to AEs, experienced SAEs, including deaths, will 
be listed separately and summarized by treatment group. 
7.8 
Analysis Populations 
Safety Population: The safety population will consist of all subjects that receive at least one 
dose of study drug. All subjects receiving a dose of study drug will be included in all safety 
summaries. 
Intent-To-Treat Population (ITT): The primary efficacy analysis will be performed on the 
ITT population defined as all subjects who were randomized to study treatment. 
Efficacy Evaluable (EE): The EE population will include all subjects randomized and who 
received study treatment but excluding those identified as major protocol violators and those 
who discontinued the study within one week of first study drug administration. In addition, 
subjects in the EE population will be analyzed according to the study medication which they 
have taken, even if they were not randomized to that arm. If fewer than 5% subjects are 
excluded from the EE population, no analysis will be performed by EE population. 


Protocol Number: B-701-U21 
CONFIDENTIAL 
Amendment 6 
 
BioClin Therapeutics, Inc. 
 
31 July 2018 
88 
7.9 
Subject Disposition 
The disposition of subjects will be tabulated for all subjects. The number of subjects 
allocated into the study will be summarized by treatment group. Subjects who discontinue 
treatment, are removed from the study, randomization errors, major protocol violations, will 
also be tabulated by treatment group.  
7.10 
Demographic and Baseline Characteristics 
Demographic and baseline characteristics will be summarized with descriptive statistics, 
including sample size, mean, median, standard deviation, and range for continuous variables 
and frequency counts and percentages for categorical data. The demographic and baseline 
characteristics will be compared between the two arms to assess the degree to which 
randomization achieved comparability between treatment arms. A one-way analysis of 
variance (ANOVA) with factors of treatment will be used for continuous variables. A 
Fisher’s exact test will be used for categorical variables.  
7.11 
Medical History and Physical Examination 
The medical history and physical examination of each subject will be presented in subject 
listings. No statistical tests will be performed. 
7.12 
Study Drug Administration 
The total number of doses administered, the median (range) number of doses administered, 
dose modifications, dose delays, dose omissions, and reasons for deviation from planned 
therapy will be described by study treatment arm.  
7.13 
Laboratory Tests 
Descriptive summary statistics (mean, standard deviation, median, minimum, maximum, 
frequencies, and percentages, as appropriate) for key laboratory values will be presented at 
baseline and the follow-up time points for each study treatment group. 
In addition, changes in key laboratory data will be summarized by grade using NCI CTCAE 
v4.0. Shift tables will be used for key laboratory parameters showing the number of subjects 
who experience changes in laboratory grade during the course of the study compared to 
baseline will be displayed for each study treatment group.  
Grade 3 and 4 laboratory values and laboratory values outside the normal range will be 
flagged in the data listings. 
7.14 
Vital Signs and Physical Examination  
Vital signs (including temperature, respiratory rate, blood pressure, heart rate, and weight) 
will be presented descriptively at baseline and for each follow-up time point for each study 
treatment group. The number (n), mean, standard deviation, median, range will be presented. 
Changes from baseline to each time point will also be summarized.  


Protocol Number: B-701-U21 
CONFIDENTIAL 
Amendment 6 
 
BioClin Therapeutics, Inc. 
 
31 July 2018 
89 
Clinically significant abnormalities on physical examination noted at baseline will be 
presented as preexisting conditions. New clinically significant abnormalities on study will be 
presented as AEs. 
7.15 
12-Lead Electrocardiogram (ECG)  
Results of the 12-lead ECG will be summarized by treatment group using descriptive 
statistics at baseline and end-of-treatment. The number (n), mean, standard deviation, 
median, range will be presented. Changes from baseline will also be summarized. 
7.16 
ECOG Performance Status 
The ECOG PS at baseline and during the treatment period will be presented using frequency 
counts and percentages for each treatment group.  
7.17 
Concomitant Medications 
The World Health Organization (WHO) Drug Dictionary will be used to classify concomitant 
medications by therapeutic class and preferred term. Concomitant medications include 
medications that started at any time and were taken at any time after the start of treatment 
until the end of the entire treatment period.  
The frequency counts and percentages of subjects in the using different concomitant 
medications will be tabulated and summarized by treatment group by WHO Drug anatomical 
therapeutic chemical (ATC) and preferred term. Although a subject may have taken two or 
more medications, the subject is counted only once within an ATC classification. The same 
subject may contribute to two or more preferred terms in the same classification. These data 
will also be presented in subject listings. 
7.18 
Interim Analysis  
No formal interim analysis is planned for Phase 2b Monotherapy Expansion and Phase 2b 
Randomized Phases. 
7.19 
Safety Review 
Safety analyses will be performed by a vofatamab Safety Oversight Committee (SOC) for 
Phase 1b, Phase 2 and Phase 2b Monotherapy Expansion and by study-specific Data 
Monitoring Committee (DMC) for Phase 2b Randomized Phase based on guidelines outlined 
in the SOC and DMC Charters. The safety review will include AE as well as laboratory and 
ECG data. The safety assessments for Phase 1b, Phase 2 and Phase 2b Monotherapy 
Expansion will be conducted in an open fashion.  
The safety assessments during the Randomized Phase will be conducted in a blinded fashion 
on treatment arm and aggregate data. Unblinding in the Randomized Phase will only occur if 
deemed necessary by the DMC and then only on an individual subject basis. 


Protocol Number: B-701-U21 
CONFIDENTIAL 
Amendment 6 
 
BioClin Therapeutics, Inc. 
 
31 July 2018 
90 
8 
SAFETY AND ADVERSE EVENTS  
8.1 
Definitions 
Adverse Event 
An AE is defined as any untoward medical occurrence associated with the use of a drug in 
humans, whether or not considered drug-related. An AE can therefore be any unfavorable 
and unintended sign (including an abnormal laboratory finding, for example), symptom, or 
disease temporally associated with the use of a medicinal (investigational) product, whether 
or not related to the medicinal (investigational) products. 
All AEs resulting in discontinuation from the study should be followed until resolution or 
stabilization. Subjects who are discontinued from study drug will be followed for safety 
outcomes through the safety follow-up visit after the subject’s last dose of study drug or until 
the subject receives another anti-cancer therapy, whichever occurs first. 
Suspected Adverse Reaction is any AE for which there is a reasonable possibility that the 
drug caused the AE. For the purposes of expedited safety reporting, “reasonable possibility” 
means there is evidence to suggest a causal relationship between the drug and the AE. 
Suspected adverse reaction implies a lesser degree of certainty about causality than adverse 
reaction, which means any AE caused by a drug. 
A life-threatening AE or life-threatening suspected adverse reaction is an AE or suspected 
adverse reaction that, in the view of either the investigator or Sponsor, places the subject at 
immediate risk of death. It does not include an AE or suspected adverse reaction that, had it 
occurred in a more severe form, might have caused death. 
Serious Adverse Event 
An SAE or serious suspected adverse reaction is an AE or suspected adverse reaction that at 
any dose, in the view of either the investigator or Sponsor, results in any of the following 
outcomes:  
• Death 
• A life-threatening AE 
• Inpatient hospitalization or prolongation of existing hospitalization 
• Persistent or significant incapacity or substantial disruption of the ability to conduct 
normal life functions 
• A congenital anomaly/birth defect 
Important medical events that may not result in death, be immediately life-threatening, or 
require hospitalization may be considered serious when, based upon appropriate medical 
judgment, they may jeopardize the subject and may require medical or surgical intervention 
to prevent one of the outcomes listed in the definition.  


Protocol Number: B-701-U21 
CONFIDENTIAL 
Amendment 6 
 
BioClin Therapeutics, Inc. 
 
31 July 2018 
91 
All AEs that do not meet any of the criteria for serious should be regarded as non-serious 
AEs. 
The definition of an SAE also includes any important medical event. Medical and scientific 
judgment should be exercised in deciding whether expedited reporting is appropriate in other 
situations, such as important medical events that may not be immediately life-threatening or 
result in death or hospitalization, but may jeopardize the patient or may require intervention 
to prevent one of the other outcomes listed in the previous definition. These should also 
usually be considered serious. Examples of such events are intensive treatment in an 
emergency room or at home for allergic bronchospasm; blood dyscrasias or convulsions that 
do not result in hospitalization; or development of drug dependency or drug abuse.  
It is important to distinguish between serious and severe adverse events. Severity is a 
measure of intensity; however, an AE of severe intensity need not necessarily be considered 
serious. For example, nausea which persists for several hours may be considered severe 
nausea, but may not be considered an SAE. On the other hand, a stroke which results in only 
a limited degree of disability may be considered only a mild stroke, but would be considered 
an SAE. 
All deaths should be reported with the primary cause of death as the AE term, as death is 
typically the outcome of the event, not the event itself. 
8.2 
Severity of Adverse Events 
Each AE and SAE should be graded as mild, moderate, severe, life-threatening, or death 
using the following definitions. The severity of all adverse events will be graded using the 
NCI CTCAE v4.0 in Table 5. 


Protocol Number: B-701-U21 
CONFIDENTIAL 
Amendment 6 
 
BioClin Therapeutics, Inc. 
 
31 July 2018 
92 
Table 5 
Adverse Event Severity Grading Scale 
Grade 
Severity 
Alternate Description a 
1 
Mild (apply event-specific NCI CTCAE 
grading criteria) 
Asymptomatic or mild symptoms; clinical or 
diagnostic observations only; intervention not 
indicated 
2 
Moderate (apply event-specific  
NCI CTCAE grading criteria) 
Minimal, local or noninvasive intervention 
indicated; limiting age-appropriate 
instrumental ADLb 
3 
Severe (apply event-specific  
NCI CTCAE grading criteria) 
Severe or medically significant but not 
immediately life-threatening; hospitalization 
or prolongation of hospitalization indicated; 
disabling; limiting self-care ADLc 
4 
Very severe, life threatening,  
or disabling (apply event-specific NCI 
CTCAE grading criteria) 
Life-threatening consequences; urgent 
intervention indicated 
5 
Death related to AE 
 
ADL = activities of daily living; AE = adverse event; CTCAE = Common Terminology Criteria for Adverse 
Events; NCI = National Cancer Institute. 
The NCI CTCAE v4.0 can be found at: 
http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm#ctc_40. 
Note: Regardless of severity, some events may also meet regulatory serious criteria. Refer to definition of an 
SAE (see Section 8.1). 
a 
Use these alternative definitions for Grade 1, 2, 3, and 4 events when the observed or reported AE is not 
in the NCI CTCAE listing. 
b 
Instrumental ADL refer to preparing meals, shopping for groceries or clothes, using the telephone, 
managing money, etc. 
c 
Self-care ADL refer to bathing, dressing and undressing, feeding self, using the toilet, taking 
medications, and not bedridden. 
 
To make sure there is no confusion or misunderstanding of the difference between the terms 
"serious" and "severe," which are not synonymous, the following note of clarification is 
provided. The term "severe" is often used to describe the intensity (severity) of a specific 
event (as in mild, moderate, or severe myocardial infarction); the event itself, however, may 
be of relatively minor medical significance (such as severe headache). This is not the same as 
"serious" which is based on subject/event outcome or action criteria usually associated with 
events that pose a threat to a subject's life or functioning. Seriousness (not severity) serves as 
a guide for defining regulatory reporting obligations. 
8.3 
Relationship of Adverse Events to Study Drug 
The investigator will assess the potential relationship of each AE and SAE to study drug 
using the following descriptions. 
• Definitely Not Related: This category applies to an AE or SAE that is clearly not related 
to the investigational agent/procedure, beyond a reasonable doubt. That is, another cause 
of the event is most plausible; and/or a clinically plausible temporal sequence is 


Protocol Number: B-701-U21 
CONFIDENTIAL 
Amendment 6 
 
BioClin Therapeutics, Inc. 
 
31 July 2018 
93 
inconsistent with the onset of the event and the exposure to study drug and/or a causal 
relationship is considered biologically implausible. 
• Unlikely Related: This category applies to an AE with a temporal relation to 
administration of the drug which makes a causal relation improbable, and where other 
drugs, chemicals, or underlying disease provide plausible explanations. 
• Possibly Related: This category applies to an AE that follows a reasonable temporal 
sequence from administration of the study drug and that follows a known or expected 
response pattern to the suspected study drug, but that could readily have been produced 
by a number of other factors. 
• Probably/Likely Related: This category applies to an AE that is likely related to the 
investigational agent/procedure. That is, the AE has a reasonable temporal relationship to 
the administration of the investigational agent(s) or research intervention; is unlikely to 
be attributed to concurrent disease or other drugs or chemicals, and follows a clinically 
reasonable response on withdrawal  
• Definitely Related: This category applies to an AE that is certainly related to the 
investigational agent/procedure. That is, the AE has a temporal relationship to the 
administration of the investigational agent(s) or research intervention, which cannot be 
explained by concurrent disease or other drugs or chemicals; the response to withdrawal 
of drug is clinically plausible; and the event has been shown to be definitively 
pharmacologically or phenomenologically related using a satisfactory rechallenge 
procedure. 
Note: The investigator’s assessment of causality for individual AE reports is part of the study 
documentation process. Regardless of the “Yes” or “No” causality assessment for individual 
AE reports, the Sponsor will promptly evaluate all reported SAEs against cumulative product 
experience to identify and expeditiously communicate possible new safety findings to 
investigators and applicable regulatory authorities.  
8.4 
Adverse Event Reporting Period 
After informed consent, but prior to initiation of study drug, only SAEs caused by a 
protocol-mandated intervention will be collected (e.g., SAEs related to invasive procedures 
such as biopsies, medication washout, or no treatment run-in). All medical occurrences from 
the time of signing the informed consent that meet this definition should be recorded. Events 
preceding first study drug administration, however, should be recorded as medical history, 
not as AEs. 
After initiation of study drug, all AEs and SAEs regardless of attribution will be collected 
until 30 days following the last administration of study drug, 30 days after subject 
discontinuation, initiation of another anti-tumor therapy, resolution, stabilization, or until it 
has been determined that the study treatment or participation is not the cause. After this 
period, investigators should report only SAEs that are felt to be related to prior study 
treatment (see Section 8.8). 


Protocol Number: B-701-U21 
CONFIDENTIAL 
Amendment 6 
 
BioClin Therapeutics, Inc. 
 
31 July 2018 
94 
8.4.1 
Eliciting Adverse Events 
A consistent methodology of non-directive questioning for eliciting AEs at all subject 
evaluation time points should be adopted. Examples of non-directive questions include: 
“How have you felt since your last clinic visit?” 
“Have you had any new or changed health problems since you were last here?”  
8.5 
Recording of Adverse Events 
8.5.1 
Recording Adverse Events on the eCRF 
Information on all adverse events should be recorded immediately in the source document, 
and also in the appropriate adverse event module of the eCRF. All clearly related signs, 
symptoms, and abnormal diagnostic procedures results should be recorded in the source 
document, though should be grouped under one diagnosis. 
8.5.1.1 
Diagnosis versus Signs and Symptoms 
If known, a diagnosis should be recorded on the eCRF rather than individual signs and 
symptoms (e.g., record only liver failure or hepatitis rather than jaundice, asterixis, and 
elevated transaminases). However, if a constellation of signs and/or symptoms cannot be 
medically characterized as a single diagnosis or syndrome at the time of reporting, each 
individual event should be recorded as an AE or SAE on the eCRF. If a diagnosis is 
subsequently established, it should be reported as follow-up information. 
For this study, the NCI CTCAE terms “cytokine release syndrome” or “acute infusion 
reaction” should not be used. For infusion reactions, each sign and symptom should be 
recorded as an individual event. If multiple signs or symptoms occur with a given event, each 
sign or symptom should be recorded separately with its level of severity. 
8.5.1.2 
Adverse Events Occurring Secondary to Other Events 
In general, AEs occurring secondary to other events (e.g., cascade events or clinical 
sequelae) should be identified by their primary cause. For example, if severe diarrhea is 
known to have resulted in dehydration, it is sufficient to record only diarrhea as an AE or 
SAE on the eCRF.  
However, medically significant AEs occurring secondary to an initiating event that are 
separated in time should be recorded as independent events on the Adverse Event eCRF. For 
example, if a severe gastrointestinal hemorrhage leads to renal failure, both events should be 
recorded separately on the Adverse Event eCRF. 
8.5.1.3 
Preexisting Medical Conditions 
A preexisting medical condition is one that is present at the start of the study. Such 
conditions should be recorded on the General Medical History and Baseline Conditions 
eCRF. 


Protocol Number: B-701-U21 
CONFIDENTIAL 
Amendment 6 
 
BioClin Therapeutics, Inc. 
 
31 July 2018 
95 
A preexisting medical condition should be recorded as an AE or SAE only if the frequency, 
severity, or character of the condition worsens during the study. When recording such events 
on an Adverse Event eCRF, it is important to convey the concept that the preexisting 
condition has changed by including applicable descriptors (e.g., “more frequent headaches”). 
8.5.1.4 
Persistent or Recurrent Adverse Events 
A persistent AE is one that extends continuously, without resolution between subject 
evaluation time points. Such events should only be recorded once in the eCRF unless their 
severity increases. If a persistent AE becomes more severe, it should be recorded as a new 
entry on the Adverse Event eCRF. If a previously reported SAE increases in severity, it 
should be reported on the previously submitted eCRF as a follow-up or update and not as a 
new event. 
A recurrent AE is one that occurs and resolves between subject evaluation time points and 
subsequently recurs. All recurrent AEs should be recorded on an Adverse Event eCRF. 
8.5.1.5 
Abnormal Laboratory Values 
Only clinically significant laboratory abnormalities that require active management will be 
recorded as AEs or SAEs on the Adverse Event eCRF (e.g., abnormalities that require study 
drug dose modification, discontinuation of study treatment, more frequent follow-up 
assessments, further diagnostic investigation, etc.). 
If the clinically significant laboratory abnormality is a sign of a disease or syndrome 
(e.g., ALP and bilirubin 5  the ULN associated with cholecystitis), only the diagnosis 
(e.g., cholecystitis) needs to be recorded on the Adverse Event eCRF. 
If the clinically significant laboratory abnormality is not a sign of a disease or syndrome, 
the abnormality itself should be recorded as an AE or SAE on the Adverse Event eCRF. 
If the laboratory abnormality can be characterized by a precise clinical term, the clinical term 
should be recorded as the AE or SAE. For example, an elevated serum potassium level of 
7.0 mEq/L should be recorded as “hyperkalemia.” 
Observations of the same clinically significant laboratory abnormality from visit to visit 
should not be repeatedly recorded as AEs or SAEs on the Adverse Event eCRF, unless their 
severity, seriousness, or etiology changes.  
8.5.1.6 
Worsening of Urothelial Cell Carcinoma  
Progression of underlying malignancy is not reported as an AE if it is clearly consistent with 
the suspected progression of the underlying cancer, as defined by respective disease criterion 
or other criteria as determined by protocol. Hospitalization due solely to the progression of 
underlying malignancy should NOT be reported as an SAE. Clinical symptoms of 
progression may be reported as AEs, if the symptom cannot be determined as exclusively due 
to the progression of the underlying malignancy, or does not fit the expected pattern of 
progression for the disease under study.  


Protocol Number: B-701-U21 
CONFIDENTIAL 
Amendment 6 
 
BioClin Therapeutics, Inc. 
 
31 July 2018 
96 
8.5.1.7 
Hospitalization, Prolonged Hospitalization, or Surgery 
Any AE that results in hospitalization or prolonged hospitalization should be documented 
and reported as an SAE unless specifically instructed otherwise in this protocol.  
There are some hospitalization scenarios that do not require reporting as an SAE when there 
is no occurrence of an AE. These scenarios include a planned hospitalization or prolonged 
hospitalization to: 
• Perform an efficacy measurement for the study 
• Undergo a diagnostic or elective surgical procedure for a preexisting medical condition 
that has not changed 
• Receive scheduled therapy for the target disease of the study 
8.5.1.8 
Deaths 
Deaths that occur during the protocol-specified AE reporting period that are attributed by the 
investigator solely to progression of UCC will be recorded only on the Study Discontinuation 
eCRF. All other on study deaths, regardless of attribution, will be recorded on an Adverse 
Event eCRF and expeditiously reported to the Sponsor.  
8.5.1.9 
Pregnancy 
Conditions of pregnancy and lactation are excluded from study participation. During the 
course of the study, females of childbearing potential must contact the treating Investigator 
immediately if they suspect that they may be pregnant (a missed or late menstrual period 
should be reported to the treating Investigator).  
If an investigator suspects that a subject may be pregnant after the subject started study drug, 
the study drug or docetaxel, as applicable, must immediately be withheld until the result of 
the pregnancy test is confirmed. If a pregnancy is confirmed, the study drug(s) must be 
immediately and permanently stopped, the subject must be discontinued from the study, and 
the Investigator must notify the study Sponsor within 24 hours of confirmation. 
If a female subject becomes pregnant while receiving investigational therapy or within 
90 days after the last dose of the study drug, a Pregnancy Report eCRF should be completed, 
printed and faxed to the Sponsor’s Drug Safety Department or its designee within 24 hours of 
learning of the pregnancy, using the fax number listed in Section 8.6.1. Pregnancy should not 
be recorded on the Adverse Event eCRF. 
Abortion, whether therapeutic or spontaneous, should always be classified as serious (as the 
Sponsor considers these medically significant), recorded on an Adverse Event eCRF, and 
expeditiously reported to the Sponsor. After the study period, such events should still be 
reported expeditiously to the Sponsor.  


Protocol Number: B-701-U21 
CONFIDENTIAL 
Amendment 6 
 
BioClin Therapeutics, Inc. 
 
31 July 2018 
97 
Any congenital anomaly/birth defect in a child born to a female subject or female partner of a 
male subject exposed to the investigational product should be classified as serious and 
recorded on an Adverse Event eCRF and expeditiously reported to the Sponsor during the 
study period. After the study period, such events should still be reported expeditiously to the 
Sponsor recorded and reported as an SAE. 
In the event the electronic data capture (EDC) system is unavailable, a paper Pregnancy 
Report Form and Pregnancy Fax Coversheet should be completed and faxed to the Sponsor’s 
Drug Safety Department or its designee at the fax number listed in Section 8.6.1. 
8.6 
Expedited Reporting Requirements for Serious Adverse Events and 
Serious Drug Reactions 
8.6.1 
Reporting Requirements for All SAEs and DLTs 
Investigators will submit reports of all SAEs, regardless of attribution, DLTs, and all 
protocol-defined non-serious expedited AEs to the Sponsor within 24 hours of learning of the 
events. For initial SAE, DLT, and protocol-defined non-serious expedited AE reports, 
investigators should record all case details that can be gathered within 24 hours on an 
Adverse Event eCRF and submit the report via the EDC system. A report will be generated 
and sent to the Sponsor’s Drug Safety Department or its designee by the EDC system. In the 
event the EDC system is unavailable, a completed SAE paper reporting form and fax 
coversheet should be faxed immediately upon completion to the Sponsor’s Drug Safety 
Department or its designee at the fax number indicated on the SAE report form. Once the 
EDC system is available, all information will need to be entered and submitted via the EDC 
system.  
Investigators will submit written reports of any AEs that meet the definition of a DLT 
(Section 5.1.2.1) within 24 hours of learning of the events. Note that the DLT assessment 
period is from Days 1−21 of Cohort 1. 
Real-time safety monitoring will be employed for DLT assessment and dosing modification 
decisions. During the DLT assessment period this period, investigators must report Grade 3 
or 4 AEs (in addition to SAEs) within 24 hours of observing or learning of the events. The 
Medical Monitor will expeditiously review AEs to determine if they meet the criteria for 
DLTs (Section 5.1.2.1). 
8.6.2 
Reporting Requirements for Fatal/Life-Threatening SAEs Related to 
Investigational Product 
Any life-threatening (i.e., imminent risk of death) or fatal AE that is attributed by the 
investigator to the investigational product will be telephoned to the Medical Monitor 
immediately, followed by submission of written case details on an Adverse Event eCRF 
within 24 hours as described in Section 8.6.1. 


Protocol Number: B-701-U21 
CONFIDENTIAL 
Amendment 6 
 
BioClin Therapeutics, Inc. 
 
31 July 2018 
98 
8.6.3 
IRB/EC Notification by the Investigator 
Reports of all SAEs (including follow-up information) must be submitted to the IRB/EC 
within 10 working days. Copies of each report and documentation of IRB/EC notification 
and receipt will be kept in the Clinical Investigator’s binder. A copy of this notification must 
be provided to the Sponsor or its designee. 
8.6.4 
Regulatory Agency Notification by the Sponsor 
The study sponsor or designee shall notify all applicable regulatory agencies by telephone, 
facsimile transmission, or registration in EudraVigilance database of any unexpected fatal or 
life-threatening experience associated with the use of the drug as soon as possible but no later 
than 7 calendar days from the Sponsor’s original receipt of the information. 
If a previous AE that was not initially deemed reportable is later found to fit the criteria for 
reporting, the study sponsor will submit the AE in a written report to the appropriate 
regulatory agencies as soon as possible, but no later than 15 calendar days from the time the 
determination is made. 
8.7 
Type and Duration of Follow-Up after Adverse Events 
The investigator should follow all unresolved AEs and SAEs until the events are resolved to 
baseline grade, the event is assessed by the investigator as stable, new anti-cancer treatment 
is initiated, the subject is lost to follow up, or it has been determined that the study treatment 
or participation is not the cause of the AE/SAE. Resolution of AEs and SAEs (with dates) 
should be documented on the appropriate Adverse Event eCRF and in the subject’s medical 
record to facilitate source data verification (SDV) during the study period. 
For some SAEs, the Sponsor or its designee may follow up by telephone, fax, electronic 
mail, and/or a monitoring visit to obtain additional case details deemed necessary to 
appropriately evaluate the SAE report (e.g., hospital discharge summary, consultant report, or 
autopsy report). 
8.8 
Post-Study Adverse Events 
At the last scheduled visit, the investigator should instruct each subject to report to the 
investigator any subsequent SAEs that the subject’s personal physician believes could be 
related to prior study treatment.  
The investigator should notify the Sponsor of any death or other SAE occurring at any time 
after a subject has discontinued or terminated study participation if felt to be related to prior 
study treatment. The Sponsor should also be notified if the investigator should become aware 
of the development of cancer or of a congenital anomaly in a subsequently conceived 
offspring of a subject who participated in this study. The investigator should report these 
events to the Sponsor’s Drug Safety Department or its designee on the study Adverse Event 
eCRF. If the study Adverse Event eCRF is not available, the investigator should report 
the event directly to the Sponsor’s Drug Safety Department or its designee. 


Protocol Number: B-701-U21 
CONFIDENTIAL 
Amendment 6 
 
BioClin Therapeutics, Inc. 
 
31 July 2018 
99 
9 
STUDY CONDUCT 
9.1 
Ethics 
9.1.1 
Institutional Review Board (IRB) / Independent Ethics Committee (IEC) 
The IRB/EC must be a properly constituted board or committee operating in accordance with 
21 CFR Part 56, "Institutional Review Boards." This protocol, any protocol amendments, the 
associated informed consent forms, and the informed consent procedures must be submitted 
to the IRB/EC for review and must be approved before the enrollment of any subject into the 
study. Investigational Product may not be shipped to the investigator until the Sponsor or its 
designee has received a copy of the letter or certificate of approval from the IRB/EC for the 
protocol and any protocol amendments, as applicable. 
All subject recruitment and/or advertising information must be submitted to the IRB/EC and 
the Sponsor or its designee for review and approval prior to implementation. IRB/EC 
approval of any protocol amendments must be received before any of the changes outlined in 
the amendments are put into effect, except when the amendment has been enacted to protect 
subject safety. In such cases, the chair of the IRB/EC should be notified immediately and the 
amendment forwarded to the IRB/EC for review and approval. 
9.1.2 
Ethical Conduct of the Study 
This protocol is written in accordance with the principles established by the 18th World 
Medical Assembly General Assembly (Helsinki, 1964) and subsequent amendments and 
clarifications adopted by the General Assemblies. The investigator will make every effort 
that the study described in this protocol is conducted in full conformance with those 
principles, current FDA regulations, International Conference on Harmonisation (ICH) Good 
Clinical Practices (GCP) guidelines, and local ethical and regulatory requirements. Should a 
conflict arise, the investigator will follow whichever law or guideline affords the greater 
protection to the individual subject. The investigator will also make sure he or she is 
thoroughly familiar with the appropriate administration and potential risks of administration 
of the Investigational Product, as described in this protocol and the Investigator's Brochure, 
prior to the initiation of the study. 
9.1.3 
Informed Consent 
Appropriate forms for documenting written informed consent will be provided by the 
investigator and reviewed and approved by the Sponsor or its designee before submission to 
the IRB/EC. The Sponsor or its designee must receive a copy of the IRB/EC’s approval of 
the Informed Consent Form (ICF) before the shipment of Investigational Product to the study 
site. 
It is the investigator's responsibility to obtain signed written informed consent from each 
potential study subject prior to the conduct of any study procedures. This written informed 
consent will be obtained after the methods, objectives, requirements, and potential risks of 
the study have been fully explained to each potential subject. The investigator must explain 


Protocol Number: B-701-U21 
CONFIDENTIAL 
Amendment 6 
 
BioClin Therapeutics, Inc. 
 
31 July 2018 
100 
to each subject that the subject is completely free to refuse to enter the study or to withdraw 
from it at any time. 
The method of obtaining and documenting informed consent and the contents of the ICF will 
comply with ICH GCP guidelines, the requirements of 21 CFR Part 50, “Protection of 
Human Subjects,” the Health Insurance Portability and Accountability Act (HIPAA) 
regulations, and all other applicable regulatory requirements. Subjects will be given a copy of 
the signed ICF and will be provided any new information during the course of the study that 
might affect their continued participation in the study. The investigator or a qualified 
designee will be available to answer each subject's questions throughout the study, and all of 
the subject's questions must be answered to the subject's satisfaction. If the protocol is 
amended and the ICF is revised, each subject will be required to provide written informed 
consent again using the revised ICF. 
Receipt of written informed consent will be documented in each potential subject’s eCRF. 
The signed ICF will remain in each subject's study file and must be available to the study 
monitor(s) at all times. 
9.2 
Regulatory Requirements 
This study will be submitted to the local regulatory authority for approval or notification 
whichever is applicable. The study will only be undertaken in compliance with the local 
regulatory requirements. 
In accordance with Directive 2001/20/EC, the Sponsor will notify the relevant (European) 
regulatory authority(ies) and IRBs/ECs within 90 days of the end of the study. If the study 
terminates early, the Sponsor will notify the relevant (European) regulatory authority(ies) and 
IRBs/ECs within 15 days and will provide the reasons for early termination. 
Safety updates for vofatamab will be prepared by the Sponsor as required, for submission to 
the relevant regulatory authority(ies). 
9.3 
Investigators and Administrative Structure 
Each investigator must provide the Sponsor and/or its designee a completed and signed Form 
FDA 1572 and a Financial Disclosure Form. All sub-investigators must be listed on Form 
FDA 1572 and Financial Disclosure Forms must be completed for all sub-investigators listed 
on Form FDA 1572. 
The Sponsor and/or its designee will be responsible for managing and monitoring the clinical 
study to ensure compliance with FDA and ICH GCP guidelines. A trained designated 
representative (the monitor) will conduct regular visits to the clinical site, to perform SDV. 
The monitor will verify the investigator's ongoing qualifications, to inspect clinical site 
facilities, and to inspect study records, including proof of IRB review, with the stipulation 
that subject confidentiality will be maintained in accordance with local and federal 
regulations, including HIPAA requirements.  


Protocol Number: B-701-U21 
CONFIDENTIAL 
Amendment 6 
 
BioClin Therapeutics, Inc. 
 
31 July 2018 
101 
A Coordinating Investigator will be identified for multicenter studies. The Coordinating 
Investigator will be selected on the basis of active participation in the study, thorough 
knowledge of the therapeutic area being studied, and the ability to interpret data. The 
Coordinating Investigator will read and sign the Clinical Study Report. 
9.4 
Data Handling and Record Keeping 
9.4.1 
Case Report Forms and Source Documents 
The investigator is required to initiate and maintain, for each subject, an adequate and 
accurate case history that records all observations and other data related to the study for that 
subject. A validated EDC system will be used for entry of the data into eCRFs. Data must be 
recorded on eCRFs approved by the Sponsor or its designee. All information recorded on 
eCRFs for this study must be consistent with the subject's source documentation.  
Initial data entry and any changes to the data will be made only by authorized users, and data 
entries and changes will be captured in an electronic audit trail. An explanation of any data 
change should be recorded in the eCRF. All data entered in to the eCRF must be verifiable; 
therefore, eCRFs will be routinely checked for accuracy, completeness, and clarity and will 
be cross-checked for consistency with source documents, including laboratory test reports 
and other subject records by the Sponsor or its designee. The investigator must allow direct 
access to all source documents. 
9.4.2 
Data Quality Assurance 
Monitoring and auditing procedures developed by the Sponsor and/or its designee will be 
implemented to ensure compliance with FDA and ICH GCP guidelines. The Sponsor's 
designated representative (the monitor) will contact the investigator and conduct regular 
visits to the study site. The monitor will be expected and allowed to verify the investigator's 
qualifications, to inspect clinical site facilities, and to inspect study records, including proof 
of IRB/EC review, with the stipulation that subject confidentiality will be maintained in 
accordance with local and federal regulations, including HIPAA requirements. The monitor 
will also be responsible for confirming adherence to the study protocol, inspecting eCRFs 
and source documents, and ensuring the integrity of the data. Electronic CRFs will be 
checked for accuracy, completeness, and clarity and will be cross-checked for consistency 
with source documents, including laboratory test reports and other subject records. Instances 
of missing or uninterruptable data will be resolved in coordination with the investigator. 
The monitor will also investigate any questions concerning adherence to regulatory 
requirements. Any administrative concerns will be clarified and followed. The monitor will 
maintain contact with the site through frequent direct communications with the study site by 
e-mail, telephone, facsimile, and/or mail. The investigator and all other site personnel agree 
to cooperate fully with the monitor and will work in good faith with the monitor to resolve 
any and all questions raised and any and all issues identified by the monitor. 
The investigator understands that regulatory authorities, the IRB/EC, and/or the Sponsor or 
its designees have the right to access all eCRFs, source documents, and other study 
documentation for on-site audit or inspection and will retain this right from the start of the 


Protocol Number: B-701-U21 
CONFIDENTIAL 
Amendment 6 
 
BioClin Therapeutics, Inc. 
 
31 July 2018 
102 
study to at least 2 years after the last approval of a marketing application or for at least 
2 years after clinical development of the study drug for the indication being studied has been 
discontinued. The investigator is required to guarantee access to these documents and to 
cooperate with and support such audits and inspections. 
9.4.3 
Records Retention 
All study records must be retained for at least 2 years after the last approval of a marketing 
application in the US or an ICH region and until (1) there are no pending or contemplated 
marketing applications in the US or an ICH region or (2) at least 2 years have elapsed since 
the formal discontinuation of clinical development of the investigational product under study. 
The Investigator/institution should retain subject identifiers for at least 15 years after the 
completion or discontinuation of the study. Subject files and other source data must be kept 
for the maximum period of time permitted by the hospital, institution or private practice, but 
not less than 15 years. These documents should be retained for a longer period, however, if 
required by the applicable regulatory requirements or by agreement. The Sponsor must be 
notified and will assist with retention should the Investigator/institution be unable to continue 
maintenance of subject files for the full 15 years. All study records must be stored in a secure 
and safe facility. 
9.4.4 
Disclosure of Source Data and Documents 
Subject medical information obtained by this study is confidential and may only be disclosed 
to third parties as permitted by the Informed Consent Form (or separate authorization to use 
and disclose personal health information) signed by the subject or unless permitted or 
required by law. 
Medical information may be given to a subject’s personal physician or other appropriate 
medical personnel responsible for the subject’s welfare for treatment purposes. 
Source data/documents generated by this study must be available for inspection upon request 
by representatives of the FDA and other regulatory agencies, national and local health 
authorities, Sponsor monitors/representatives and collaborators, and the IRB/EC for each 
study site, if appropriate. 
9.5 
Subject Confidentiality 
The investigator must ensure that each subject’s anonymity is maintained as described below. 
On the eCRFs or other documents submitted to the Sponsor, subjects must be identified by 
no more than their initials, date of birth, and a subject number. Signed ICFs and other 
documents should be kept in strict confidence by the investigator in compliance with 
applicable regulations and ICH GCP Guidelines. The investigator and institution must permit 
authorized representatives of the Sponsor, of regulatory agencies, and the IRB/EC direct 
access to review the subject’s original medical records for verification of study-related 
procedures and data. Direct access includes examining, analyzing, verifying, and reproducing 
any records and reports that are needed for the evaluation of the study. The investigator is 
obligated to inform the subject in the ICF that the above named representatives may review 
study-related records from subjects. 


Protocol Number: B-701-U21 
CONFIDENTIAL 
Amendment 6 
 
BioClin Therapeutics, Inc. 
 
31 July 2018 
103 
9.6 
Procedures for Protocol Amendments 
Any changes to the study, which arise after approval of the protocol, must be documented as 
protocol amendments. Protocol amendments which are deemed substantial (e.g. affecting the 
safety of the subject, the scope of the study and/or the scientific quality) will be submitted to 
regulatory authorities and/or to the IEC/IRB as appropriate. For substantial amendment, the 
changes will become effective only after approval by the Sponsor, the responsible 
Investigator, IEC/IRB and competent authorities. All other amendments (i.e. non-substantial 
or administrative amendments) will be documented in the Trial Master File (TMF). 
The Investigator may implement a deviation from, or a change of, the protocol to eliminate 
an immediate hazard(s) to study subjects without prior IRB/IEC approval/favorable opinion. 
As soon as possible, the implemented deviation or change, the reasons for it, and, if 
appropriate, the proposed protocol amendment(s) should be submitted to the following: 
• IRB/IEC for review and approval/favorable opinion 
• Sponsor for agreement  
• Regulatory authority(ies), if required 
9.7 
Study Report 
At the conclusion of the study (but within 1 year after study closure), when the data are 
analyzed, the Sponsor will prepare an integrated Clinical Study Report in compliance with 
ICH E3. A draft copy of the report will be available for review by the coordinating 
investigator. The final version will be signed by the Sponsor and the coordinating 
investigator. 
At the conclusion of the study (but within 1 year after study closure), when the data are 
analyzed, the Sponsor will also post the study results on the European database referred 
(EudraCT) per Article 11(1) of Directive 2001/20/EC. 
9.8 
Financing and Insurance 
Financing and insurance will be addressed by separate agreements with the study sites. 
9.9 
Publication Policy 
The investigator shall not prepare and/or submit any manuscripts or slide shows based on the 
Sponsor data for publication or oral presentation prior to the publication of the primary 
manuscript of the study. The Sponsor shall acknowledge the investigator’s contribution to the 
study in any Sponsor publications regarding the study. 
The Sponsor will comply with the requirements for publication of study results and 
determination of authorship in accordance with standard editorial and ethical practice and 
with the International Committee of Medical Journal Editors (ICMJE) requirements. 


Protocol Number: B-701-U21 
CONFIDENTIAL 
Amendment 6 
 
BioClin Therapeutics, Inc. 
 
31 July 2018 
104 
10 
REFERENCES 
Bellmunt J, Theodore C, Demkov T, et al. Phase III Trial of Vinflunine Plus Best Supportive 
Care Compared With Best Supportive Care Alone After a Platinum-Containing Regimen in 
Patients With Advanced Transitional Cell Carcinoma of the Urothelial Tract. J Clin Oncol 
(2009) 27(27):4454-61. 
Bellmunt J, Orsola A., Maldonado X., Kataja V., Bladder cancer: ESMO Practice Guidelines 
for diagnosis, treatment and follow-up. Oncology (2010) 21(Supp 5):134-6. 
Bernard-Pierrot I, Brams A, Dunois-Larde C, et al. Oncogenic properties of the mutated 
forms of fibroblast growth factor receptor 3b. Carcinogenesis (2006) 27(4):740-7. 
Bourdin J, Sastre-Garau X, Chopin D, Thiery JP, Radvanyi F. Frequent activating mutations 
ofFGFR3 in human bladder and cervix carcinomas. Nat Genet (1999) 23(1):18–20. 
Brookmeyer R and Crowley JA. Confidence Interval for the Median Survival Time. 
Biometrics (1982) 38(1):29-41. 
Cancer Genome Atlas Research Network., Comprehensive molecular characterization of 
urothelial bladder carcinoma. Nature. 2014 Mar 20;507(7492):315-22.  
Cappellen D, De Oliveira C, Ricol D et al. Frequent activating mutations of FGFR3 in human 
bladder and cervix carcinomas. Nat Genet (1999) 23:18-20. 
Chesi,M, Nardini,E., Brents,L.A., Schrock,E., Ried,T., Kuehl,W.M. Bergsagel,P.L. Frequent 
translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased 
expression and activating mutations of fibroblast growth factor receptor 3. Nat Genet (1997) 
16:260–4. 
Chesi,M, Brents,L.A., Ely,S.A., Bais,C., Robbiani,D.F., Mesri,E.A., Kuehl,W.M. and 
Bergsagel,P.L. Activated fibroblast growth factor receptor 3 is an oncogene that contributes 
to tumor progression in multiple myeloma. Blood (2001) 97:729–36. 
Clopper CJ and Pearson ES. The use of confidence or fiducial limits illustrated in the case of 
the binomial. Biometrika (1934) 26(4):404-413. 
Costantini C, Millard F. Update on Chemotherapy in the Treatment of Urothelial Carcinoma. 
The Scientific World Journal (2011) 11:1981–94. 
Delezoide AL, Benoist-Lasselin C, Legeai-Mallet L et al. Spatio-temporal expression of 
FGFR 1, 2 and 3 genes during human embryo-fetal ossification. Mech Dev (1998) 77:19-30. 
Du X, Li H, Ingalla E, et al. Abstract C63: Targeting FGFR3 with a monoclonal antibody 
impairs bladder cancer growth in vivo. Poster session presented at: AACR-NCI-EORTC 
International Conference: Molecular Targets and Cancer Therapeutics. Nov 12-16, 2011; San 
Francisco, CA. 


Protocol Number: B-701-U21 
CONFIDENTIAL 
Amendment 6 
 
BioClin Therapeutics, Inc. 
 
31 July 2018 
105 
Eble JNSG, Epstein JI, Sesterhenn IA. World Health Organization: Classification of 
Tumours, Pathology, and Genetics of Tumours of the Urinary System and Male Genital 
Organs, IARC Press, Lyon, France, 2004. 
Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid 
tumours: Revised RECIST guideline (version 1.1). EJC (2009) 45:228-47. 
Finkelstein DM, Muzikansky A, Schoenfeld DA, et al., Comparing Survival of a Sample to 
That of a Standard Population. J Natl Cancer Inst (2003) 95(19):1434-9. 
Galsky MD. The Role of Taxanes in the Management of Bladder Cancer. The Oncologist 
(2005) 10(10):792-8. 
Gómez-Román JJ, Saenz P, Cuevas González J, et al. Fibroblast growth factor receptor 3 is 
overexpressed in urinary tract carcinomas and modulates the neoplastic cell growth. Clin 
Cancer Res (2005) 11:459-65. 
Grossman HB, Natale RB, Tangen CM, et al. Neoadjuvant chemotherapy plus cystectomy 
compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med (2003) 
349:859-66. 
Gust KM, McConkey DJ, Awrey S, et al. Fibroblast Growth Factor Receptor 3 is a Rational 
Therapeutic Target in Bladder Cancer. Mol Cancer Ther (2013) 12(7):1245–4. 
Hays RD, Bjorner JB, Revicki DA, et al. Development of physical and mental health 
summary scores from the patient-reported outcomes measurement information system 
(PROMIS) global items. Qual Life Res (2009) 18(7):873–80. 
Jemal A et al. Global Center Statistics. CA Cancer J Clin (2011) 61:69-90.  
Kalbfleisch JD and Prentice RL. The Statistical Analysis of Failure Time Data. New York: 
John Wiley & Sons; 1980. 
Lachin J and Foulkes MA. Evaluation of Sample Size and Power for Analyses of Survival 
with Allowance for Nonuniform Patient Entry, Losses to Follow-Up, Noncompliance, and 
Stratification. Biometrics (1986) 42(3):507-19. 
Lamont FR, Tomlinson DC, Cooper PA, et al. Small molecule FGF receptor inhibitors block 
FGFR-dependent urothelial carcinoma growth in vitro and in vivo. Br J Cancer (2011) 
104:75-82. 
Martínez-Torrecuadrada J, Cifuentes G, López-Serra Pet al. Targeting the extracellular 
domain of fibroblast growth factor receptor 3 with human single-chain Fv antibodies inhibits 
bladder carcinoma cell line proliferation. Clin Cancer Res (2005) 11:6280-90. 
McCaffrey JA, Hilton S, Mazumdar M et al. Phase II trial of docetaxel in patients with 
advanced or metastatic transitional-cell carcinoma. J Clin Oncol (1997) 15:1853–7. 


Protocol Number: B-701-U21 
CONFIDENTIAL 
Amendment 6 
 
BioClin Therapeutics, Inc. 
 
31 July 2018 
106 
Murgue M, Tsunekawa S, Rosenberg I, deBeaumont M, Podolsky DK. Identification of a 
novel variant of fibroblast growth factor receptor 3 (FGFR3 IIIb) in human colonic 
epithelium. Cancer Res (1994) 54:5206-11. 
National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology: Bladder 
cancer. Version 1: 2014. (NCCN.org). 
Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP: 
Toxicity And Response Criteria Of The Eastern Cooperative Oncology Group. Am J Clin 
Oncol (1982) 5:649-55. 
Papamichael D, Gallagher CJ, Oliver RT, Johnson PW, Waxman J. Phase II study of 
paclitaxel in pretreated patients with locally advanced/metastatic cancer of the bladder and 
ureter. Br J Cancer (1997) 75:606–7. 
Qing J, Du X, Chen Y, et al. Antibody-based targeting of FGFR3 in bladder carcinoma and t 
(4; 14)-positive multiple myeloma in mice. J Clin Invest (2009) 119:1077-9. 
Richelda R, Ronchetti D, Baldini L. et al. A novel chromosomal translocation t(4; 14)(p16.3; 
q32) in multiple myeloma involves the fibroblast growth-factor receptor 3 gene. Blood 
(1997) 90:4062–70. 
Ronchetti D, Greco A, Compasso S, Colombo G, Dell'Era P, Otsuki T, Lombardi L, and Neri 
A. Deregulated FGFR3 mutants in multiple myeloma cell lines with t(4;14): comparative 
analysis of Y373C, K650E and the novel G384D mutations. Oncogene (2001) 20:3553–62. 
Tomlinson DC, Baldo O, Harnden P, et al. FGFR3 protein expression and its relationship to 
mutation status and prognostic variables in bladder cancer. J Pathol (2007a) 213:91-8. 
Tomlinson DC, Hurst CD, Knowles MA. Knockdown by shRNA identifies S249C mutant 
FGFR3 as a potential therapeutic target in bladder cancer. Oncogene (2007b) 26:5889-99. 
UK MHRA. Recommendations related to contraception and pregnancy testing in clinical 
trials. Advisory non-binding guidance supported by national competent authorities 
represented at the CTFG-meeting in Rome 2014-09-15 (2014). 
Vallot C, Stransky N, Bernard-Pierrot I, et al. A novel epigenetic phenotype associated with 
the most aggressive pathway of bladder tumor progression. J Natl Cancer Inst (2011) 
103:47-60. 
Vaughn DJ. Review and outlook for the role of paclitaxel in urothelial carcinoma. Semin 
Oncol. (1999) 26(1 Suppl 2):117-22. 
Williams SV, Hurst CD, Knowles MA. Oncogenic FGFR3 gene fusions in bladder cancer. 
Hum Mol Genet. 2013 Feb 15;22(4):795-803. 
Woolson RF. Rank-tests and a one-sample log-rank test for comparing observed survival 
data to a standard population. Biometrics (1981) 37: 687-96. 


Protocol Number: B-701-U21 
CONFIDENTIAL 
Amendment 6 
 
BioClin Therapeutics, Inc. 
 
31 July 2018 
107 
Wu XR. Urothelial tumorigenesis: a tale of divergent pathways. Nat Rev Cancer (2005) 
5:713-25. 
http://www.cancer.org/acs/groups/content/@research/documents/webcontent/acspc-
042151.pdf 
 


Protocol Number: B-701-U21 
CONFIDENTIAL 
Amendment 6 
BioClin Therapeutics, Inc. 
 
31 July 2018 
108 
11 
SIGNATURE PAGE 
Protocol Title: 
A Dose Escalation, Expansion Study of Vofatamab (B-701) 
Alone, Plus Docetaxel, or Versus Docetaxel in Subjects with 
Locally Advanced or Metastatic Urothelial Cell Carcinoma 
who have Relapsed After, or are Refractory to Standard 
Therapy 
Protocol Number: 
FIERCE-21 (B-701-U21) 
Date of Amendment 6: 
Date of Amendment 5: 
Date of Amendment 4: 
Date of Amendment 3: 
Date of Amendment 2: 
Date of Amendment 1: 
Date of Original Protocol: 
July 31, 2018 
July 6, 2017 
November 21, 2016 
February 17, 2016 
December 28, 2015 
February 24, 2015 
November 26, 2014 
By signing below, I agree to the conditions relating to this study as set out in this protocol 
(FIERCE-21, B-701-U21, Amendment 6, dated July 31, 2018). I agree to conduct this 
clinical study according to the International Conference of Harmonisation Guideline on Good 
Clinical Practice (ICH GCP E6). I fully understand that any changes instituted by me without 
previous discussion with BioClin Therapeutics, Inc. (BioClin) or their designated 
representative constitute a violation of the protocol. I agree to adhere to the protocol in all 
circumstances other than where necessary to protect the well-being of the subject. I will 
ensure that the study products supplied by BioClin will be used only for administration to 
subjects included in this study protocol and for no other purpose. 
 
 
 
Investigator Signature 
 
Date 
 
Print Name 
 
Accepted by the Sponsor 
As the Sponsor representative, I confirm the Sponsor will comply with all obligations as 
detailed in all applicable regulations and guidelines. I will ensure that the Investigator is 
informed of all relevant information that becomes available during the conduct of this study.  
 
 
 
Steve Abella, MD 
Chief Medical Officer  
BioClin Therapeutics Inc. 
 
Date 


Protocol Number: B-701-U21 
CONFIDENTIAL 
Amendment 6 
BioClin Therapeutics, Inc. 
 
31 July 2018 
109 
APPENDIX 1 
EASTERN COOPERATIVE ONCOLOGY GROUP 
PERFORMANCE STATUS SCALE 
Grade 
Description 
0 
Fully active, able to carry on all pre-disease performance without restriction 
1 
Restricted in physically strenuous activity but ambulatory and able to carry out 
work of a light or sedentary nature, e.g., light housework or office work 
2 
Ambulatory and capable of all self-care but unable to carry out any work 
activities. Up and about > 50% of waking hours 
3 
Capable of only limited self-care, confined to a bed or chair > 50% of waking 
hours 
4 
Completely disabled. Cannot carry on any self-care. Totally confined to bed or 
chair 
5 
Dead 
Source: Oken 1982. 


Protocol Number: B-701-U21 
CONFIDENTIAL 
Amendment 6 
BioClin Therapeutics, Inc. 
 
31 July 2018 
110 
APPENDIX 2 
NEW YORK HEART ASSOCIATION CLASSIFICATION OF 
FUNCTIONAL CARDIAC CAPACITY 
Class 
Description 
I 
No limitation: Ordinary physical activity does not cause undue fatigue, dyspnea, 
or palpitation. 
II 
Slight limitation of physical activity: Such subjects are comfortable at rest. 
Ordinary physical activity results in fatigue, palpitations, dyspnea, or angina. 
III 
Marked limitation of physical activity: Although subjects are comfortable at rest, 
less than ordinary physical activity will lead to symptoms. 
IV 
Inability to carry on physical activity without discomfort: Symptoms of 
congestive heart failure are present even at rest. With any physical activity, 
increased discomfort is experienced. 
Source: Criteria Committee, New York Heart Association, Inc. Diseases of the heart and blood vessels. 
Nomenclature and criteria for diagnosis. 6th ed. Boston, Little, Brown and Co, 1964:114. 


Protocol Number: B-701-U21 
CONFIDENTIAL 
Amendment 6 
BioClin Therapeutics, Inc. 
 
31 July 2018 
111 
APPENDIX 3 
RESPONSE EVALUATION CRITERIA IN SOLID TUMORS 
(RECIST) VERSION 1.1 
Selected sections from the Response Evaluation Criteria in Solid Tumors (RECIST), version 
1.1 (Eisenhauer 2009) are presented below, with slight modifications and the addition of 
explanatory text as needed for clarity. 
Measurability of Tumor at Baseline 
Definitions 
At baseline, tumor lesions/lymph nodes will be categorized as measurable or non-measurable 
as described below. 
a. Measurable Tumor Lesions 
Tumor Lesions. Tumor lesions must be accurately measured in at least one dimension 
(longest diameter in the plane of measurement is to be recorded) with a minimum size as 
follows: 
• 10 mm by computed tomography (CT) or magnetic resonance imaging (MRI) scan 
(CT/MRI scan slice thickness/interval no greater than 5 mm) 
• 10 mm caliper measurement by clinical examination (lesions that cannot be accurately 
measured with calipers should be recorded as non-measurable) 
• 20 mm by chest X-ray. 
Malignant Lymph Nodes. To be considered pathologically enlarged and measurable, a 
lymph node must be ≥ 15 mm in the short axis when assessed by CT scan (CT scan slice 
thickness recommended to be no greater than 5 mm). At baseline and follow-up, only the 
short axis will be measured and followed. See also notes below on “Baseline Documentation 
of Target and Non-Target Lesions” for information on lymph node measurement. 
b. Non-Measurable Tumor Lesions 
Non-measurable tumor lesions encompass small lesions (longest diameter < 10 mm or 
pathological lymph nodes with short axis ≥ 10 but < 15 mm), as well as truly non-measurable 
lesions. Lesions considered truly non-measurable include leptomeningeal disease, ascites, 
pleural or pericardial effusion, inflammatory breast disease, lymphangitic involvement of 
skin or lung, and abdominal mass/abdominal organomegaly identified by physical 
examination that is not measurable by reproducible imaging techniques. 
c. Special Considerations Regarding Lesion Measurability 
Bone lesions, cystic lesions, and lesions previously treated with local therapy require 
particular comment, as outlined below. 


Protocol Number: B-701-U21 
CONFIDENTIAL 
Amendment 6 
BioClin Therapeutics, Inc. 
 
31 July 2018 
112 
Bone Lesions: 
• Bone scan, positron emission tomography (PET) scan, or plain films are not considered 
adequate imaging techniques for measuring bone lesions. However, these techniques can 
be used to confirm the presence or disappearance of bone lesions. 
• Lytic bone lesions or mixed lytic–blastic lesions, with identifiable soft tissue 
components, that can be evaluated by cross-sectional imaging techniques such as CT or 
MRI can be considered as measurable lesions if the soft tissue component meets the 
definition of measurability described above.  
• Blastic bone lesions are non-measurable. 
Cystic Lesions: 
• Lesions that meet the criteria for radiographically defined simple cysts should not be 
considered as malignant lesions (neither measurable nor non-measurable) since they are, 
by definition, simple cysts. 
• Cystic lesions thought to represent cystic metastases can be considered as measurable 
lesions, if they meet the definition of measurability described above. However, if non-
cystic lesions are present in the same subject, these are preferred for selection as target 
lesions. 
Lesions with Prior Local Treatment: 
• Tumor lesions situated in a previously irradiated area, or in an area subjected to other 
loco-regional therapy, are usually not considered measurable unless there has been 
demonstrated progression in the lesion.  
Target Lesions: Specifications by Methods of Measurements 
a. Measurement of Lesions 
All measurements should be recorded in metric notation, using calipers if clinically assessed. 
All baseline evaluations should be performed as close as possible to the treatment start and 
never more than 4 weeks before the beginning of the treatment. 
b. Method of Assessment 
The same method of assessment and the same technique should be used to characterize each 
identified and reported lesion at baseline and during the study. Imaging-based evaluation 
should always be the preferred option. 
Clinical Lesions. Clinical lesions will only be considered measurable when they are 
superficial and ≥ 10 mm in diameter as assessed using calipers (e.g., skin nodules). For the 
case of skin lesions, documentation by color photography including a ruler to estimate the 
size of the lesion is suggested. 


Protocol Number: B-701-U21 
CONFIDENTIAL 
Amendment 6 
BioClin Therapeutics, Inc. 
 
31 July 2018 
113 
Chest X-Ray. Chest CT is preferred over chest X-ray, particularly when progression is an 
important endpoint, since CT is more sensitive than X-ray, particularly in identifying new 
lesions. However, lesions on a chest X-ray may be considered measurable if they are clearly 
defined and surrounded by aerated lung. 
CT, MRI. CT is the best currently available and reproducible method to measure lesions 
selected for response assessment. This guideline has defined measurability of lesions on CT 
scan based on the assumption that CT slice thickness is 5 mm or less. When CT scans have 
slice thicknesses greater than 5 mm, the minimum size for a measurable lesion should be 
twice the slice thickness. MRI is also acceptable. If prior to enrollment it is known that a 
subject is unable to undergo CT scans with intravenous (IV) contrast because of allergy or 
renal insufficiency, the decision as to whether a non-contrast CT or MRI (without IV 
contrast) will be used to evaluate the subject at baseline and during the study should be 
guided by the tumor type under investigation and the anatomic location of the disease. For 
subjects who develop contraindications to contrast after baseline contrast CT is done, the 
decision as to whether non-contrast CT or MRI (enhanced or non-enhanced) will be 
performed should also be based on the tumor type and the anatomic location of the disease 
and should be optimized to allow for comparison with the prior studies if possible. Each case 
should be discussed with the radiologist to determine if substitution of these other approaches 
is possible and, if not, the subject should be considered not evaluable from that point 
forward. Care must be taken in measurement of target lesions on a different modality and 
interpretation of non-target disease or new lesions since the same lesion may appear to have a 
different size using a new modality.  
Ultrasound. Ultrasound is not useful in assessment of lesion size and should not be used as a 
method of measurement. 
Endoscopy, Laparoscopy, Tumor Markers, Cytology, Histology. The utilization of these 
techniques for objective tumor evaluation cannot generally be advised. 
Tumor Response Evaluation 
Assessment of Overall Tumor Burden and Measurable Disease 
To assess objective response or future progression, it is necessary to estimate the overall 
tumor burden at baseline and use this as a comparator for subsequent measurements. 
Measurable disease is defined by the presence of at least one measurable lesion, as detailed 
above. 
Baseline Documentation of Target and Non-Target Lesions 
When more than one measurable lesion is present at baseline, all lesions up to a maximum of 
five lesions total (and a maximum of two lesions per organ) representative of all involved 
organs should be identified as target lesions and will be recorded and measured at baseline. 
This means that, for instances in which subjects have only one or two organ sites involved, a 
maximum of two lesions (one site) and four lesions (two sites), respectively, will be 
recorded. Other lesions (albeit measurable) in those organs will be recorded as non-
measurable lesions (even if the size is > 10 mm by CT scan). 


Protocol Number: B-701-U21 
CONFIDENTIAL 
Amendment 6 
BioClin Therapeutics, Inc. 
 
31 July 2018 
114 
Target lesions should be selected on the basis of their size (lesions with the longest diameter) 
and be representative of all involved organs, but in addition, should lend themselves to 
reproducible repeated measurements. It may be the case that, on occasion, the largest lesion 
does not lend itself to reproducible measurement, in which circumstance, the next largest 
lesion that can be measured reproducibly should be selected. 
Lymph nodes merit special mention since they are normal anatomical structures that may be 
visible by imaging even if not involved by tumor. As noted above, pathological nodes that 
are defined as measurable and may be identified as target lesions must meet the criterion of a 
short axis of ≥ 15 mm by CT scan. Only the short axis of these nodes will contribute to the 
baseline sum. The short axis of the node is the diameter normally used by radiologists to 
judge if a node is involved by solid tumor. Nodal size is normally reported as two dimensions 
in the plane in which the image is obtained (for CT, this is almost always the axial plane; for 
MRI, the plane of acquisition may be axial, sagittal, or coronal). The smaller of these 
measures is the short axis. For example, an abdominal node that is reported as being 20 mm 
× 30 mm has a short axis of 20 mm and qualifies as a malignant, measurable node. In this 
example, 20 mm should be recorded as the node measurement. All other pathological nodes 
(those with short axis ≥ 10 mm but < 15 mm) should be considered non-target lesions. Nodes 
that have a short axis of < 10 mm are considered non-pathological and should not be 
recorded or followed. 
A sum of the diameters (longest for non-nodal lesions, short axis for nodal lesions) for all 
target lesions will be calculated and reported as the baseline sum of diameters. If lymph 
nodes are to be included in the sum, then as noted above, only the short axis is added into the 
sum. The baseline sum of diameters will be used as a reference to further characterize any 
objective tumor regression in the measurable dimension of the disease. 
All other lesions (or sites of disease), including pathological lymph nodes, should be 
identified as non-target lesions and should also be recorded at baseline. Measurements are 
not required and these lesions should be followed as “present,” “absent,” or in rare cases 
“unequivocal progression.” 
In addition, it is possible to record multiple non-target lesions involving the same organ as a 
single item on the electronic Case Report Form (eCRF) (e.g., “multiple enlarged pelvic 
lymph nodes” or “multiple liver metastases”). 
Response Criteria 
a.  Evaluation of Target Lesions 
This section provides the definitions of the criteria used to determine objective tumor 
response for target lesions. 
• Complete response (CR): disappearance of all target lesions 
Any pathological lymph nodes (whether target or non-target) must have reduction in 
short axis to < 10 mm. 


Protocol Number: B-701-U21 
CONFIDENTIAL 
Amendment 6 
BioClin Therapeutics, Inc. 
 
31 July 2018 
115 
• Partial response (PR): at least a 30% decrease in the sum of diameters of target lesions, 
taking as reference the baseline sum of diameters 
• Progressive disease (PD): at least a 20% increase in the sum of diameters of target 
lesions, taking as reference the smallest sum on study (nadir), including baseline 
In addition to the relative increase of 20%, the sum must also demonstrate an absolute 
increase of at least 5 mm. 
The appearance of one or more new lesions is also considered progression. 
• Stable disease (SD): neither sufficient shrinkage to qualify for PR nor sufficient increase 
to qualify for PD, taking as reference the smallest sum on study 
b. Special Notes on the Assessment of Target Lesions 
Lymph Nodes. Lymph nodes identified as target lesions should always have the actual short 
axis measurement recorded (measured in the same anatomical plane as the baseline 
examination), even if the nodes regress to < 10 mm on study. This means that when lymph 
nodes are included as target lesions, the sum of lesions may not be zero even if CR criteria 
are met, since a normal lymph node is defined as having a short axis of < 10 mm. 
Target Lesions that Become too Small to Measure. During the study, all lesions (nodal and 
non-nodal) recorded at baseline should have their actual measurements recorded at each 
subsequent evaluation, even when very small (e.g., 2 mm). However, sometimes lesions or 
lymph nodes that are recorded as target lesions at baseline become so faint on CT scan that 
the radiologist may not feel comfortable assigning an exact measure and may report them as 
being too small to measure. When this occurs, it is important that a value be recorded on the 
eCRF as follows: 
• If it is the opinion of the radiologist that the lesion has likely disappeared, the 
measurement should be recorded as 0 mm. 
• If the lesion is believed to be present and is faintly seen but too small to measure, a 
default value of 5 mm should be assigned and below measurable limit (BML) should be 
ticked. (Note: It is less likely that this rule will be used for lymph nodes since they 
usually have a definable size when normal and are frequently surrounded by fat such as 
in the retroperitoneum; however, if a lymph node is believed to be present and is faintly 
seen but too small to measure, a default value of 5 mm should be assigned in this 
circumstance as well and BML should also be ticked.) 
To reiterate, however, if the radiologist is able to provide an actual measure, that should be 
recorded, even if it is below 5 mm, and in that case, BML should not be ticked. 
Lesions that Split or Coalesce on Treatment. When non-nodal lesions fragment, the 
longest diameters of the fragmented portions should be added together to calculate the target 
lesion sum. Similarly, as lesions coalesce, a plane between them may be maintained that 
would aid in obtaining maximal diameter measurements of each individual lesion. If the 
lesions have truly coalesced such that they are no longer separable, the vector of the longest 
diameter in this instance should be the maximum longest diameter for the coalesced lesion. 


Protocol Number: B-701-U21 
CONFIDENTIAL 
Amendment 6 
BioClin Therapeutics, Inc. 
 
31 July 2018 
116 
c. Evaluation of Non-Target Lesions 
This section provides the definitions of the criteria used to determine the tumor response for 
the group of non-target lesions. While some non-target lesions may actually be measurable, 
they need not be measured and, instead, should be assessed only qualitatively at the time 
points specified in the protocol. 
• CR: disappearance of all non-target lesions and (if applicable) normalization of tumor 
marker level 
All lymph nodes must be non-pathological in size (< 10 mm short axis). 
• Non-CR/Non-PD: persistence of one or more non-target lesions and/or (if applicable) 
maintenance of tumor marker level above the normal limits 
• PD: unequivocal progression of existing non-target lesions. The appearance of one or 
more new lesions is also considered progression. 
d. Special Notes on Assessment of Progression of Non-Target Disease  
When the Subject Also Has Measurable Disease. In this setting, to achieve unequivocal 
progression on the basis of the non-target disease, there must be an overall level of 
substantial worsening in non-target disease in a magnitude that, even in the presence of SD or 
PR in target disease, the overall tumor burden has increased sufficiently to merit 
discontinuation of therapy. A modest increase in the size of one or more non-target lesions is 
usually not sufficient to qualify for unequivocal progression status. The designation of 
overall progression solely on the basis of change in non-target disease in the face of SD or 
PR of target disease will therefore be extremely rare. 
When the Subject Has Only Non-Measurable Disease. This circumstance arises in some 
Phase III trials when it is not a criterion of study entry to have measurable disease. The same 
general concepts apply here as noted above; however, in this instance there is no measurable 
disease assessment to factor into the interpretation of an increase in non-measurable disease 
burden. Because worsening in non-target disease cannot be easily quantified (by definition: if 
all lesions are truly non-measurable), a useful test that can be applied when assessing 
subjects for unequivocal progression is to consider if the increase in overall disease burden 
based on the change in non-measurable disease is comparable in magnitude to the increase 
that would be required to declare PD for measurable disease, that is, an increase in tumor 
burden representing an additional 73% increase in volume (which is equivalent to a 20% 
increase in diameter in a measurable lesion). Examples include an increase in a pleural 
effusion from “trace” to “large” or an increase in lymphangitic disease from localized to 
widespread or may be described in protocols as “sufficient to require a change in therapy.” If 
unequivocal progression is seen, the subject should be considered to have had overall PD at 
that point. While it would be ideal to have objective criteria apply to non-measurable disease, 
the very nature of that disease makes it impossible to do so; therefore, the increase must be 
substantial. 


Protocol Number: B-701-U21 
CONFIDENTIAL 
Amendment 6 
BioClin Therapeutics, Inc. 
 
31 July 2018 
117 
e. New Lesions 
The appearance of new malignant lesions denotes disease progression; therefore, some 
comments on detection of new lesions are important. There are no specific criteria for the 
identification of new radiographic lesions; however, the finding of a new lesion should be 
unequivocal, that is, not attributable to differences in scanning technique, change in imaging 
modality, or findings thought to represent something other than tumor (for example, some 
“new” bone lesions may be simply healing or flare of preexisting lesions). This is particularly 
important when the subject’s baseline lesions show partial or complete response. 
For example, necrosis of a liver lesion may be reported on a CT scan report as a “new” cystic 
lesion, which it is not. 
A lesion identified during the study in an anatomical location that was not scanned at 
baseline is considered a new lesion and will indicate disease progression. 
If a new lesion is equivocal, for example because of its small size, continued therapy and 
follow-up evaluation will clarify if it represents truly new disease. If repeat scans confirm 
there is definitely a new lesion, then progression should be declared using the date of the 
initial scan. 
Evaluation of Response 
a. Time Point Response (Overall Response) 
It is assumed that at each protocol-specified time point, a response assessment occurs. 
Table 6 provides a summary of the overall response status calculation at each time point for 
subjects who have measurable disease at baseline. When subjects have non-measurable 
(therefore non-target) disease only, Table 7 is to be used. 
Table 6 
Time Point Response: Subjects with Target Disease (With or Without 
Non-Target Lesions) 
Target Lesions 
Non-Target Lesions 
New Lesions 
Overall Response 
CR 
CR 
No 
CR 
CR 
Non-CR/non-PD 
No 
PR 
CR 
Not evaluated 
No 
PR 
PR 
Non-PD or not all 
evaluated 
No 
PR 
SD 
Non-PD or not all 
evaluated 
No 
SD 
Not all evaluated 
Non-PD 
No 
NE 
PD 
Any 
Yes or no 
PD 
Any 
PD 
Yes or no 
PD 
Any 
Any 
Yes 
PD 
CR = complete response; NE = not evaluable; PD = progressive disease; PR = partial response; SD = stable 
disease. 
 


Protocol Number: B-701-U21 
CONFIDENTIAL 
Amendment 6 
BioClin Therapeutics, Inc. 
 
31 July 2018 
118 
Table 7 
Time Point Response: Subjects with Non-Target Disease Only 
Non-Target Lesions 
New Lesions 
Overall Response 
CR 
No 
CR 
Non-CR/non-PD 
No 
Non-CR/non-PD a 
Not all evaluated 
No 
NE 
Unequivocal PD 
Yes or no 
PD 
Any 
Yes 
PD 
CR = complete response; NE = not evaluable; PD = progressive disease. 
a 
“Non-CR/non-PD” is preferred over “stable disease” for non-target disease since stable disease is 
increasingly used as an endpoint for assessment of efficacy in some trials; thus, assigning “stable disease” 
when no lesions can be measured is not advised. 
 
b. Missing Assessments and Not-Evaluable Designation 
When no imaging/measurement is done at all at a particular time point, the subject is not 
evaluable at that time point. If only a subset of lesion measurements are made at an 
assessment, usually the case is also considered not evaluable at that time point unless a 
convincing argument can be made that the contribution of the individual missing lesion(s) 
would not change the assigned time point response. This would be most likely to happen in 
the case of PD. For example, if a subject had a baseline sum of 50 mm with three measured 
lesions, and during the study, only two lesions were assessed but those gave a sum of 80 mm, 
the subject will have achieved PD status, regardless of the contribution of the missing lesion. 
If one or more target lesions were not assessed either because the scan was not done or the 
scan could not be assessed because of poor image quality or obstructed view, the response for 
target lesions should be “unable to assess” since the subject is not evaluable. Similarly, if one 
or more non-target lesions are not assessed, the response for non-target lesions should be 
“unable to assess” except where there is clear progression. Overall response would be 
“unable to assess,” if either the target response or the non-target response is “unable to 
assess” except where this is clear evidence of progression, as this equates with the case being 
not evaluable at that time point. 
c. Best Overall Response: All Time Points 
The best overall response is determined once all the data for the subject is known. 
Best response determination in trials where confirmation of complete or partial response IS 
NOT required: Best response in these trials is defined as the best response across all time 
points (for example, a subject who has SD at first assessment, PR at second assessment, and 
PD on last assessment has a best overall response of PR). When SD is believed to be best 
response, it must also meet the protocol specified minimum time from baseline. If the 
minimum time is not met when SD is otherwise the best time point response, the patient’s 
best response depends on the subsequent assessments. For example, a subject who has SD at 
first assessment, PD at second and does not meet minimum duration for SD, will have a best 
response of PD. The same subject lost to follow-up after the first SD assessment would be 
considered inevaluable at a subsequent time point as specified in the protocol (generally 


Protocol Number: B-701-U21 
CONFIDENTIAL 
Amendment 6 
BioClin Therapeutics, Inc. 
 
31 July 2018 
119 
4 weeks later). In this circumstance, the best overall response can be interpreted as in 
Table 8. 
Table 8 
Best Overall Response When Confirmation of CR and PR required 
Overall Response 
First Time Point 
Overall Response 
Subsequent Time 
Point 
Best Overall Response 
CR 
CR 
CR 
CR  
PR  
SD, PD or PRa 
CR  
SD  
SD provided minimum criteria for SD duration 
met, otherwise, PD 
CR  
PD  
SD provided minimum criteria for SD duration 
met, otherwise, PD 
CR  
NE 
SD provided minimum criteria for SD duration 
met, otherwise NE 
PR 
CR 
PR 
PR 
PR 
PR 
PR 
SD 
SD 
PR  
PD  
SD provided minimum criteria for SD duration 
met, otherwise, PD 
PR  
NE  
SD provided minimum criteria for SD duration 
met, otherwise NE 
NE 
NE 
NE 
CR = complete response; NE = not evaluable; PD = progressive disease; PR = partial response; SD = stable 
disease. 
a 
If a CR is truly met at first time point, then any disease seen at a subsequent time point, even disease 
meeting PR criteria relative to baseline, makes the disease PD at that point (since disease must have 
reappeared after CR). Best response would depend on whether minimum duration for SD was met. 
However, sometimes ‘CR’ may be claimed when subsequent scans suggest small lesions were likely still 
present and in fact the patient had PR, not CR at the first time point. Under these circumstances, the 
original CR should be changed to PR and the best response is PR. 
 
d. Special Notes of Response Assessment 
When nodal disease is included in the sum of target lesions and the nodes decrease to 
“normal” size (< 10 mm), they may still have a measurement reported on scans. This 
measurement should be recorded even though the nodes are normal in order not to overstate 
progression should it be based on increase in size of the nodes. As noted earlier, this means 
that subjects with CR may not have a total sum of “zero” on the eCRF. 
Subjects w a global deterioration of health status requiring discontinuation of treatment 
without objective evidence of disease progression at that time should be reported as 
“symptomatic deterioration.” Every effort should be made to document objective progression 
even after discontinuation of treatment. Symptomatic deterioration is not a descriptor of an 
objective response; it is a reason for stopping study therapy. The objective response status of 
such subjects is to be determined by evaluation of target and non-target disease. 


Protocol Number: B-701-U21 
CONFIDENTIAL 
Amendment 6 
BioClin Therapeutics, Inc. 
 
31 July 2018 
120 
For equivocal findings of progression (e.g., very small and uncertain new lesions; cystic 
changes or necrosis in existing lesions), treatment may continue until the next scheduled 
assessment. If at the next scheduled assessment, progression is confirmed, the date of 
progression should be the earlier date when progression was suspected. 
In studies for which subjects with advanced disease are eligible (i.e., primary disease still or 
partially present), the primary tumor should also be captured as a target or non-target lesion, 
as appropriate. This is to avoid an incorrect assessment of CR if the primary tumor is still 
present but not evaluated as a target or non-target lesion. 


Protocol Number: B-701-U21 
CONFIDENTIAL 
Amendment 6 
BioClin Therapeutics, Inc. 
 
31 July 2018 
121 
APPENDIX 4 
ANAPHYLAXIS PRECAUTIONS AND PROCEDURES 
The following equipment is needed in the event of a suspected anaphylactic reaction during 
study drug infusion: 
• Tourniquet 
• Oxygen 
• Epinephrine for subcutaneous, intravenous, and/or endotracheal use in accordance with 
standard practice as needed 
• Antihistamines 
• Corticosteroids 
• Intravenous infusion solutions, tubing, catheters, and tape. 
The following are the procedures to follow in the event of a suspected anaphylactic reaction 
during study drug infusion: 
1. Stop the study drug infusion. 
2. Apply a tourniquet proximal to the injection site to slow systemic absorption of 
study drug. Do not obstruct arterial flow in the limb. 
3. Maintain an adequate airway. 
4. Administer antihistamines, epinephrine, or other medications, as required by subject 
status and directed by the physician in charge. 
5. Continue to observe the subject and document observations. 
 


Protocol Number: B-701-U21 
CONFIDENTIAL 
Amendment 6 
BioClin Therapeutics, Inc. 
 
31 July 2018 
122 
APPENDIX 5 
PROMIS GLOBAL PHYSICAL HEALTH SHORT SURVEY 
 
 
Excellent 
Very 
Good 
Good 
Fair 
Poor 
 
 
 
 
 
 
 
In general, how would you 
rate your physical health? 
 
 
 
 
 
 
 
 
5 
4 
3 
2 
1 
 
 
 
 
Completely 
Mostly 
Moderately 
A little 
Not at all 
 
 
 
 
 
 
 
To what extent are you able to 
carry out your everyday 
physical activities such as 
walking, climbing stairs, 
carrying groceries, or moving 
a chair? 
 
 
 
 
 
 
 
 
5 
4 
3 
2 
1 
 
 
 
 
None 
Mild 
Moderate 
Severe 
Very Severe 
 
 
 
 
 
 
 
How would you rate your 
fatigue on average? 
 
 
 
 
 
 
 
 
1 
2 
3 
4 
5 
 
 
 
 
 
 
 
 
 
How would you rate your pain 
on average? 
 
 
 
 
 
 
 
0 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
 
No 
pain 
 
 
 
 
 
 
 
 
 
Worst 
Imaginable 
pain 
 
Source: Hays 2009. 


Protocol Number: B-701-U21 
CONFIDENTIAL 
Amendment 6 
BioClin Therapeutics, Inc. 
 
31 July 2018 
123 
APPENDIX 6 
INFORMATION REGARDING EFFECTIVENESS OF 
CONTRACEPTIVE METHODS 
The following methods of contraception can achieve a failure rate of less than 1% per year 
when used consistently and correctly, and are considered highly effective birth control 
methods: 
• Combined (estrogen and progestogen containing) hormonal contraception associated with 
inhibition of ovulation1 
o oral 
o intravaginal 
o transdermal 
• Progestogen-only hormonal contraception associated with inhibition of ovulation1 
o oral 
o injectable 
o implantable2 
• Intrauterine device (IUD)2 
• Intrauterine hormone-releasing system (IUS)2 
• Bilateral tubal occlusion2 
• Vasectomized partner2,3 
• Sexual abstinence4 
Acceptable birth control methods that result in a failure rate of more than 1% per year 
include: 
• Progestogen-only oral hormonal contraception, where inhibition of ovulation is not the 
primary mode of action 
• Male or female condom with or without spermicide5 
• Cap, diaphragm or sponge with spermicide5 
1 
Hormonal contraception may be susceptible to interaction with the IMP, which may reduce the efficacy of 
the contraception method. 
2 
Contraception methods that in the context of this guidance are considered to have low user dependency. 
3 
Vasectomized partner is a highly effective method provided of avoiding pregnancy that partner is the sole 
sexual partner of the WOCBP trial participant and that the vasectomized partner has received medical 
assessment of the surgical success.  
4 
In the context of this guidance, sexual abstinence is considered a highly effective method only if defined as 
refraining from heterosexual intercourse during the entire period of risk associated with the study 
treatments. The reliability of sexual abstinence needs to be evaluated in relation to the duration of the 
clinical trial and the preferred and usual lifestyle of the subject. 


Protocol Number: B-701-U21 
CONFIDENTIAL 
Amendment 6 
BioClin Therapeutics, Inc. 
 
31 July 2018 
124 
5 
A combination of male condom with either cap, diaphragm or sponge with spermicide (double barrier 
methods) are also considered acceptable, but not highly effective, birth control methods. 
Source:  CTFG 2014. 
 


Protocol Number: B-701-U21 
CONFIDENTIAL 
Amendment 6 
BioClin Therapeutics, Inc. 
 
31 July 2018 
125 
APPENDIX 7 
EUROPEAN ORGANIZATION FOR RESEARCH AND 
TREATMENT QUALITY OF LIFE QUESTIONNAIRE 
(EORTC QLQ-C30) 
 
 
 


Protocol Number: B-701-U21 
CONFIDENTIAL 
Amendment 6 
BioClin Therapeutics, Inc. 
 
31 July 2018 
126 
 
 
 


Protocol Number: B-701-U21 
CONFIDENTIAL 
Amendment 6 
BioClin Therapeutics, Inc. 
 
31 July 2018 
127 
APPENDIX 8 
PHARMACOKINETIC SUB-STUDY 
 
1. OBJECTIVES 
• To characterize the serum vofatamab concentration in cycle 1, cycle 5 and at steady 
state for the U21 monotherapy arm. 
 
2. RATIONALE 
This sub-study will allow a detailed characterization of the PK of vofatamab  
 
 
3. SUB-STUDY DESIGN 
Eligible subjects at all centers may be enrolled into the PK sub-study: up to 10 subjects in the 
monotherapy arm will be enrolled. Subjects have to provide sub-study specific informed 
consent to participate. A balanced regional and racial distribution is targeted for enrollment.  
 
4. ENDPOINT 
o Vofatamab serum concentrations before and after vofatamab administration 
 
5. ELIGIBILITY 
 
• Inclusion 
o Subject has provided informed consent for participation in this sub-study. 
Upon agreement with BioClin Therapeutics, subjects may be consented 
following Day 1. Back-up samples collected for other testing may be analyzed 
for any PK timepoint that may have been missed due to later consent. 
 
• Exclusion 
o Subject will not be available for protocol-required study visits or procedures, 
to the best of the subject and investigator’s knowledge 
 
6. PROCEDURES 
Sample collection, handling and storage and general procedures for laboratory assessments 
relevant for this sub-study are described in Section 6.2.9.  
 
• In the sub-study. PK samples for the assessment of vofatamab will be collected as 
follows (PK samples collected for all study participants are shown in non-bolded font; 
additional PK samples required of subjects participating in the PK sub-study are in 
bolded font): 
o Cycle 1 
▪ Day 1, before vofatamab infusion AND within 30 (±15) minutes after 
completion vofatamab infusion  
▪ Day 2 and Day 4  
▪ Day 8, before vofatamab infusion AND within 30 (±15) minutes after 
completion vofatamab infusion  


Protocol Number: B-701-U21 
CONFIDENTIAL 
Amendment 6 
BioClin Therapeutics, Inc. 
 
31 July 2018 
128 
o Cycle 2 
▪ Day 1, before vofatamab infusion AND within 30 (±15) minutes after 
completion vofatamab infusion  
o Cycle 3 
▪ Day 1 before vofatamab infusion AND within 30 (±15) minutes 
after completion vofatamab infusion 
o Cycle 5 
▪ Day 1, before vofatamab infusion AND within 30 (±15) minutes after 
completion vofatamab infusion  
▪ Day 2, Day 8, Day 15, and Day 21  
o Cycle 6 
▪ Day 1 before vofatamab infusion AND within 30 (±15) minutes 
after completion vofatamab infusion 
o Cycle 10 
▪ Day 1 before vofatamab infusion AND within 30 (±15) minutes after 
completion vofatamab infusion 
o End of Treatment 
 
 
 
7. STATISTICAL CONSIDERATIONS 
Enrollment of up to 10 subjects represents approximately a 10% sampling of the 
monotherapy arm and as such is expected to be representative of the overall study 
population. Statistical methods are described in Section 7.3.1